

**PATENT APPLICATION TRANSMITTAL LETTER**  
(Large Entity)

Docket No.  
1038-921 MIS:jb

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Transmitted herewith for filing under 35 U.S.C. 111 and 37 C.F.R. 1.53 is the patent application of:

Sheena M. Loosmore; Ken Sasaki; Yan Ping Yang; and Michel H. Klein

For: **RECOMBINANT HIGH MOLECULAR WEIGHT MAJOR OUTER MEMBRANE PROTEIN OF MORAXELLA**

Enclosed are:

- ☐ Certificate of Mailing with Express Mail Mailing Label No.
- ☒ Sixty-Eight (68) sheets of drawings.
- ☐ A certified copy of a application.
- ☒ Declaration ☐ Signed. ☒ Unsigned.
- ☐ Power of Attorney
- ☐ Information Disclosure Statement
- ☐ Preliminary Amendment
- ☐ Other:


1c542 U.S. PTO  
09/361619  
07/27/99

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	23	- 20 =	3	x \$18.00	\$54.00
Indep. Claims	8	- 3 =	5	x \$78.00	\$390.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$760.00
TOTAL FILING FEE					\$1,204.00

- ☒ A check in the amount of **\$1,204.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed.
  - ☐ Charge the amount of as filing fee.
  - ☒ Credit any overpayment.
  - ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
  - ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: July 26, 1999

  
Michael I. Stewart Signature  
(24,973)

CC:

TITLE OF INVENTION

RECOMBINANT HIGH MOLECULAR WEIGHT MAJOR OUTER MEMBRANE  
PROTEIN OF MORAXELLA

FIELD OF INVENTION

5           The present invention relates to the field of immunology and is particularly concerned with outer membrane proteins from *Moraxella*, methods of recombinant production thereof, genes encoding such proteins and uses thereof.

10                           BACKGROUND OF THE INVENTION

          Otitis media is the most common illness of early childhood with approximately 70% of all children suffering at least one bout of otitis media before the age of seven. Chronic otitis media can lead to hearing, speech and cognitive impairment in children. It is caused by bacterial infection with *Streptococcus pneumoniae* (approximately 50%), non-typable *Haemophilus influenzae* (approximately 30%) and *Moraxella* (*Branhamella*) *catarrhalis* (approximately 20%). In the United States alone, treatment of otitis media costs between one and two billion dollars per year for antibiotics and surgical procedures, such as tonsillectomies, adenoidectomies and insertion of tympanostomy tubes. Because otitis media occurs at a time in life when language skills are developing at a rapid pace, developmental disabilities specifically related to learning and auditory perception have been documented in youngsters with frequent otitis media.

*M. catarrhalis* mainly colonizes the respiratory tract and is predominantly a mucosal pathogen. Studies using cultures of middle ear fluid obtained by tympanocentesis have shown that *M. catarrhalis* causes approximately 20% of cases of otitis media (ref. 1 - Throughout this application, various references are referred to in parenthesis to more fully describe the

state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby  
 5 incorporated by reference into the present disclosure).

The incidence of otitis media caused by *M. catarrhalis* is increasing. As ways of preventing otitis media caused by pneumococcus and non-typable *H. influenzae* are developed, the relative importance of *M.*  
 10 *catarrhalis* as a cause of otitis media can be expected to further increase.

*M. catarrhalis* is also an important cause of lower respiratory tract infections in adults, particularly in the setting of chronic bronchitis and emphysema (refs.  
 15 2, 3, 4, 5, 6, 7, and 8). *M. catarrhalis* also causes sinusitis in children and adults (refs. 9, 10, 11, 12, and 13) and occasionally causes invasive disease (refs. 14, 15, 16, 17, 18, and 19).

Like other Gram-negative bacteria, the outer  
 20 membrane of *M. catarrhalis* consists of phospholipids, lipopolysaccharide (LPS), and outer membrane proteins (OMPs). Eight of the *M. catarrhalis* OMPs have been identified as major components. These are designated by letters A to H, beginning with OMP A which has a  
 25 molecular mass of 98 kDa to OMP H which has a molecular mass of 21 kDa (ref. 20).

Recently, Klingman and Murphy purified and characterized a high molecular-weight outer membrane protein of *M. catarrhalis* (ref. 21). The apparent  
 30 molecular mass of this protein varies from 350 kDa to 720 kDa as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This protein appears to be an oligomer of much smaller proteins or subunits thereof of molecular mass about 120  
 35 to 140 kDa and is antigenically conserved among strains of *Moraxella*.

662620" 6F5F5E60

Helminen et al also identified a protein of molecular mass of about 300 to 400 kDa, named UspA, that was reported to be present on the surface of *Moraxella* (ref. 22).

5 In WO 96/34960 and US Patent No. 5,808,024, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described a new protein of *M. catarrhalis* which had an apparent molecular mass of about 200 kDa. Western blot  
10 analysis using antiserum raised against the 200 kDa protein suggested that this protein was different from the large UspA protein (> 300 kDa), reported by the two groups in refs. 21 and 22. Recently, the gene sequences encoding two related proteins, UspA1 and UspA2, have  
15 been published (ref. 23). A sequence comparison between the two genes encoding the UspA proteins and the gene encoding the 200 kDa protein confirmed that the 200 kDa protein is different from either of the UspA1 and UspA2 proteins.

20 Fitzgerald et al (ref. 29) have identified a 200 kDa protein associated with haemagglutination. Transmission electron microcopy studies (ref. 30) showed that the 200 kDa protein associated with haemagglutination is present on the outer fibrillar  
25 layer of *M. catarrhalis*. Recently, a non-clumping variant of strain 4223 was prepared by serial passaging and it was observed that the non-clumping variant had reduced expression of both UspA and a 200 kDa protein that is not UspA (ref. 31). It is possible that this 200  
30 kDa protein is the same as that described in WO 96/34960 and herein.

The 200 kDa protein described herein has been detected in most, but not all, strains of *Moraxella catarrhalis*, which have been isolated from various  
35 sources, including otitis media (OM), sputum, nasopharynx, expectorate and bronchial secretions. Table 1A below contains a listing of *M. catarrhalis* strains

tested, their source and whether or not the 200 kDa protein is expressed.

*M. catarrhalis* infection may lead to serious disease. It would be advantageous to provide recombinant means for providing large quantities of 200 kDa outer membrane protein of *M. catarrhalis* strains and genes encoding such proteins from various *M. catarrhalis* strains for use as antigens in immunogenic preparations including vaccines, carriers for other antigens and immunogens and the generation of diagnostic reagents.

#### SUMMARY OF THE INVENTION

The present invention is directed towards the provision of a recombinantly-produced purified and isolated outer membrane protein of *Moraxella catarrhalis* and other *Moraxella* strains, having an apparent molecular mass of about 200 kDa, as well as genes encoding the same from various strains of *Moraxella catarrhalis*.

In one aspect of the present invention, there is provided an isolated and purified nucleic acid molecule having (a) a nucleotide sequence set forth in Figure 3, 4 or 5 (SEQ ID Nos: 5, 6, 8, 9, 11, 12) for *Moraxella catarrhalis* strains 4223, Q8 and LES-1 respectively or the complementary sequence thereto; (b) a nucleotide sequence encoding an about 200 kDa outer membrane protein of a strain of *Moraxella catarrhalis* and having the derived amino acid sequence shown in Figures 3, 4 or 5 (SEQ ID Nos: 7, 10, 13) for *Moraxella catarrhalis* strains 4223, Q8 and LES-1 respectively; and (c) a nucleotide sequence encoding an about 200 kDa outer membrane protein of another strain of *Moraxella catarrhalis* which is characterized by a tract of consecutive G nucleotides which is 3 or a multiple thereof in length, an ATG start codon about 80 to 90 bp upstream of said tract and said tract being located between about amino acids 25 and 35 encoded by the nucleotide sequence.

The another strain of *Moraxella catarrhalis* in (c) is a strain as identified in Table 1A other than strains 4223, Q8 and LES-1 and expressing an about 200 kDa protein.

5 In another aspect of the invention, there is provided (a) a nucleotide sequence set forth in Figure 8 (SEQ ID No: 12) for a 5'-truncation of the gene encoding an about 200 kDa outer membrane protein of *Moraxella catarrhalis* strain 4223; (b) a nucleotide  
10 sequence encoding the derived amino acid sequence set forth in Figure 9 (SEQ ID No: 13) for a N-terminal truncation of an about 200 kDa outer membrane protein of *Moraxella catarrhalis* strain 4223; and (c) a nucleotide  
15 sequence encoding a 5'-truncation of a gene encoding an about 200 kDa outer membrane protein of another strain of *Moraxella catarrhalis* and being capable of expressing the corresponding N-terminally truncated about 200 kDa outer membrane protein from *E. coli*.

A further aspect of the invention providing an  
20 isolated and purified nucleic acid molecule which is a contiguous *Nde* I - *Pst* I fragment of SEQ ID No: 5.

The invention, in an additional aspect, provides a vector for transforming a host comprising a nucleic acid molecule as provided herein, which may be a plasmid  
25 vector. The plasmid vector may be one which has the identifying characteristics of pKS348 (ATCC 203,529) or pKS294 (ATCC 203,528). The plasmid vector also may be one having the identifying characteristics of pQWE or pQWF.

30 A further aspect of the invention provides a host cell, such as *E. coli*, transformed by a vector provided herein and expressing an about 200 kDa protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof. The invention further provides,  
35 in an additional aspect, a recombinant about 200 kDa outer membrane protein of a strain of *Moraxella*

09361619 "072799  
662220" 679960

[illegible][illegible][illegible][illegible][illegible]

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

[illegible][illegible][illegible][illegible]

chromatographically purifying the solution of recombinant about 200 kDa protein free from contaminating proteins, and

isolating the purified recombinant about 200 kDa protein.

#### BRIEF DESCRIPTION OF DRAWINGS

Figure 1 shows restriction maps of subclones of a gene encoding the 200 kDa outer membrane protein of *M. catarrhalis* from  $\lambda$ EMBL3 clone 8II and the location of PCR primers used to amplify the 5'-region of the gene. The open reading frame of the about 200 kDa outer membrane protein is indicated by the shaded box. The numbers in parenthesis are approximate sizes of DNA inserts in plasmids. Restrictions sites are Sal: *Sal*I, N: *Nco*I, B: *Bgl*II, K: *Kpn*I, Xb: *Xba*I, Xh: *Xho*I, RV: *Eco*RV;

Figure 2 shows the nucleotide sequence (SEQ ID No: 1 - entire sequence, SEQ ID No: 2 - coding sequence) of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain 4223, as determined from  $\lambda$ EMBL3 clone 8II, and deduced amino acid sequence (SEQ ID No: 3 - identified GTG start codon, SEQ ID No: 4 - putative ATG start codon shaded) of the about 200 kDa outer membrane protein. A ten-G nucleotide segment of the 5'-UTR is identified by underlining. An ATG start codon for the same sequence but with a nine-G nucleotide segment is identified by a shaded box (see Figure 3);

Figure 3 shows the nucleotide sequence (SEQ ID No: 5 - entire sequence, SEQ ID No: 6 - coding sequence) of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain 4223, as determined from PCR-amplified genomic DNA of strain 4223 and the deduced amino acid sequence (SEQ ID No: 7) of the corresponding about 200 kDa outer membrane protein. A nine-G nucleotide segment of the sequence corresponding to the 10-G nucleotide segment of Figure 2, is



identified by underlining. The GTG start codon identified in Figure 2 is identified by a light box;

Figure 4 shows the nucleotide sequence (SEQ ID No: 8) of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain Q8 and the deduced amino acid sequence (SEQ ID No: 9) of the corresponding about 200 kDa outer membrane protein. A nine-G nucleotide segment is identified by underlining;

Figure 5 shows the nucleotide sequence (SEQ ID No: 10) of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain LES-I and the deduced amino acid sequence (SEQ ID No: 11) of the corresponding about 200 kDa outer membrane protein. A three-G nucleotide segment is identified by underlining;

Figure 6 contains an alignment of the amino acid sequence (in single letter code) of the about 200 kDa proteins of *M. catarrhalis* strain 4223 (SEQ ID No: 7), Q8 (SEQ ID No: 9) and LES-I (SEQ ID No: 11). The alignments of the sequences were made using BLAST and manual methods and are compared to the 4223 sequence. Gaps in the sequence where no corresponding or related amino acid exists are designated by "-" while identical amino acids are designed by ".";

Figure 7 shows the restriction sites of the *M. catarrhalis* strain 4223 derived 200 kDa protein gene as well as the identity of various plasmids containing partial or full length 200 kDa genes;

Figure 8 shows the nucleotide sequence (SEQ ID No: 12) and deduced amino acid sequence (SEQ ID No: 13) of the 5'-truncated gene encoding the M56 200 kDa protein of *M. catarrhalis* strain 4223 contained in pKS348;

Figures 9A and 9B contain a schematic of the procedure for producing plasmid pKS294 expressing the full length 200 kDa protein of *M. catarrhalis* strain 4223;



strain RH408, a spontaneous mutant of strain 4223 which does not produce the 200 kDa protein;

Figure 17 is a partial nucleotide and derived amino acid sequence for the 200 kDa protein of *M. catarrhalis* strain 4223, indicating by arrows the locations of the initial amino acid of the respective three truncations ALA<sup>12</sup>, VAL<sup>19</sup> and GLY<sup>39</sup>;

Figure 18 shows schematic diagrams for two 3' half clones of the 4223 200 kDa gene. Clone pQWE contains a fusion between the 5' end of the 200 kDa gene and the 3' half of the gene. Clone pQWF contains the 3' half of the gene alone. The location of the PCR primers used to generate pQWF is indicated.

Figure 19 is a construction diagram for producing plasmid pQWE expressing a C-terminal portion of the 200 kDa protein of *M. catarrhalis* strain 4223 fused to the N-terminus; and

Figure 20 is a construction diagram for producing plasmid pQWF expressing a C-terminal portion of the 200 kDa protein of *M. catarrhalis* strain 4223.

#### GENERAL DESCRIPTION OF THE INVENTION

In WO 96/34960 (Figure 6), the sequence of a cloned gene from *M. catarrhalis* 4223 encoding an about 200 kDa protein, was described. The open reading frame was predicted to start at a GTG codon. Sequence analysis of 200 kDa genes from additional strains, suggested that a slightly longer open reading frame was more generally found. A re-examination of the sequence from the lambda phage-derived 200 kDa gene confirmed the GTG start codon and an upstream stretch of 10 G nucleotides in a G tract. However, when sequence analysis was performed on 4223 genomic PCR-amplified subclones, the longer open reading frame was found starting from an ATG codon. The G-tract was found to contain 9 G nucleotides in the chromosomal gene. An additional G nucleotide had been inserted during cloning from the phage library. Analysis of the 5' end of the 200 kDa gene from 24 strains

suggests that the number of G nucleotides in the G tract acts as regulator of expression.

Utilizing the techniques described herein, the genes encoding the about 200 kDa protein from *M. catarrhalis* strains Q8 and LES-1 have been cloned and sequenced. Figures 4 and 5 show respectively the nucleotide and derived amino acid sequences. An amino acid sequence comparison of the derived amino acid sequences of the 200 kDa protein from the three strains of *M. catarrhalis* is contained in Figure 6.

Based on the sequence information, a plasmid (pKS294) was constructed that contained the full-length 200 kDa protein gene of strain 4223 starting at the ATG codon, under control of the bacteriophage T7 promoter. However, even a basal level of expression of the full-length gene from the ATG was lethal to *E. coli*. Deletion of a 165 bp 5' fragment of the 200 kDa coding region greatly reduced the toxicity of the resultant protein to *E. coli*. Plasmid pKS348 contains the T7 promoter transcriptionally driving a 200 kDa protein gene which starts at amino acid residue 56. The V56 codon was changed to M56. The M56 r200 kDa protein was produced and the purified protein was used to generate guinea pig antiserum.

In WO 96/34960, a bactericidal antibody assay was described that was used to demonstrate that anti-200 kDa antibody was bactericidal for *M. catarrhalis*. The assay was used herein to demonstrate broad bactericidal antibody activity against heterologous clinical isolates from different geographical locations, by anti-M56 r200 kDa antibody. A single anti-M56 r200 kDa antibody was lytic for 62% of strains tested.

The 200 kDa protein was originally identified as a putative adhesin when its presence was detected in a clumping strain, but not a non-clumping derivative. In order to determine whether it were truly an adhesin, an *in vitro* adherence assay was developed in which the

09361619.072799

inhibition of binding by antibody between *M. catarrhalis* and epithelial cells was measured. Using this assay, anti-M56 r200 kDa antibody was capable of inhibiting adherence of the homologous strain by 48%, demonstrating  
 5 that the 200 kDa protein was an adhesin. When an additional 25 strains of *M. catarrhalis* were assayed, 21 were found to have reduced adherence to epithelial cells in the presence of anti-M56 r200 kDa antibody. 19 of these strains had not been killed by the same antibody.  
 10 Thus, a single anti-M56 r200 kDa antibody was capable of killing or blocking adherence of 91% of the strains tested.

The sequence comparison for the 200 kDa gene from three strains of *M. catarrhalis* showed that the C-  
 15 terminal half of the protein was quite conserved. Strain LES-1 contained an insert of about 300 amino acids. Thus, based upon the C-terminal region, the strains may be divided into two families depending upon whether they contained the insert 4223 and Q8 formed one family while  
 20 LES-1 formed the other. The carboxy terminal halves (3' halves) of the 4223 or LES-1 200 kDa genes were expressed in *E. coli* with good yields and the purified carboxy terminal half of the proteins were used to generate antibodies. When tested in the bactericidal  
 25 antibody assay, these antisera were bactericidal, as seen in Table 1B.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination,  
 30 diagnosis, treatment of *Moraxella* infections, and in the generation of immunological reagents. A further non-limiting discussion of such uses is further presented below.

#### 1. Vaccine Preparation and Use

35 Immunogenic compositions, including those suitable to be used as vaccines, may be prepared from the about 200 kDa outer membrane protein as disclosed herein, as

03361619 072755

well as immunological fragments and fusions thereof, which may be purified from the bacteria or which may be produced recombinantly. The vaccine elicits an immune response in a subject which produces antibodies, including anti-200 kDa outer membrane protein antibodies and antibodies that are opsonizing or bactericidal. Should the vaccinated subject be challenged by *Moraxella* or other bacteria that produce proteins capable of producing antibodies that specifically recognize 200 kDa outer membrane protein, the antibodies bind to and inactivate the bacterium. Furthermore, opsonizing or bactericidal anti-200 kDa outer membrane protein antibodies may also provide protection by alternative mechanisms.

Immunogenic compositions including vaccines may be prepared as injectables, as liquid solutions or emulsions. The about 200 kDa outer membrane protein may be mixed with pharmaceutically acceptable excipients which are compatible with the about 200 kDa outer membrane protein. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously or intramuscularly. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example,

polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate. These compositions can take  
5 the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain about 1 to 95% of the about 200 kDa outer membrane protein. The immunogenic preparations and vaccines are administered in a manner compatible with  
10 the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize antibodies,  
15 and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may  
20 be of the order of micrograms of the about 200 kDa outer membrane protein. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend  
25 on the route of administration and will vary according to the size of the host.

The immunogenic preparations including vaccines may comprise as the immunostimulating material a nucleotide vector comprising at least a portion of the gene  
30 encoding the about 200 kDa protein, or the at least a portion of the gene may be used directly for immunization.

The concentration of the about 200 kDa outer membrane antigen in an immunogenic composition according  
35 to the invention is in general about 1 to 95%. A vaccine which contains antigenic material of only one pathogen is a monovalent vaccine. Vaccines which

00361619 072759

contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants, commonly used as 0.05 to 0.1 percent solution in phosphate-buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered parenterally. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well established and a HBsAg vaccine has been adjuvanted with alum. While the usefulness of alum is

09361615 072393



well established for some applications, it has limitations. For example, alum is ineffective for influenza vaccination and inconsistently elicits a cell mediated immune response.

5       A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's  
10 complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

To efficiently induce humoral immune responses (HIR) and cell-mediated immunity (CMI), immunogens are  
15 typically emulsified in adjuvants. Many adjuvants are toxic, inducing granulomas, acute and chronic inflammations (Freund's complete adjuvant) FCA, cytolysis (saponins and Pluronic polymers) and pyrogenicity, arthritis and anterior uveitis (LPS and  
20 MDP). Although FCA is an excellent adjuvant and widely used in research, it is not licensed for use in human or veterinary vaccines because of its toxicity.

Desirable characteristics of ideal adjuvants include:

- 25 (1) lack of toxicity;
- (2) ability to stimulate a long-lasting immune response;
- (3) simplicity of manufacture and stability in long-term storage;
- 30 (4) ability to elicit both CMI and HIR to antigens administered by various routes, if required;
- (5) synergy with other adjuvants;
- (6) capability of selectively interacting with populations of antigen presenting cells (APC);
- 35 (7) ability to specifically elicit appropriate  $T_H1$  or  $T_H2$  cell-specific immune responses; and

(8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens.

U.S. Patent No. 4,855,283 granted to Lockhoff et al  
5 on August 8, 1989 which is incorporated herein by  
reference thereto, teaches glycolipid analogues  
including N-glycosylamides, N-glycosylureas and N-  
glycosylcarbamates, each of which is substituted in the  
sugar residue by an amino acid, as immuno-modulators or  
10 adjuvants. Thus, Lockhoff et al. (US Patent No.  
4,855,283 and ref. 27) reported that N-glycolipid  
analogs displaying structural similarities to the  
naturally-occurring glycolipids, such as  
glycosphospholipids and glycolipids, are capable  
15 of eliciting strong immune responses in both herpes  
simplex virus vaccine and pseudorabies virus vaccine.  
Some glycolipids have been synthesized from long chain-  
alkylamines and fatty acids that are linked directly  
with the sugars through the anomeric carbon atom, to  
20 mimic the functions of the naturally occurring lipid  
residues.

U.S. Patent No. 4,258,029 granted to Moloney,  
assigned to the assignee hereof and incorporated herein  
by reference thereto, teaches that octadecyl tyrosine  
25 hydrochloride (OTH) functioned as an adjuvant when  
complexed with tetanus toxoid and formalin inactivated  
type I, II and III poliomyelitis virus vaccine. Also,  
Nixon-George et al. (ref. 24), reported that octadecyl  
esters of aromatic amino acids complexed with a  
30 recombinant hepatitis B surface antigen, enhanced the  
host immune responses against hepatitis B virus.

Lipidation of synthetic peptides has also been used  
to increase their immunogenicity. Thus, Wiesmuller  
(ref. 25) describes a peptide with a sequence homologous  
35 to a foot-and-mouth disease viral protein coupled to an  
adjuvant tripalmityl-S-glycerol-cysteinyllserylserine,  
being a synthetic analogue of the N-terminal part of the

0391519 0229

5

## 2. Immunoassays

10

30

35

of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as  
5 PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound about 200 kDa outer membrane protein, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined by subjecting  
10 the immunocomplex to a second antibody having specificity for the first antibody. If the test sample is of human origin, the second antibody is an antibody having specificity for human immunoglobulins and in general IgG. To provide detecting means, the second  
15 antibody may have an associated activity such as an enzymatic activity that will generate, for example, a colour development upon incubating with an appropriate chromogenic substrate. Quantification may then be achieved by measuring the degree of colour generation  
20 using, for example, a visible spectrophotometer.

### **3. Use of Sequences as Hybridization Probes**

The nucleotide sequences of the present invention, comprising the sequence of the about 200 kDa protein gene, now allow for the identification and cloning of  
25 the about 200 kDa protein gene from any species of *Moraxella*.

The nucleotide sequences comprising the sequence of the about 200 kDa protein gene of the present invention are useful for their ability to selectively form duplex  
30 molecules with complementary stretches of other about 200 kDa protein genes. Depending on the application, a variety of hybridization conditions may be employed to achieve varying degrees of selectivity of the probe toward the other genes. For a high degree of  
35 selectivity, relatively stringent conditions are used to form the duplexes, such as low salt and/or high temperature conditions, such as provided by 0.02 M to

0.15 M NaCl at temperatures of between about 50°C to 70°C. For some applications, less stringent hybridization conditions are required such as 0.15 M to 0.9 M salt, at temperatures ranging from between about 5 20°C to 55°C. Hybridization conditions can also be rendered more stringent by the addition of increasing amounts of formamide, to destabilize the hybrid duplex.

Thus, particular hybridization conditions can be readily manipulated, and will generally be a method of 10 choice depending on the desired results. In general, convenient hybridization temperatures in the presence of 50% formamide are: 42°C for a probe which is 95 to 100% homologous to the target fragment, 37°C for 90 to 95% homology and 32°C for 85 to 90% homology.

15 In a clinical diagnostic embodiment, the nucleic acid sequences of the about 200 kDa protein genes of the present invention may be used in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator 20 means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin and digoxigenin-labelling, which are capable of providing a detectable signal. In some diagnostic embodiments, an enzyme tag such as urease, alkaline phosphatase or 25 peroxidase, instead of a radioactive tag may be used. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific 30 hybridization with samples containing about 200 kDa protein gene sequences.

The nucleic acid sequences of the about 200 kDa protein genes of the present invention are useful as hybridization probes in solution hybridizations and in 35 embodiments employing solid-phase procedures. In embodiments involving solid-phase procedures, the test

DNA (or RNA) from samples, such as clinical samples, including exudates, body fluids (e. g., serum, amniotic fluid, middle ear effusion, sputum, bronchoalveolar lavage fluid) or even tissues, is adsorbed or otherwise  
5 affixed to a selected matrix or surface. The fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes comprising the nucleic acid sequences of the about 200 kDa protein  
10 encoding genes or fragments or analogs thereof of the present invention under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required depending on, for example, the G+C contents, type of target nucleic acid, source of nucleic acid, size of hybridization  
15 probe etc. Following washing of the hybridization surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label. It is preferred to select nucleic acid sequence portions which are  
20 conserved among species of *Moraxella*. The selected probe may be at least 18bp and may be in the range of about 30 to 90 bp.

#### **4. Expression of the about 200 kDa Protein Gene**

Plasmid vectors containing replicon and control  
25 sequences which are derived from species compatible with the host cell may be used for the expression of the genes encoding the about 200 kDa protein in expression systems. The vector ordinarily carries a replication site, as well as marking sequences which are capable of  
30 providing phenotypic selection in transformed cells. For example, *E. coli* may be transformed using pBR322 which contains genes for ampicillin and tetracycline resistance and thus provides an easy means for identifying transformed cells. The plasmids or phage,  
35 must also contain, or be modified to contain, promoters which can be used by the host cell for expression of its own proteins.

In addition, phage vectors containing replicon and control sequences that are compatible with the host can be used as a transforming vector in connection with these hosts. For example, the phage in lambda GEM<sup>TM</sup>-11  
5 may be utilized in making recombinant phage vectors which can be used to transform host cells, such as *E. coli* LE392.

Promoters commonly used in recombinant DNA construction include the  $\beta$ -lactamase (penicillinase) and  
10 lactose promoter systems and other microbial promoters, such as the T7 promoter system as described in U.S. Patent No. 4,952,496. Details concerning the nucleotide sequences of promoters are known, enabling a skilled worker to ligate them functionally with genes. The  
15 particular promoter used will generally be a matter of choice depending upon the desired results. Hosts that are appropriate for expression of the about 200 kDa protein genes, fragments, analogs or variants thereof, may include *E. coli*, *Bacillus* species, *Haemophilus*,  
20 fungi, yeast, *Bordetella*, or the baculovirus expression system may be used.

In accordance with this invention, it is preferred to make the protein by recombinant methods, particularly when the naturally occurring about 200 kDa protein as  
25 purified from a culture of a species of *Moraxella* may include trace amounts of toxic materials or other contaminants. This problem can be avoided by using recombinantly produced protein in heterologous systems which can be isolated from the host in a manner to  
30 minimize contaminants in the purified material. Particularly desirable hosts for expression in this regard include Gram positive bacteria which do not have LPS and are, therefore, endotoxin free. Such hosts include species of *Bacillus* and may be particularly  
35 useful for the production of non-pyrogenic about 200 kDa protein, fragments or analogs thereof.

09361619 07299

### BIOLOGICAL DEPOSITS

Certain plasmids that contain portions and full-length of the gene having the open reading frame of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain 4223 that are described and referred to herein have been deposited with the America Type Culture Collection (ATCC) located at 10801 University Blvd., Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and pursuant to 37 CFR 1.808 and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application or relevant precursor applications. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of the invention.

	<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
	pKS47	97,111	April 7, 1995
	pKS5	97,110	April 7, 1995
	pKS9	97,114	April 18, 1995
25	pKS294	203,528	December 17, 1998
	pKS348	203,529	December 17, 1998

### EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are



intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry, and immunology used but not explicitly  
5 described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

Example 1

This Example describes the cloning of a gene  
10 encoding the *M. catarrhalis* 200 kDa outer membrane protein.

A *M. catarrhalis* genomic library in phage lambda EMBL3 was prepared as described in Example 9 of USP 5,808,024 and WO 96/34960 and was screened using guinea  
15 pig anti-200 kDa protein antiserum. A lambda phage clone 8II, which expressed an about 200 kDa protein, was confirmed by immunoblotting of the phage lysate using the about 200 kDa outer membrane-specific antiserum.

Plate lysate cultures of this recombinant phage  
20 were prepared. The DNA was extracted from the plate lysates using a Wizard Lambda Preps DNA Purification System (Promega Corp, Madison, WI) according to the manufacturer's instructions. This phage clone carried a DNA insert of about 16 kb in size (the restriction map  
25 for which is shown in Figure 1). The phage DNA was digested with a mixture of the restriction enzymes *SalI* and *XhoI*, and separated by agarose gel electrophoresis. Two DNA bands, approximately 5 kb and 11 kb in size, respectively, were cut out from the gel and extracted  
30 using a Geneclean kit (BIO 101 Inc., LaJolla, CA) according to the manufacturer's direction.

The smaller 5 kb fragment was ligated into a plasmid vector, pBluescript II SK +/- (Stratagene Cloning Systems, LaJolla, CA), which had been previously  
35 digested with *SalI* and *XhoI*, to produce plasmid pKS5. The larger 11 kb fragment was ligated into a plasmid vector, pSP72 (Promega Corp., Madison, WI), digested

with *SalI* and *XhoI*,, to produce plasmid pKS9. Both ligated plasmids were used to transform *E. coli*, strain DH5 $\alpha$ .

5 The lambda phage DNA was also digested with a mixture of *XhoI* and *KpnI* and the approximately 1.1 kb fragment was isolated after agarose gel separation as described above. This 1.1 kb fragment was ligated into a plasmid vector, pGEM-7Zf(+) (Promega Corp., Madison, WI), to produce plasmid pKS47.

10 Example 2

This Example describes the isolation of chromosomal DNA from *M. catarrhalis* for use in PCR amplification.

562620 649660  
15 *M. catarrhalis* was cultured in 25 ml of BHI broth overnight and centrifuged at 5,000 rpm for 10 min. The bacteria pellet was suspended in 10 ml of 10 mM Tris/HCl (pH 8.0) containing 100 mM EDTA and mixed with RNaseA (final concentration: 100  $\mu$ g/ml) and lysozyme (final concentration: 1 mg/ml). After incubation on ice for 10 min and at room temperature for 50 min, the suspension  
20 was gently mixed with 1 ml of 10% SDS and then heated at 65°C for 20 min. The suspension was mixed with proteinase K (final concentration: 200  $\mu$ g/ml) and incubated at 50°C for 1 h. The suspension was gently mixed with 10 ml chloroform on a nutator for 15 min and  
25 centrifuged at 5,000 rpm for 10 min. The upper phase was slowly removed with a wide-bore pipette and mixed with 10 ml of Tris-saturated phenol and 10 ml of chloroform on a nutator. After centrifugation at 5,000 rpm for 10 min, the upper phase was re-extracted with a mixture of  
30 Tris-saturated phenol and chloroform, again, and then extracted with chloroform, and then twice dialyzed against 1M NaCl at 4°C and twice against TE buffer (pH 8.0) at 4°C.

Example 3

This Example describes subcloning and sequence analysis of fragments of the 200 kDa protein gene from *M. catarrhalis* strain 4223.

5       The procedures used to produce a phage  $\lambda$ EMBL3 clone 8II, and its subclones, pKS5, pKS9 and pKS47, are described in USP 5,808,024 and WO 96/34960. pKS10 was constructed from the  $\lambda$ EMBL3 clone 8II exactly as described for pKS9. pKS59 and pKS63 were constructed by  
10 insertion of a 1.4 kb *Xba*I-*Nco*I fragment of pKS9 into pGEM5Z(+) that had been digested with *Nco*I and *Spe*I. pKS71 was made by insertion of the same 1.4 kb *Xba*I-*Nco*I fragment, isolated from the  $\lambda$ EMBL3 clone 8II into pGEM5Z(+). Sequence analysis confirmed that all three  
15 plasmids, pKS59, pKS63 and pKS71, carried identical DNA fragments. Figure 1 shows partial restriction maps for the plasmids.

      The full sequence of the 200 kDa gene locus from the  $\lambda$ DNA clone was described in USP 5,808,024 and WO  
20 96/34960 and is shown in Figure 2. There is a tract of 10 consecutive G nucleotides between position 623 and 632 in clones derived from the  $\lambda$  library. The first possible start codon is, therefore, located at nucleotides 706 to 708 and is a GTG encoding a valine,  
25 boxed lightly in Figure 2. A series of strains expressing a 200 kDa gene, were identified by immunoblot analysis and the 5' end of their 200 kDa genes was PCR amplified and sequenced. A summary of the findings is shown in Table 5 wherein the expression level of the  
30 gene appeared to be related to the number of G nucleotides in the tract and for those strains within higher expression levels, the start codon was an ATG upstream of the GTG codon identified from the 4223  $\lambda$  clones. Based upon these findings, the sequence of the  
35 5' end of the 200 kDa gene from strain 4223 was re-examined.

Plasmids pKS9 and pKS10 were directly derived from the  $\lambda$  clone. The subclones pKS59 and pKS63 were derived from pKS9 whereas pKS71 contained the same fragment derived directly from the  $\lambda$  clone. All of these plasmids contained 10 G nucleotides in the G tract, as described previously. To determine whether the  $\lambda$  clone contained an extra G nucleotide or the strain itself contained an aberrant gene, PCR amplification of the region was performed from chromosomal DNA preparations and from the  $\lambda$  subclones. The data in Table 3 show that PCR fragments of the  $\lambda$  subclones all contained 10 G nucleotides. The data in Table 4, however, demonstrate that PCR fragments derived directly from chromosomal DNA, contain 9 G nucleotides in the tract. When the single extra G nucleotide is removed from the 200 kDa sequence of strain 4223, the open reading frame is extended in the 5' direction to start from an ATG codon 156 nucleotides earlier, at positions 541 to 543 in Figure 2. This new start codon corresponds to that suggested for the 200 kDa genes sequenced from other strains and summarized in Table 5.

#### Example 4

This Example describes the construction of the full length 200 kDa protein gene from *M. catarrhalis* strain 4223. The construction scheme is shown in Figure 9.

The full-length 200 kDa protein gene was constructed from the new ATG start codon identified by analysis of the chromosomally derived DNA as described in Example 3 and shown in Figure 3. pKS47 was digested with *Xho*I and *Kpn*I and separated by agarose gel electrophoresis. The 1.1 kb fragment was isolated from the gel and inserted into pKS5, which had previously been digested with the same two enzymes and purified to form pKS80. An about 5.8 kb *Pst*I fragment from pKS80 was inserted into pT7-7 vector (ref. 28) that had been digested with *Pst*I and dephosphorylated. The orientation

of the insert was determined by restriction enzyme analysis and pKS122 was chosen for further construction (see Figure 7).

The 5' region of the 200 kDa protein gene was amplified from strain 4223 chromosomal DNA. PCR reactions were performed using Taq Plus or Tsg Plus enzyme (Sangon Ltd., Scarborough, Ont., Canada) and a Perkin Elmer DNA Thermocycler (Perkin Elmer Cetus, Foster City, CA, USA). The lower PCR reaction mixture (50  $\mu$ l) contained 5  $\mu$ l of 10X buffer, 0.4 mM each of four deoxynucleotide triphosphates (Perkin Elmer, Foster City, CA, USA) and 1 to 2  $\mu$ M each of two primers. The upper PCR reaction mixture (50  $\mu$ M) contained 5  $\mu$ l of 10X buffer, 0.5 to 1  $\mu$ l of Taq Plus or Tsg Plus enzyme, and template DNA. The lower and upper mixtures were separated by a layer of AmpliWax PCR Gem50 (Perkin Elmer, Foster City, CA, USA) before heating cycles started. The thermocycling condition employed for the provision of PCR products in the construction of various plasmids are set forth in Table 11 below. The PCR products were purified using a QIAquick PCR purification kit (Qiagen Inc., Mississauga, Ont., Canada). The purified PCR products were sequenced on both strands directly and/or after cloning in appropriate vectors using an Applied Biosystem sequencer.

The 5' primer (designated 5295.KS) was designed, so that it contained the first possible translation start codon, ATG, and its flanking sequences with a mutation to introduce an NdeI site at the ATG. The 3' primer (designated 4260.KS) was based upon the non-coding strand in the region about 1 kb downstream from the ATG start codon. (The nucleic acid sequences and SEQ ID's of the PCR primers utilized herein are identified in Table 10). The PCR-product was digested with NdeI and an approximately 650 bp DNA fragment was gel purified and

inserted into pKS122, which had previously been linearized with *Nde*I and dephosphorylated.

The new construct, designated pKS294 (Figure 8), was confirmed by restriction enzyme analyses and by sequencing of the PCR-amplified DNA and its joint regions. The number of G nucleotides in the G tract was nine, and the open reading frame continued from the newly found translation start codon, ATG, to the remaining portion of 200 kDa protein gene in pKS122. pKS294, therefore, carried the correct, full-length 200 kDa protein gene from *Moraxella catarrhalis* strain 4223. During construction of pKS294, *E. coli* strain DH5 $\alpha$  was used for transformation and plasmid analyses.

#### Example 5

This Example describes the cloning and sequence analysis of genes encoding the 200 kDa protein from additional *M. catarrhalis* clinical isolates.

A panel of *M. catarrhalis* clinical isolates was analysed by immunoblot with guinea pig anti-200 kDa antibody, as described in USP 5,808,024 and WO 96/34960. From these analyses, it was evident that there is size heterogeneity among the 200 kDa proteins from various strains. In order to assess the possible genetic heterogeneity, representative strains were chosen for gene cloning. Strain Q8 is a naturally occurring relatively non-clumping strain that produces a 200 kDa protein of about the same size as the 4223-derived protein. Strain LES-1 produces a larger 200 kDa protein. These strains were also selected based upon bactericidal antibody data as illustrated in Table 1. The 200 kDa genes were cloned from these two strains of *M. catarrhalis* and sequenced.

The nucleotide and derived amino acid sequences of the 200 kDa genes from strains Q8 and LES-1 are shown in Figures 4 and 5 respectively. An alignment of the amino acid sequences with the 4223-derived sequence is shown in Figure 6. As can be seen, the first 68 residues of

the N-terminus are quite conserved, especially between strains 4223 and Q8. In addition, the final 456 residues of the C-terminus are nearly identical among the three strains. The remainder of the sequence has regions of high homology and significant diversity, including an insert of more than 300 residues for strain LES-1.

The N-terminal sequence of the 200 kDa proteins is homologous to the *H. influenzae* Hia and Hsf proteins, as well as other high molecular weight proteins or adhesins, such as AIDA (ref. 33).

The C-terminal region also has some homology to *H. influenzae* Hia and Hsf proteins as do some stretches of internal sequence. There is also some homology in the C-terminal region to UspA (ref. 23). A further indication of the relatedness of this family of proteins, is the finding that guinea pig anti-200 kDa antibody raised to gel-purified native protein was able to recognize recombinant Hia protein by immunoblot. This data has been described in copending United States Patent Application No. 09/268,347 (Hia) filed March 16, 1999, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference.

#### Example 6

This Example shows the expression of the full-length about 200 kDa protein from pKS294.

*E. coli* strain, BL21(DE3)/pLySS was transformed by electroporation with pKS294, prepared as described in Example 4, for the expression study of the full-length 200 kDa protein gene.

The product of the pKS294 construct was found to be toxic to the host *E. coli*. At room temperature, the BL21(DE3)/pLySS transformants grew very slowly on LB-agar plates containing ampicillin (Amp) and chloramphenicol (Cm) and at 37°C, no transformants were detected. When the transformants which grew at room temperature, were cultured overnight at 30°C on BHI agar containing the two antibiotics and glucose, they grew

well, producing colonies with a normal size. However, when these clones were cultured overnight in liquid medium at 30°C, subcultured into broth without glucose, and then induced by addition of IPTG, no recombinant protein was found on Western blot using anti-200 kDa protein serum. When the cells cultured overnight were examined before subculturing, a small quantity of recombinant 200 kDa protein was detected by SDS-PAGE stained with Coomassie Blue and by Western blot, showing that the gene was expressed during the overnight culture.

When *E. coli* strain, DH5 $\alpha$ , which cannot express the gene under the control of a T7 promoter, was transformed with pKS294, the transformants grew well at 37°C both on LB-agar and in LB-broth containing the antibiotics. These results suggest that the gene product is very toxic to host *E. coli*, and that even a basal level of expression of the full-length 200 kDa protein gene from the ATG is lethal to *E. coli*.

*M. catarrhalis* strain LES-1 also produced similar toxicity in *E. coli* when the full length 200 kDa protein was expressed.

#### Example 7

This Example describes the deletion of a short 5'-sequence from the strain 4223 or strain LES-1 200 kDa protein gene and expression of the truncated genes producing a M56 r200 kDa product.

The deletion of a short 5' region from the 4223 200 kDa protein gene is shown in Figure 10 and was performed using a similar approach as described in Example 4. An about 500 bp 5' region of the 200 kDa gene was PCR amplified from strain 4223 using primers 5471.KS and 4257.KS (Table 8) from chromosomal DNA. The 5' primer (designated 5471.KS) was based upon the region surrounding the previously identified GTG downstream start codon. In primer 5471.KS, the flanking regions around the GTG codon were incorporated and the GTG was



mutated to ATG with further mutations used to introduce an *NdeI* site incorporating the new ATG. Using numbering from the full-length 200 kDa protein, the new start codon would be M56 replacing the previous V56 codon. The  
 5 3' primer (designated 4257.KS) was based upon the non-coding strand located about 500 bp downstream from the GTG codon in the 200 kDa protein gene. The PCR-product was digested with *NdeI*, purified using a QIAquick PCR purification kit (Qiagen Inc., Mississauga, Ont.), and  
 10 inserted into *NdeI* digested and dephosphorylated pKS122 to provide pKS348 (see Figure 7). Plasmid pKS348 was confirmed by restriction enzyme analyses and by sequencing of the PCR-amplified DNA piece and its joint regions. The nucleotide sequence (SEQ ID No: 12) and the  
 15 deduced amino acid sequence (SEQ ID No: 13) for the 5'-truncation contained in pKS348 are shown in Figure 8. A similar N-terminal truncated 200 kDa gene from strain LES-1 was generated in the same manner and was designated pKS444.

20 A single colony of *E. coli*, BL21(DE3)/pLysS, (KS358) which carried pKS348, was suspended in 5 ml of BHI broth containing Amp (100  $\mu$ M), Cm (50  $\mu$ M) and 0.4% of glucose, and cultured overnight at 37°C. To study the kinetics of expression, 2.5 ml of the overnight culture  
 25 was added to 250 ml of LB (Luria-Bertani) broth containing Amp (100  $\mu$ M) and Cm (50  $\mu$ M), and grown with shaking at 37°C to  $A_{600} = 0.33$  to 0.36. Another 0.3 ml of the overnight culture was added to 30 mL of LB broth containing Amp (100  $\mu$ M) and Cm (50  $\mu$ M) and grown with  
 30 shaking at 37°C to  $A_{600} = 0.26$  to 0.44. Gene expression from the cultures was induced by addition of IPTG (final concentration: 4 mM). The bacteria were grown and harvested at different time points by centrifugation. The expression of the 200 kDa protein gene in the  
 35 culture was confirmed by SDS-PAGE analysis using Coomassie Blue staining and by Western blot analysis

using guinea pig anti-200 kDa protein serum, as described in USP 5,808,024 and WO 96/34960.

When *E. coli* BL21(DE3)/pLysS was transformed with pKS348, transformants grew well even on LB agar plates and in LB broth containing antibiotics at 37°C. After induction with IPTG, these clones produced a large amount of the N-terminally truncated r200 kDa protein which was clearly seen by SDS-PAGE Coomassie Blue stain, as shown in Figure 12.

The bacterial culture induced at  $A_{600} = 0.26$  produced slightly more truncated r200 kDa protein than the culture induced when the OD reading was 0.44. The largest amount of truncated r200 kDa protein was seen at 3 hr after induction. Similar results were observed for the M56 r200 kDa expression from strain LES-1.

#### Example 8

This Example describes the purification of the M56 r200 kDa proteins from strain 4223 or LES-1, according to the procedure shown in Figure 11.

*E. coli* cell pellets were obtained from 500 ml culture prepared as described in Example 7, by centrifugation and were resuspended in 50 ml of 50 mM Tris-HCl, pH 8.0, containing 0.1 M NaCl, and disrupted by sonication. The sonicate was centrifuged at 20,000 xg for 30 min. and the resultant supernatant (sup1) was discarded. The pellet (ppt1) was extracted, in 50 ml of 50 mM Tris-HCl, pH 8.0 containing 0.5% Triton X-100 and 10 mM EDTA, then centrifuged at 20,000 xg for 30 min. and the supernatant (sup2) was discarded. The pellet (ppt2) was further extracted in 50 ml of 50 mM Tris-HCl, pH 8.0, containing 1% octylglucoside, then centrifuged at 20,000 xg for 30 min. and the supernatant (sup3) was discarded.

The resultant pellet (ppt3) contained the inclusion bodies. The pellet was solubilized in 6 ml of 50 mM Tris-HCl, pH 8.0, containing 6 M guanidine and 5 mM DTT. Twelve ml of 50 mM Tris-HCl, pH 8.0 was added, the

mixture centrifuged at 20,000 xg for 30 min, and the  
 pellet (ppt4) discarded. The supernatant (sup4) was  
 precipitated by adding polyethylene glycol (PEG) 4000 at  
 a final concentration of 5% and incubated at 4°C for 30  
 5 min. The resultant pellet (ppt5) was removed by  
 centrifugation at 20,000 xg for 30 min. The supernatant  
 was then precipitated by  $(\text{NH}_4)_2\text{SO}_4$  at 50% saturation at  
 4°C overnight. After the addition of  $(\text{NH}_4)_2\text{SO}_4$ , the  
 solution underwent phase separation with protein going  
 10 to the upper phase (as judged by the cloudiness of the  
 layer). The upper phase was collected, then subjected to  
 centrifugation at 20,000 xg for 30 min. The resultant  
 pellet was collected and dissolved in 2 ml of 50 mM  
 Tris-HCl, pH 8.0, containing 6 M guanidine and 5 mM DTT.  
 15 The clear solution was purified on a Superdex 200 gel  
 filtration column equilibrated in 50 mM Tris-HCl, pH  
 8.0, containing 2 M guanidine HCl. The fractions were  
 analysed by SDS-PAGE and those containing the purified  
 r200 kDa were pooled. The pooled fraction was  
 20 concentrated 5 to 10 fold using a centriprep 30 and then  
 dialysed overnight at 4°C against PBS, and centrifuged  
 at 20,000 xg for 30 min to clarify.

The protein remained soluble under these conditions  
 and glycerol was added to the M56 r200 kDa preparation  
 25 at a final concentration of 20% for storage at -20°C  
 (Figure 12). The average yield of the purified M56 r200  
 kDa protein is about 10 mg L<sup>-1</sup> culture. The purified  
 protein was used for the immunization of animals, as  
 described below.

30 The procedure of this Example 8 and was repeated  
 for *M. catarrhalis* strain LES-1 and a corresponding r200  
 kDa protein was produced. The N-terminal truncated M56  
 r200 kDa protein from strain LES-1 gave approximately  
 the same recovery of purified protein as described above  
 35 for strain 4223.

Example 9

This Example illustrates the immunogenicity of the M56 r200 kDa protein.

The immunogenicity of M56 r200 kDa, prepared as described in Example 8, was examined using mice and guinea pigs. Groups of five BALB/c mice (Charles River, Quebec) were immunized sub-cutaneously (s.c.) on days 1, 29 and 43 with 0.3, 1.3 and 10  $\mu\text{g}$  of 4223 M56 r200 kDa antigen, prepared as described in Example 8, in the presence  $\text{AlPO}_4$  (1.5 mg per dose). Blood samples were collected on days 0, 14, 28, 42 and 56.

Groups of five guinea pigs (Charles River, Quebec) were immunized i.m. on days 1, 29 and 43 with 25, 50 and 100  $\mu\text{g}$  of 4223 M56 r200 kDa antigen prepared as described in Example 8, in the presence  $\text{AlPO}_4$  (1.5 mg per dose). Blood samples were collected on days 0, 14, 28, 42 and 56.

Anti-M56 r200 kDa IgG titers were determined by antigen-specific enzyme-linked immunosorbent assays (EIAs). Microtiter wells (Nunc-MAXISORP, Nunc, Denmark) were coated with 50  $\mu\text{L}$  of protein antigen  $0.2 \mu\text{g mL}^{-1}$ . The reagents used in the assays were as follows: affinity-purified  $\text{F(ab')}_2$  fragments of goat anti-mouse IgG (Fc-specific) conjugated to horseradish peroxidase (Jackson ImmunoResearch Labs, Mississauga, Ontario); affinity-purified guinea pig anti-IgG antibody ( $1 \mu\text{g mL}^{-1}$ ) (prepared by the inventors); and affinity-purified  $\text{F(ab')}_2$  fragment of goat anti-guinea pig IgG (H+L) antibodies conjugated to horseradish peroxidase (HRP) (Jackson ImmunoResearch Laboratories) used as a reporter. The reactions were developed using tetramethylbenzidine ( $\text{TMB/H}_2\text{O}_2$ , ADI, Mississauga, Ontario) and absorbancies were measured at 450 nm (using 540 nm as a reference wavelength) in a Flow Multiskan MCC microplate reader (ICN Biomedicals, Mississauga, Ontario). The reactive titer of an antiserum was defined

as the reciprocal of the dilution consistently showing a two-fold increase in absorbance over that obtained with the pre-bleed serum sample.

The mice generated dose-dependent anti-M56 r200 kDa antibody responses, as shown in Figure 14. These results clearly show that the protein remained immunogenic after inclusion bodies extraction, solubilization and purification. Only a slight difference in the antibody titers were found for the higher dose range tested in guinea pigs (Figure 15), indicating that the amount of antigen used was nearly at saturation.

#### Example 10

This Example describes the generation of hyper-immune sera against the M56 r200 kDa proteins in rabbits and guinea pigs.

To generate hyper-immune sera against M56 r200 kDa proteins, groups of two rabbits and two guinea pigs (Charles River, Quebec) were immunized intramuscularly (i.m.) on day 1 with a 5 µg dose of purified M56 r200 kDa protein, prepared as described in Example 8, emulsified in complete Freund's adjuvant (CFA). Animals were boosted on days 14 and 29 with the same dose of protein emulsified in incomplete Freund's adjuvant (IFA). Blood samples were taken on day 42 for analyzing the anti-M56 r200 kDa antibody titers and bactericidal activities. Anti-r200 kDa IgG titers were determined by antigen-specific enzyme-linked immunosorbent assays (EIAs), as described in Example 9. The results obtained in the two animals using r200 kDa protein from strains 4223 and LES-1 are illustrated in Table 6.

#### Example 11

This Example describes a bactericidal antibody assay.

The bactericidal antibody activity of guinea pig anti-M56 r200 kDa sera from 4223 or LES-1 protein prepared as described in Example 10 against various

09364519 072799

strains of *M. catarrhalis* was estimated using a viability plating assay. Each test strain of *M. catarrhalis* was cultured overnight in brain heart infusion (BHI) broth (Difco Laboratories, Detroit, MI) at 37°C. The overnight culture was subcultured into 10 ml BHI broth, and grown to an absorbance at 578 nm of 0.5. The number of bacteria at  $A_{578} = 0.5$  changes from strain to strain. Therefore, several ten-fold dilutions of each strain were used in order to achieve 100 to 300 colonies per plate for the preimmune serum group. Bacteria were diluted in Veronal buffered saline (VBS, pH 7.6) containing 140 mM NaCl, 93 mM NaHCO<sub>3</sub>, 2 mM Na-barbiturate, 4 mM barbituric acid, 0.5 mM MgCl<sub>2</sub>·6H<sub>2</sub>O, 0.4 mM CaCl<sub>2</sub>·2H<sub>2</sub>O, and 0.1% bovine serum albumin. Guinea pig anti-M56 r200 kDa serum and pre-immune control serum were heated at 56°C for 30 min. to inactivate endogenous complement. Serum and antiserum were diluted in VBS, and placed on ice.

Twenty-five  $\mu$ l of diluted pre-immune serum or test antiserum were added to the wells of a 96-well Nunclon microtitre plate (Nunc, Roskilde, Denmark). Twenty-five  $\mu$ l of diluted bacterial cells were added to each of the wells. A guinea pig complement (BioWhittaker, Walkerville, MD) was diluted 1:10 in VBS, and 25  $\mu$ l portions were added to each well. The plates were incubated for 60 min, gently shaking at 70 rpm on a rotary platform. Fifty  $\mu$ l of each reaction mixture were plated onto Mueller Hinton agar plates (Becton-Dickinson, Cockeysville, MD). The plates were incubated at 37°C for 24 hours, and then left at room temperature for a further 24 hours. The number of colonies per plate was counted, and average values of colonies per plate were estimated from duplicate pairs.

When pre-immune serum plates were compared with PBS control plates (no serum), pre-immune serum had no bactericidal effect on the homologous strain 4223.

Therefore, it was assumed that the number of colonies per plate on pre-immune serum plates represented 100% viability for each strain and percent bactericidal killing was calculated as follows:

$$100\% - \left[ \frac{\text{average number of colonies per plate in anti-r200 kDa antiserum group} \times 100}{\text{average number of colonies per plate in pre-immune serum group}} \right] \%$$

5        When the bactericidal antibody activity of the 4223 anti-M56 r200 kDa antiserum was examined against the homologous strain (Table 7), 50% killing was observed at a serum dilution between 1/512 and 1/1024, showing that the antiserum raised against M56 r200 kDa protein  
10       possesses bactericidal antibody activity. Next, the bactericidal antibody activity of the antiserum was tested at a dilution of 1/64 against a total of 55 different strains, which were isolated from otitis media patients in various geographical locations (Table 1B).  
15       The antiserum raised against the M56 r200 kDa protein from strain 4223 showed more than 30% bactericidal antibody activity against 38 out of 56 (68%) strains examined. When LES-1 anti-M56 r200 kDa antibody was tested in the bactericidal antibody assay, 36/55 (65%)  
20       strains were killed, including 11 strains that were not killed by the 4223 anti-M56 r200 kDa antibody. Only six strains out of 55 strains examined were not killed by either one of the two antisera. These results indicate that the 200 kDa protein is a very good candidate for  
25       inclusion in an otitis media vaccine.

#### Example 12

This Example describes the inhibition of binding of *M. catarrhalis* strains to either Chang or Hep-2 epithelial cells by 4223 anti-M56 r200 kDa serum.

30       The 200 kDa protein had previously been proposed to be an adhesin on the basis of its apparent absence from a spontaneous non-clumping variant of strain 4223. This strain, obtained by serial passaging of culture supernatants, was designated RH408 and is described in  
35       WO 96/34960. Electron microcopy also suggested that the

200 kDa protein was an adhesin. The sequence homology demonstrated between the *M. catarrhalis* 200 kDa proteins and other high molecular weight adhesins from different organisms, also suggested that it was an adhesin. Based  
5 upon these observations, an assay was developed to try to demonstrate that anti-r200 kDa antibody could block adherence between *M. catarrhalis* and epithelial cells, thus identifying it definitively as an adhesin.

On day 1, 24 well tissue culture plates were seeded  
10 with approximately  $3 \times 10^5$  Chang cells per well, to achieve a confluent monolayer following overnight incubation at 37°C in the presence of 5% CO<sub>2</sub>. *M. catarrhalis* 4223 or Q8 was cultured in 10 ml of BHI broth at 37°C for 18 hr, shaking at 200 rpm.

On day 2, bacterial cultures were pelleted by  
15 centrifugation at 3500 rpm for 10 min, and washed with 10 ml of PBS. After a centrifugation as above, each pellet was resuspended in 2 ml of DMEM supplemented with 10% FBS and 2 mM glutamine. The bacteria cultures were  
20 diluted 1/10 in the supplemented DMEM to OD of approximately 1.8 at 578 nm. Confluent monolayers of Chang cells were washed once with 1 ml of PBS per well, and 0.5 ml of 10% BSA in PBS was added to each well as a blocking agent. Plates were incubated at 37°C for 30 min  
25 and monolayers were washed twice with PBS as above.

A guinea pig anti-4223 M56 r200 kDa antiserum, prepared as described in Example 10 and pooled pre-immune guinea pig sera were heated at 56°C for 30 min to  
30 inactivate endogenous complement. Equal volumes of appropriately diluted antisera and bacteria were mixed, and 200 µl of the mixture were added into each well. Examples of antiserum dilutions tested included 1/4, 1/16 and 1/64. The plate was incubated at 37°C for 1 hr, with gentle shaking. The plate was carefully washed four  
35 times with 1 ml of PBS per well to remove the bacteria. To each well, 100 µl of trypsin were added, and the



plate was incubated at 37°C for 5 min. After inactivation of trypsin by addition of 900 µl Dulbecco's Minimal Essential Medium (DMEM) to each well, the cells were resuspended by pipetting up and down several times.

5        Ten-fold dilutions of resuspended cells were prepared in a new 96-well plate. Fifty µl each of the  $1 \times 10^{-2}$ ,  $1 \times 10^{-3}$ ,  $1 \times 10^{-4}$  and  $1 \times 10^{-5}$  diluted samples were plated on a Mueller-Hinton agar plate. Plates were incubated at 37°C overnight, and then left at room  
10       temperature for a further 24 hours. The number of colonies per plate was counted for the estimation of the total bound bacteria.

Dilution plating was also carried out for each bacterial strain, to estimate bacterial concentrations  
15       and to calculate the total amount of bacteria added to each well. It was assumed that the number of bacteria bound to tissue culture cells in the presence of pre-immune sera represented 100% optimal binding for each assay, and 0% inhibition. Therefore, in order to  
20       calculate the percent inhibition of the antiserum, we used the following formula:

$$\% \text{ inhibition} = 100 - \left[ \frac{\text{total bacteria bound in 4223 anti-r200 kDa antiserum samples} \times 100}{\text{total bacteria bound in pre-immune sera samples}} \right]$$

When the guinea pig 4223 anti-M56 r200 kDa protein serum was examined for the inhibition of binding of strain 4223 to Chang cells (Table 8), inhibition of 98%,  
25       92% and 83% was observed at antiserum dilutions of 1/4, 1/16 and 1/64, respectively. With the heterologous strain Q8, the inhibition of binding to the tissue culture cells was estimated to be 77%, 82% and 55% at antiserum dilutions of 1/4, 1/16 and 1/64, respectively.  
30       The results clearly showed that anti-M56 r200 kDa protein serum inhibited the binding of *M. catarrhalis* to cultured human epithelial cells.

Having demonstrated that 4223 anti-M56 r200 kDa antibody could block adherence of *M. catarrhalis* strains  
35       4223 or Q8 to Chang epithelial cells in a dose-dependent

manner, the studies were extended to other strains. Of particular interest, were those strains that were not killed by anti-M56 r200 kDa antisera in the bactericidal antibody assay. To perform the *in vitro* adherence assay on several strains, a single antibody dilution of 1/16 was used. The data for inhibition of *in vitro* adherence to Hep-2 cells is summarized in Table 9. The procedure for the Hep-2 epithelial cells was identical to the Chang cell procedure described above. The 4223 anti-M56 r200 kDa antibody effectively blocked adherence of the homologous strain by 48%. Strain RH408 does not express the 200 kDa gene and in the assay, antibody inhibited adherence of RH408 to 9%. This would be assumed to be a background level. Of 20 strains tested, 16 were inhibited at rates higher than 9%. Among these strains were 19 strains that had not been killed by the 4223 anti-M56 r200 kDa antibody.

To summarize and as shown in Tables 1, 8 and 9, in our collection of 89 strains of *Moraxella catarrhalis*, 80 express 200 kDa. Of 57 strains tested with 4223 anti-M56 r200 kDa antibody in the bactericidal antibody assay, 39 were killed (58%). An additional 15 strains were inhibited from binding to epithelial cells by the same antibody for a total of 54 strains (95%), against which a single antibody was effective. These data demonstrate the very high potential of r200 kDa proteins as vaccine antigens.

#### Example 13

This Example describes the sequence analysis of the 200 kDa protein gene from *M. catarrhalis* strain RH408, the non-clumping variant of 4223 described in WO 96/34960.

As described in Example 4 and Table 5, it appeared that the number of G nucleotides in the G tract had a regulatory function on the expression of the 200 kDa gene. *M. catarrhalis* strain 4223 and its non-clumping derivative RH408 appeared to differ only in the

expression of the 200 kDa gene. The 200 kDa gene from strain RH408 was subcloned and sequenced and its sequence compared to the parental gene from strain 4223.

Four partially overlapping fragments of the 200 kDa protein gene were PCR amplified from strain *M. catarrhalis* RH408, using primers illustrated in Figure 16 and Table 10, under the conditions set out in Table 11. The combined sequences of the four PCR products covered approximately 6.5 kb including the entire 200 kDa protein gene and its flanking regions. When the sequence of the 6.5 kb fragment was compared with the sequence of the same region from its parent strain 4223, the only difference was the number of G nucleotides in the G tract. As described in Example 4, the correct number of G nucleotides in the G tract was nine. However, the number G nucleotides in the G tract of RH408 was only eight.

This result, along with the analysis of this region in 24 other strains of *M. catarrhalis* (Table 5) strongly suggests that the number of G nucleotides in the G tract controls the expression of the 200 kDa gene in *M. catarrhalis* strains. Similar mechanisms of transcriptional control are found for other bacterial genes, such as the *N. gonorrhoeae Pilc* gene (ref. 32).

#### 25 Example 14

This Example describes the generation of additional N-terminal truncated r200 kDa proteins and expression studies.

As described in Example 6, the full-length r200 kDa protein appeared to be toxic to *E. coli* and could not be expressed under normal induction conditions. The M56 r200 kDa proteins were readily expressed, as described in Example 7, and were subsequently shown to be highly promising vaccine candidates in *in vitro* assays (Examples 11 and 12). The expression of r200 kDa proteins of intermediate length and their properties was studied.

Three additional N-terminal truncated 200 kDa genes were constructed from the 4223 200 kDa gene using the procedures described in Example 7. The sites of truncation were chosen based upon and are illustrated in Figure 17. The arrows in Figure 17 indicate the sites of truncation, namely ALA<sup>12</sup>, VAL<sup>19</sup> and GLY<sup>39</sup>, each modified to MET. A 5' fragment up to an internal site was PCR amplified using primers illustrated in Table 8. For the ALA<sup>12</sup> truncation, the primers were 5' 6242.ks and 3' 4257.ks, for the VAL<sup>19</sup> truncation, the primers were 5' 6243.ks and 3' 4257.ks and for the GLY<sup>39</sup> truncation, the primers were 5' 6244.ks and 3' 4257.ks (Table 10). The amplification conditions were the same as those used for pKS348 (Table 11). The PCR products were restricted with *Nde*I and ligated into the *Nde*I sites of pKS348 for expression. While some expression of r200 kDa was obtained with each of the N-terminal truncations, the level did not approach the levels obtained using pKS348.

#### Example 15

This Example illustrates the construction of plasmids pQWE and pQWF expressing C-terminal fragments of the 200 kDa gene.

As shown in the amino acid comparison of Figure 6, the carboxy half of the 200 kDa protein is quite conserved, the main difference being a large approximately 300 amino acid residue insert in strain LES-1. Since so much cross-reactivity for the anti-M56 r200 kDa antisera had been observed, the conserved carboxy half of the protein was expressed.

Plasmid pKS348 prepared as described in Example 7 was digested with restriction enzymes, *Nde* I and *Nae* I, producing four fragments. The approximately 5.8 kb *Nde* I/*Nae* I fragment containing the T7 promoter, ampicillin antibiotic resistance marker and the 3' end of the 200 kDa gene was agarose gel purified. The approximately 480 bp *Nde* I/*Nde* I fragment containing the 5' end of the 200 kDa gene was also gel purified. This approximately

480 bp fragment was then restriction digested with the enzymes *Nla* IV and *Pst* I and the *Nde* I/*Nla* IV fragment ligated to the previously isolated 5.8 kb *Nde* I/*Nae* I fragment to produce plasmid pQWE, as illustrated in Figure 19. This plasmid construct contained a 200 kDa gene with the *Nla* IV to *Nae* I fragment deleted. This plasmid construct resulted, upon expression as described in Example 7, in a fusion 200 kDa protein containing a very short piece of the 5' end and the 3' half of the 200 kDa protein.

An approximately 500 bp fragment around the *Eco* RI site in the 200 kDa gene from plasmid pKS348 was PCR amplified utilizing a 5' oligonucleotide, 6425.KS and a 3' oligonucleotide 4272.KS (Table 10) using the conditions outlined in Table 11. The 5' oligonucleotide was synthesized with an ATG translational start codon and a *Nde* I restriction site, while the 3' oligonucleotide was synthesized with an *Eco* RI site. The approximately 500 bp PCR fragment was the restriction digested with the enzymes *Nde* I and *Eco* RI. Plasmid pQWE, prepared as described above, was restriction digested with *Nde* I and *Eco* RI as illustrated in Figure 20, and this larger fragment agarose gel purified. The *Nde* I/*Eco* RI PCR fragment was then ligated into the isolated *Nde* I/*Eco* RI fragment from pQWE, to produce plasmid pQWF. This construct expresses a 5' truncated 200 kDa protein, having only the 3' half of this protein from the region about 40 bp upstream of the *Nde* I site to the 3' end.

The constructs pQWE and pQWF, prepared as described above and as illustrated in Figures 19 and 20, were expressed in *E. coli* strain BL21(DE3)/pLysS as described in Example 7. The C-terminal half proteins were obtained at levels of expression approximately twice those achieved using pKS348. Corresponding constructs were prepared from strain LES-1 and produced comparable results.

Antiserum was raised against the C-terminal half of 200 kDa protein produced from construct pQWE following the procedure of Example 10 and was employed in the bactericidal assay described in Example 11. As may be  
5 seen in Table 1B the antiserum showed more than 30% of killing against 30 out of 31 strains which were killed by the bactericidal assay using antiserum raised against the product from pKS348.

#### SUMMARY OF THE DISCLOSURE

10 In summary of this disclosure, nucleotide sequences encoding an about 200 kDa outer membrane protein from several strains of *Moraxella catarrhalis* are described along with recombinant production of such protein. Modifications are possible within the scope of this  
15 invention.

0361619 073390

Table 1A

Examination of 200 kDa protein in *M. catarrhalis* strains

STRAIN	ANATOMICAL ORIGIN	SOURCE	EXPRESSION OF 200 kDa PROTEIN
4223	MID. EAR FLUID	T.F. MURPHY	+++
RH408	MUTANT OF 4223		-
3	SPUTUM	"	-
56	SPUTUM	"	-
135	MID. EAR FLUID	"	+++
585	BACTEREMIA	"	+
5191	MID. EAR FLUID	"	+++
8185	NASOPHARYNX	"	+++
M2	SPUTUM	"	+++
M5	SPUTUM	"	-
ATCC25240		ATCC	-
H-04	OTITIS	G.D. CAMPBELL	+++
H-12	"	"	-
PO-34	"	"	+++
PO-51	"	"	+++
E-07	"	"	+++
E-22	"	"	+++
E-23	"	"	+++
E-24	"	"	+++
M-02	"	"	+++
M-20	"	"	+++
M-29	"	"	+++
M-32	"	"	+++
M-35	"	"	+++
Q-2	EXPECTORATION	M.G. BERGERON	+
Q-6	"	"	-
Q-8	"	"	+++
Q-9	"	"	-
Q-10	"	"	+++
Q-11	"	"	+++
Q-12	"	"	-
R-1	BRONCHIAL SECRETIONS	"	+
R-2	"	"	-
R-4	OTITIS	"	+++
R-5	"	"	+++
R-6	"	"	+++
R-7	"	"	+++
N-209	BLOOD	"	+++
VH-1	OTITIS	V. HOWIE	+++
VH-2	"	"	+++
VH-3	"	"	+++
VH-4	"	"	+++
VH-5	"	"	+++
VH-6	"	"	+++
VH-7	"	"	+++

VH-8	"	"	+++
VH-9	"	"	+++
VH-10	"	"	+++
VH-11	"	"	+++
VH-12	"	"	+++
VH-13	"	"	+++
VH-14	"	"	+++
VH-15	"	"	+++
VH-16	"	"	+++
VH-17	"	"	+++
VH-18	"	"	+++
VH-19	"	"	+++
VH-20	"	"	+++
VH-23	"	"	+++
VH-24	"	"	+++
VH-25	"	"	+++
VH-26	"	"	+++
VH-27	"	"	+++
VH-28	"	"	+++
VH-29	"	"	+++
VH-30	"	"	+++
LES1	OTITIS	L.S. STENFORS	+++
LES2	"	"	+++
LES4	"	"	+++
LES5	"	"	+++
LES6	"	"	+++
LES7	"	"	+++
LES8	"	"	+++
LES9	"	"	+++
LES10	"	"	+++
LES11	"	"	+++
LES12	"	"	+++
LES13	"	"	+++
LES16	"	"	+++
LES17	"	"	+++
LES21	"	"	+++
30607	OTITIS	C.W. FORD	+++
CJ1	"	C. JOHNSON	+++
CJ3	"	"	+++
CJ4	"	"	+++
CJ7	"	"	+++
CJ8	"	"	+++
CJ9	"	"	+++
CJ11	"	"	+++

Bacteria were lysed and proteins were separated on SDS-PAGE gels. The expression of 200 kDa protein was examined by Coomassie Blue staining and by Western blot using anti-200 kDa protein guinea pig serum.



TABLE 1B

Bactericidal assay results against *Moraxella catarrhalis* using antisera raised against recombinant M56 200 kDa protein from strains 4223 and LES1, and recombinant C-terminal half of 200 kDa protein from strain 4223.

STRAIN	Killed by anti-M56 200 kDa from 4223	Killed by anti-C-terminal half of 200 kDa from 4223	Killed by anti-M56 200 kDa from LES1
4223	++	++	-
135	++	++	++
H-04	++	++	?
H-12*	-	NT	-
PO-34	-	NT	++
PO-51	-	NT	-
E-07	-	NT	++
E-22	++	++	-
E-24	-	NT	-
M-02	++	++	++
M-20	++	+	-
M-29	++	++	++
M-32	++	++	++
M-35	++	++	++
R4	-	NT	++
R5	++	++	++
R6	++	+	+
R7	++	NT	?
Q8**	++	+	NT
VH-1	++	NT	++
VH-2	++	NT	++
VH-4	-	NT	++
VH-5	++	++	-
VH-7	++	+	?
VH-8	++	++	++
VH-9	-	NT	++
VH-10	++	++	++
VH-13	-	NT	-
VH-15	++	++	++
VH-17	-	NT	-
VH-19	++	++	++
VH-20	+	+	++
VH-23	+	NT	++
VH-24	++	++	-
VH-25	-	NT	++
VH-26	-	NT	++
VH-27	-	NT	-
VH-28	+	NT	-
VH-29	++	++	++
VH-30	-	NT	++
LES1	-	NT	++
LES2	++	++	+
LES4	+	NT	++
LES5	-	NT	++
LES9	++	++	++
LES11	+	+	+
LES12	-	NT	?
LES13	-	NT	++
LES16	+	++	++
LES17	++	++	-
LES21	++	++	-
30607	+	NT	++

03649560

CJ1	++	++	++
CJ3	++	-	++
CJ4	++	++	++
CJ7	++	++	++
CJ8	++	++	?

\* This strain does not produce 200 kDa protein.

\*\* This is the only non-otitis media strain (isolated from expectorate) in this Table.

++: Killed more than 60% (>60%), +: killed between 30% and 60%,  
 -: killed 30% or less, NT: not tested, ?: the results not tested.

093454 079960

TABLE 2

The number of G nucleotides in the G tract of the 200 kDa protein gene determined by sequencing of subcloned genes from a  $\lambda$ EMBL3 clone.

Plasmid*	Number of G's
pKS10	10
pKS59	10
PKS63	10
PKS71	10

\* pKS10 and pKS71 carried a DNA insert directly subcloned from a  $\lambda$ EMBL3 clone. pKS59 and pKS63 carried a subcloned DNA fragment, pKS9, which was a subclone from an  $\lambda$ EMBL3 clone. pKS59, pKS63 and pKS71 carried identical DNA inserts.

TABLE 3

The number of G nucleotides in the G tract of the 200 kDa protein gene amplified by PCR from subcloned genes

Primers	Template DNA	Number of G's
4211 and 4213	pKS9	10
4211 and 4213	pKS10	10
4211 and 4213	pKS71	10

\* pKS9, pKS10 and pKS71, which contain a 5' fragment of the 200 kDa protein gene, were independently subcloned from the  $\lambda$ EMBL3 clone.

TABLE 4

The number of G nucleotides in the G tract of the 200 kDa protein gene amplified by PCR from chromosomal DNA of strain 4223

Primers	Template	Number of G
4211 and 4166	4223B	9
4211 and 4213	4223B	9
4211 and 4213	4223R	9

\* The template chromosomal DNAs, 4223B and 4223R, were independently prepared from *M. catarrhalis* strain 4223.

TABLE 5

The number of G nucleotides in the G tract in different strains of *M. catarrhalis*

Expression	Number of G	Number of strains examined	Possible start codon
+++	3	1	ATG
+++	6	7	ATG
+++	9	7	ATG
+	10	3	GTG
-	7	3	GTG
-	8	2	GTG
-	9	1*	ATG
Total		24	

\* The 200 kDa protein gene of this strain was prematurely terminated by a stop codon.

TABLE 6

Anti-M56 r200 kDa antibody titers in guinea pig and rabbit sera

ANTISERA	ANTIBODY TITERS	
	Against M56 r200 kDa (4223)	Against M56 r200 kDa (LES-1)
Gp anti-r200 kDa (4223)	204,800 409,600	102,400 409,600
Gp anti-r200 kDa (LES1)	204,800 102,400	1,638,400 1,638,400
Rb anti-r200 kDa (4223)	102,400 102,400	102,400 102,400
Rb anti-r200 kDa (LES1)	25,600 102,400	204,800 409,600

63 40 64 94 96 60

Killing of *M. catarrhalis* strain 4223 by the bactericidal antibody activity of guinea pig anti-M56 r200 kDa protein serum

\* The guinea pig antiserum was raised against M56 r200 kDa protein from strain 4223, and the bactericidal antibody activity of the serum at various dilutions were examined against the strain 4223.

Inhibition of the binding of *M. catarrhalis* strains to Chang cells by guinea pig anti-M56 r200 kDa protein serum

\* The guinea pig antiserum was raised against M56 r200 kDa protein from strain 4223.

TABLE 9

Inhibition of *in vitro* adherence of *Moraxella catarrhalis* to Hep-2 cells by antiserum raised against recombinant 200 kDa protein from strain 4223

STRAIN	Inhibition
4223*	+++
PO-34	+++
PO-51	++
E-07	++
R4	++
VH-4	++
VH-9	-
VH-13	+
VH-17	++
VH-23	++
VH-25	++
VH-26	+++
VH-27	+
VH-28	+++
LES1	++
LES4	-
LES12	-
LES13	-
30607	+

+++ : Inhibition was 30% or higher, ++ : Inhibition was 20% to 30%, + : Inhibition was 15% to 20%, - : Inhibition was lower than 15%.

\*: This strain is the positive control, and the only strain in this Table, which was killed by the bactericidal activity of anti-recombinant 200 kDa protein serum.

TABLE 10

Nucleotide sequences of primers used for PCR  
amplifications

PRIMER	NUCLEOTIDE SEQUENCE	SEQ ID No:
4211.KS	GATGCCTACGAGTTGATTTGGGT	14
4213.KS	GAGCGTTGCACCGATCACGAGGA	15
4166.KS	CACTAGCCTTTACATCACCACCGATG	16
5295.KS	AAGGTAAACCCATATGAATCACATCTATAAAGTCA	17
4260.KS	GCTTCTAGCTGTGCCACATTGA	18
5471.KS	CGCTCGCTGTCCATATGATCGGTGCAACGCTCA	19
4257.KS	GACCCTGTGCATATGACATGGCT	20
4254.KS	CCTTGGCATCAATCGTGGCACA	21
4278.KS	TTACCTGCATCAATGCCATTGTCT	22
4329.KS	CTGAGGTGAATACAACACTACA	23
4272.KS	CATCAGAGGTCTTTGAGGTGTCAT	24
4118.KS	CATCACCGTGGGTCAAAGAACGCA	25
4267.KS	GATGTCGGCAATGTTTACCTGA	26
4269.KS	CCACATTGACCAGTACTGGCACAGGTGCTA	27
4981.KS	ACCTATGATCAATGGCGATTTGGT	28
6425.KS	AAAGATCATATGGTTACCTTTGGCATTAAC	29
6242	GTCATCTTTCATATGGCCACAGGCACA	30
6243	ACATTTATGCATATGGCAGAGTACGCCA	31
6244	GCTACAGGGCATATGGGCAGTGTATGCACT	32

66220"6494966



TABLE 11

PCR Cycle Conditions

1. For the construction of pKS294, oligonucleotides 5295 and 4260 and of pKS348, oligonucleotides 5471 and 4257:  
95°C for 2 min → 95°C for 1 min, 60°C for 30 sec, 72°C for 1 min (10 cycles) → 95°C for 1 min, 62°C for 30 sec, 72°C for 1 min (20 cycles with extension of 1 sec/cycle) → 72°C for 10 min → 4°C.
2. For the construction of pQWF, oligonucleotides 6425 and 4272:  
95°C for 2 min → 95°C for 1 min, 60°C for 30 sec, 72°C for 1 min (10 cycles) → 95°C for 1 min, 60°C for 30 sec, 72°C for 1 min (20 cycles with extension of 1 sec/cycle) → 72°C for 10 min → 4°C.
3. For the amplification of 700 bp fragment for sequencing the G-nucleotide tract from different strains, oligonucleotides 4211 and 4166.  
95°C for 2 min → 95°C for 1 min, 60°C for 1 min, 72°C for 2 min (10 cycles) → 95°C for 1 min, 60°C for 1 min, 72°C for 2 min (20 cycles with extension of 5 sec/cycle) → 72°C for 10 min → 4°C.
4. For sequencing 200 kDa protein from *M. catarrhalis* strain RH408,  
(a) oligonucleotides 4254 and 4278; 4118 and 4267; and 4269 and 4981:  
95°C for 2 min → 95°C for 1 min, 62°C for 30 sec, 72°C for 1 min (10 cycles) → 95°C for 1 min, 62°C for 30 sec, 72°C for 1 min (20 cycles with extension of 2 sec/cycle) → 72°C for 10 min → 4°C.  
(b) oligonucleotides 4329 and 4272  
95°C for 2 min → 95°C for 1 min, 58°C for 30 sec, 72°C for 1 min 30 sec (10 cycles) → 95°C for 1 min, 58°C for 30 sec, 72°C for 1 min 30 sec (20 cycles with extension of 1 sec/cycle) → 72°C for 10 min → 4°C.

# REFERENCES

1. Van Hare, G.F., P.A. Shurin, C.D. Marchant, N.A. Cartelli, C.E. Johnson, D. Fulton, S. Carlin, and C.H. Kim. Acute otitis media caused by *Branhamella catarrhalis*: biology and therapy. (1987) Rev. Infect. Dis. 9:16-27.
2. Chapman, A.J., D.M. Musher, S. Jonsson, J.E. Clarridge, and R.J. Wallace. 1985. Development of bactericidal antibody during *Branhamella catarrhalis* infection. J. Infect. Dis. 151:878-882.
3. Hager, H., A. Verghese, S. Alvarez, and S.L. Berk. 1987. *Branhamella catarrhalis* respiratory infections. Rev. Infect. Dis. 9:1140-1149.
4. McLeod, D.T., F. Ahmad, M.J. Croughan, and M.A. Calder. 1986. Bronchopulmonary infection due to *M. catarrhalis*. Clinical features and therapeutic response. Drugs 31(Suppl.3):109-112.
5. Nicotra, B., M. Rivera, J.I. Luman, and R.J. Wallace. 1986. *Branhamella catarrhalis* as a lower respiratory tract pathogen in patients with chronic lung disease. Arch. Intern. Med. 146:890-893.
6. Ninane, G., J. Joly, and M. Kraytman. 1978. Bronchopulmonary infection due to *Branhamella catarrhalis* : 11 cases assessed by transtracheal puncture. Br. Med. Jr. 1:276-278.
7. Srinivasan, G., M.J. Raff, W.C. Templeton, S.J. Givens, R.C. Graves, and J.C. Mel. 1981. *Branhamella catarrhalis* pneumonia. Report of two cases and review of the literature. Am. Rev. Respir. Dis. 123:553-555.
8. West, M., S.L. Berk, and J.K. Smith. 1982. *Branhamella catarrhalis* pneumonia. South. Med. J. 75:1021-1023.
9. Brorson, J-E., A. Axelsson, and S.E. Holm. 1976. Studies on *Branhamella catarrhalis* (*Neisseria catarrhalis*) with special reference to maxillary sinusitis. Scan. J. Infect. Dis. 8:151-155.
10. Evans, F.O., Jr., J.B. Sydnor, W.E.C. Moore, G.R. Moore, J.L. Manwaring, A.H. Brill, R.T. Jackson, S. Hanna, J.S. Skaar, L.V. Holdeman, G.S. Fitz-Hugh, M.A. Sande, and J.M. Gwaltney, Jr. 1975. Sinusitis of the maxillary antrum. N. Engl. J. Med. 293:735-739.

00345 029960

11. Tinkelman, D.G., and H.J. Silk. 1989. Clinical and bacteriologic features of chronic sinusitis in children. *Am.J.Dis.Child.* 143:938-942.
12. Wald, E.R., C. Byers, N.Guerra, M.Casselbrant, and D. Beste. 1989. Subacute sinusitis in children. *J.Pediatr.* 115:28-32.
13. Wald, E.R., G.J. Milmo, A. Bowen, J.Ledesma-Medina, N. Salamon, and C.D.Bluestone. 1981. Acute maxillary sinusitis in children. *N.Engl.J.Med.* 304:749-754.
14. Christensen, J.J., and B. Bruun. 1985. Bacteremia caused by a beta-lactamase producing strain of *Branhamella catarrhalis*. *Acta.Pathol. Microbiol. Immunol. Scand. Sect.B* 93:273-275.
15. Craig, D.B., and P.A. Wehrle. 1983. *Branhamella catarrhalis* septic arthritis. *J. Rheumatol.* 10:985-986.
16. Gray, L.D., R.E. Van Scoy, J.P. Anhalt, and P.K.W. Yu. 1989. Wound infection caused by *Branhamella catarrhalis*. *J.Clin.Microbiol.* 27:818-820.
17. Guthrie, R., K. Bakenhaster, R.Nelson, and R. Woskobnick. 1988. *Branhamella catarrhalis* sepsis: a case report and review of the literature. *J.Infect.Dis.* 158:907-908.
18. Hiroshi, S., E.J. Anaissie, N.Khardori, and G.P. Bodey. 1988. *Branhamella catarrhalis* septicemia in patients with leukemia. *Cancer* 61:2315-2317.
19. O'Neill, J.H., and P.W. Mathieson. 1987. Meningitis due to *Branhamella catarrhalis*. *Aust. N.Z. J. Med.* 17:241-242.
20. Murphy, T.F. 1989. The surface of *Branhamella catarrhalis*: a systematic approach to the surface antigens of an emerging pathogen. *Pediatr. Infect. Dis. J.* 8:S75-S77.
21. Klingman, K.L., and T.F. Murphy. 1994. Purification and characterization of a high-molecular-weight outer membrane protein of *Moraxella* (*Branhamella*) *catarrhalis*. *Infect. Immun.* 62:1150-1155.
22. Helminen, M.E., I. Maciver, J.L. Latimer, J. Klesney-Tait, L.D. Cope, M. Paris, G.H. McCracken, Jr., and E.J. Hansen. 1994. A large, antigenically conserved protein on the surface of *Moraxella catarrhalis* is a target for protective antibodies. *J. Infect. Dis.* 170:867-872.

23. Aebi, C., I. Maciver, J.L. Latimer, L.D. Cope, M.K. Stevens, S.E. Thomas, G.H. McCracken, Jr., and E.J. Hansen. 1997. A protective epitope of *Moraxella catarrhalis* is encoded by two different genes. *Infect. Immun.* 65:4367-4377.
24. Nixon-George et al. The adjuvant effect of Stearyl Tyrosine on a recombinant subunit hepatitis B surface antigen. (1990), *J. Immunology* 144:4798-4802.
25. Wiesmuller (1989), Novel low-molecular weight synthetis vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator, *Vaccine* 8:29-33.
26. Deres et al. (1989), *Nature* 342:561.
27. Lockhoff, O. Glycolipids as Immmunomodulators: Synthesis and Properties. 1991. *Chem. Int. Ed. Engl.* 30:1611-1620.
28. Taber and Richardson, 1985, *PNAS* 82(4):1074-8.
29. Fitzgerald et al, *FEMS Immunol. & Med. Microbiol.* 18:209-216, 1997.
30. Fitzgerald et al, *FEMS Immunol. & Med Microbiol.* 23:57-66, 1999.
31. Kyd et al, *J. Med. Microbiology*, 47:159-168, 1998.
32. Johson et al, 1997, *EMBO J.* 10(2):477-488.
33. Benz, I. and Schmidt, M.A., 1992. *Mol Microbiol* 6:1539-1546.

090619 075600

CLAIMS

What we claim is:

1. An isolated and purified nucleic acid molecule having a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence set forth in Figure 3, 4 or 5 (SEQ ID Nos: 5, 6, 8, 9, 11, 12) for *Moraxella catarrhalis* strains 4223, Q8 and LES-1 respectively or the complementary sequence thereto,
- (b) a nucleotide sequence encoding an about 200 kDa outer membrane protein of a strain of *Moraxella catarrhalis* and having the derived amino acid sequence shown in Figures 3, 4 or 5 (SEQ ID Nos: 7, 10, 13) for *Moraxella catarrhalis* strains 4223, Q8 and LES-1 respectively, and
- (c) a nucleotide sequence encoding an about 200 kDa outer membrane protein of another strain of *Moraxella catarrhalis* which is characterized by a tract of consecutive G nucleotides which is 3 or a multiple thereof in length, an ATG start codon about 80 to 90 bp upstream of said tract and said tract being located between about amino acids 25 and 35 encoded by the nucleotide sequence.

2. The nucleic acid molecule of claim 1 wherein said another strain of *Moraxella catarrhalis* in (c) is a strain as identified in Table 1A other than strains 4223, Q8 and LES-1 and expressing an about 200 kDa protein.

3. An isolated and purified nucleic acid molecule having a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence set forth in Figure 8 (SEQ ID No: 12) for a 5'-truncation of the gene encoding an about 200 kDa outer membrane protein of *Moraxella catarrhalis* strain 4223,

09361619 072799

- (b) a nucleotide sequence encoding the derived amino acid sequence set forth in Figure 9 (SEQ ID No: 13) for a N-terminal truncation of an about 200 kDa outer membrane protein of *Moraxella catarrhalis* strain 4223, and
- (c) a nucleotide sequence encoding a 5'-truncation of a gene encoding an about 200 kDa outer membrane protein of another strain of *Moraxella catarrhalis* and being capable of expressing the corresponding N-terminally truncated about 200 kDa outer membrane protein from *E. coli*.
4. An isolated and purified nucleic acid molecule which is a contiguous *Nde* I - *Pst* I fragment of SEQ ID No: 5.
5. A vector for transforming a host comprising a nucleic acid molecule as claimed in any one of claims 1 to 4.
6. The vector of claim 5 which is a plasmid vector.
7. The vector of claim 5 which has the identifying characteristics of pKS348 (ATCC 203529) shown in Figure 10 or pKS294 (ATCC 203528) shown in Figure 9.
8. The vector of claim 5 which has the identifying characteristic of pQWE shown in Figure 19 or pQWF shown in Figure 20.
9. A host cell transformed by a vector as claimed in claim 5 and expressing an about 200 kDa protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof.
10. The host cell of claim 9 which is *E. coli*.
11. A recombinant about 200 kDa outer membrane protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof producible by the transformed host of claim 9.
12. The recombinant protein of claim 11 producible in inclusion bodies.

09364645 072299

13. An immunogenic composition comprising the recombinant about 200 kDa outer membrane protein or an approximately C-terminal half thereof of claim 11.
14. The immunogenic composition of claim 13 formulated as a vaccine for *in vivo* administration to protect against disease caused by *Moraxella catarrhalis*.
15. The immunogenic composition of claim 13 in combination with a targeting molecule for delivery to specific cells of the immune system or to mucosal surfaces.
16. The immunogenic composition of claim 13 formulated as a microparticle, capsule or liposome preparation.
17. The immunogenic composition of claim 13 further comprising an adjuvant.
18. A method of inducing protection against disease caused by *Moraxella catarrhalis*, comprising administering to a susceptible host an effective amount of the immunogenic composition of claim 13.
19. The method of claim 18 wherein said susceptible host is a human.
20. A method for the production of an about 200 kDa outer membrane protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof, which comprises:
- transforming a host with a vector as claimed in claim 5,
  - growing the host cell to express the encoded about 200 kDa protein or an approximately C-terminal half thereof, and
  - isolating and purifying the expressed about 200 kDa protein or an approximately C-terminal half thereof.
21. The method of claim 20 wherein the host cell is *E. coli*.
22. The method of claim 20 wherein said encoded about 200 kDa protein is expressed in inclusion bodies.

23. The method of claim 22 wherein said isolation and purification of the expressed about 200 kDa protein is effected by:

disrupting the grown transformed cells to produce a supernatant and the inclusion bodies,

solubilizing the inclusion bodies to produce a solution of the recombinant about 200 kDa protein,

chromatographically purifying the solution of recombinant about 200 kDa protein free from contaminating proteins, and

isolating the purified recombinant about 200 kDa protein.

093645 079960



An isolated and purified outer membrane protein of a *Moraxella* strain, particularly *M. catarrhalis*, having a molecular mass of about 200 kDa, is provided by 5 recombinant means. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for *in vivo* administration to a host to confer protection against 10 disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.



Figure 2. *M. catarrhalis* strain 4223  $\lambda$ EMBL3 clone 200kDa gene

```

ccatggatat gggcaggtgt gctcgccctgc cgtatgatgg cgatgacacc ccatttgccc 60
catatctgta cgatttgaca tgtgatatga tttaacatgt gacatgattt aacattgttt 120
aatactgttg ccatcattac cataatttag taacgcattt agtaacgcat ttgtaaaaat 180
cattgcgccc ctttatgtgt atcatatgaa tagaatatta tgattgtatc tgattattgt 240
atcagaatgg tgatgctata tgatgatgcc tacgagttga tttgggttaa tcaactctatg 300
atttgatata ttttgaaact aatctattga cttaaatacac catatgggta taatttagca 360
taatggtagg ctttttgtaa aaatcacatc gcaatattgt tctactgtta ctaccatgct 420
tgaatgacga tcccaatacac cagattcatt caagtgatgt gtttgatata gcaccattta 480
ccctaattat ttcaatcaaa tgcctatgtc agcatgtatc atttttttta ggtaaaccac 540
catgaatcac atctataaag tcatctttta caaagccaca ggcacattta tggcagtggc 600
agagtacgcc aaatcccaca gcacggggggg ggggtagctg tgctacaggg caagttggca 660
gtgtatgcac tctgagcttt gcccgatttg ccgcgctcgc tgtcctc gtg atc ggt 716
                               Val Ile Gly
                               1

gca acg ctc agt ggc agt gct tat gct caa aaa aaa gat acc aaa cat 764
Ala Thr Leu Ser Gly Ser Ala Tyr Ala Gln Lys Lys Asp Thr Lys His
      5                10                15

atc gca att ggt gaa caa aac cag cca aga cgc tca ggc act gcc aag 812
Ile Ala Ile Gly Glu Gln Asn Gln Pro Arg Arg Ser Gly Thr Ala Lys
      20                25                30                35

gcg gac ggt gat cga gcc att gct att ggt gaa aat gct aac gca cag 860
Ala Asp Gly Asp Arg Ala Ile Ala Ile Gly Glu Asn Ala Asn Ala Gln
                        40                45                50

ggc ggt caa gcc atc gcc atc ggt agt agt aat aaa act gtc aat gga 908
Gly Gly Gln Ala Ile Ala Ile Gly Ser Ser Asn Lys Thr Val Asn Gly
                        55                60                65

agc agt ttg gat aag ata ggt acc gat gct acg ggt caa gag tcc atc 956
Ser Ser Leu Asp Lys Ile Gly Thr Asp Ala Thr Gly Gln Glu Ser Ile
      70                75                80

gcc atc ggt ggt gat gta aag gct agt ggt gat gcc tcg att gcc atc 1004
Ala Ile Gly Gly Asp Val Lys Ala Ser Gly Asp Ala Ser Ile Ala Ile
      85                90                95

ggt agt gat gac tta cat ttg ctt gat cag cat ggt aat cct aaa cat 1052
Gly Ser Asp Asp Leu His Leu Leu Asp Gln His Gly Asn Pro Lys His
      100                105                110                115

ccg aaa ggt act ctg att aac gat ctt att aac ggc cat gca gta tta 1100
Pro Lys Gly Thr Leu Ile Asn Asp Leu Ile Asn Gly His Ala Val Leu
                        120                125                130

```

aaa gaa ata cga agc tca aag gat aat gat gta aaa tat aga cgc aca	1148
Lys Glu Ile Arg Ser Ser Lys Asp Asn Asp Val Lys Tyr Arg Arg Thr	
135 140 145	
acc gca agc gga cac gcc agt act gca gtg gga gcc atg tca tat gca	1196
Thr Ala Ser Gly His Ala Ser Thr Ala Val Gly Ala Met Ser Tyr Ala	
150 155 160	
cag ggt cat ttt tcc aac gcc ttt ggt aca cgg gca aca gct aaa agt	1244
Gln Gly His Phe Ser Asn Ala Phe Gly Thr Arg Ala Thr Ala Lys Ser	
165 170 175	
gcc tat tcc ttg gca gtg ggt ctt gcc gcc aca gcc gag ggc caa tct	1292
Ala Tyr Ser Leu Ala Val Gly Leu Ala Ala Thr Ala Glu Gly Gln Ser	
180 185 190 195	
aca atc gct att ggt tct gat gca aca tct agc tcg ttg gga gcg ata	1340
Thr Ile Ala Ile Gly Ser Asp Ala Thr Ser Ser Ser Leu Gly Ala Ile	
200 205 210	
gcc ctt ggt gca ggt act cgt gct cag cta cag ggc agt att gcc cta	1388
Ala Leu Gly Ala Gly Thr Arg Ala Gln Leu Gln Gly Ser Ile Ala Leu	
215 220 225	
ggt caa ggt tct gtt gtc act cag agt gat aat aat tct aga ccg gcc	1436
Gly Gln Gly Ser Val Val Thr Gln Ser Asp Asn Asn Ser Arg Pro Ala	
230 235 240	
tat aca cca aat acc cag gca cta gac ccc aag ttt caa gcc acc aat	1484
Tyr Thr Pro Asn Thr Gln Ala Leu Asp Pro Lys Phe Gln Ala Thr Asn	
245 250 255	
aat acg aag gcg ggt cca ctt tcc att ggt agt aac tct atc aaa cgt	1532
Asn Thr Lys Ala Gly Pro Leu Ser Ile Gly Ser Asn Ser Ile Lys Arg	
260 265 270 275	
aaa atc atc aat gtc ggt gca ggt gtt aat aaa acc gat gcg gtc aat	1580
Lys Ile Ile Asn Val Gly Ala Gly Val Asn Lys Thr Asp Ala Val Asn	
280 285 290	
gtg gca cag cta gaa gcg gtg gtg aag tgg gct aag gag cgt aga att	1628
Val Ala Gln Leu Glu Ala Val Val Lys Trp Ala Lys Glu Arg Arg Ile	
295 300 305	
act ttt cag ggt gat gat aac agt act gac gta aaa ata ggt ttg gat	1676
Thr Phe Gln Gly Asp Asp Asn Ser Thr Asp Val Lys Ile Gly Leu Asp	
310 315 320	
aat act tta act att aaa ggt ggt gca gag acc aac gca tta acc gat	1724
Asn Thr Leu Thr Ile Lys Gly Gly Ala Glu Thr Asn Ala Leu Thr Asp	
325 330 335	
aat aat atc ggt gtg gta aaa gag gct gat aat agt ggt ctg aaa gtt	1772
Asn Asn Ile Gly Val Val Lys Glu Ala Asp Asn Ser Gly Leu Lys Val	
340 345 350 355	
aaa ctt gct aaa act tta aac aat ctt act gag gtg aat aca act aca	1820
Lys Leu Ala Lys Thr Leu Asn Asn Leu Thr Glu Val Asn Thr Thr Thr	



Asn	Ala	Ile	Thr	Val	Ala	Lys	Asp	Thr	Thr	Lys	Asn	Ala	Gly	Ala	Val		
				600					605				610				
agc	atc	tta	aaa	ctc	aaa	ggg	aaa	aac	ggg	cta	acg	ggt	gct	acc	aaa	2588	
Ser	Ile	Leu	Lys	Leu	Lys	Gly	Lys	Asn	Gly	Leu	Thr	Val	Ala	Thr	Lys		
				615					620				625				
aaa	gat	ggg	acg	gtt	acc	ttt	ggg	ctt	agc	caa	gat	agc	ggg	ctg	acc	2636	
Lys	Asp	Gly	Thr	Val	Thr	Phe	Gly	Leu	Ser	Gln	Asp	Ser	Gly	Leu	Thr		
				630					635				640				
att	ggc	aaa	agc	acc	cta	aac	aac	gat	ggc	ttg	act	ggt	aaa	gat	acc	2684	
Ile	Gly	Lys	Ser	Thr	Leu	Asn	Asn	Asp	Gly	Leu	Thr	Val	Lys	Asp	Thr		
				645					650				655				
aac	gaa	caa	atc	caa	gtc	ggg	gct	aat	ggc	att	aaa	ttt	act	aat	gtg	2732	
Asn	Glu	Gln	Ile	Gln	Val	Gly	Ala	Asn	Gly	Ile	Lys	Phe	Thr	Asn	Val		
				660					665				670				675
aat	ggg	agt	aat	cca	ggg	act	ggc	att	gca	aat	acc	gct	cgc	att	acc	2780	
Asn	Gly	Ser	Asn	Pro	Gly	Thr	Gly	Ile	Ala	Asn	Thr	Ala	Arg	Ile	Thr		
				680					685				690				
aga	gat	aaa	att	ggc	ttt	gct	ggg	tct	gat	ggg	gca	ggt	gat	aca	aac	2828	
Arg	Asp	Lys	Ile	Gly	Phe	Ala	Gly	Ser	Asp	Gly	Ala	Val	Asp	Thr	Asn		
				695					700				705				
aaa	cct	tat	ctt	gat	caa	gac	aag	cta	caa	ggt	ggc	aat	ggt	aag	att	2876	
Lys	Pro	Tyr	Leu	Asp	Gln	Asp	Lys	Leu	Gln	Val	Gly	Asn	Val	Lys	Ile		
				710					715				720				
acc	aac	act	ggc	att	aac	gca	ggg	ggg	aaa	gcc	atc	aca	ggg	ctg	tcc	2924	
Thr	Asn	Thr	Gly	Ile	Asn	Ala	Gly	Gly	Lys	Ala	Ile	Thr	Gly	Leu	Ser		
				725					730				735				
cca	aca	ctg	cct	agc	att	gcc	gat	caa	agt	agc	cgc	aac	ata	gaa	ctg	2972	
Pro	Thr	Leu	Pro	Ser	Ile	Ala	Asp	Gln	Ser	Ser	Arg	Asn	Ile	Glu	Leu		
				740					745				750				755
ggc	aat	aca	atc	caa	gac	aaa	gac	aaa	tcc	aac	gct	gcc	agc	att	aat	3020	
Gly	Asn	Thr	Ile	Gln	Asp	Lys	Asp	Lys	Ser	Asn	Ala	Ala	Ser	Ile	Asn		
				760					765				770				
gat	ata	tta	aat	aca	ggc	ttt	aac	cta	aaa	aat	aat	aac	aac	ccc	att	3068	
Asp	Ile	Leu	Asn	Thr	Gly	Phe	Asn	Leu	Lys	Asn	Asn	Asn	Asn	Pro	Ile		
				775					780				785				
gac	ttt	gtc	tcc	act	tat	gac	att	ggt	gac	ttt	gcc	aat	ggc	aat	gcc	3116	
Asp	Phe	Val	Ser	Thr	Tyr	Asp	Ile	Val	Asp	Phe	Ala	Asn	Gly	Asn	Ala		
				790					795				800				
acc	acc	gcc	aca	gta	acc	cat	gat	acc	gct	aac	aaa	acc	agt	aaa	gtg	3164	
Thr	Thr	Ala	Thr	Val	Thr	His	Asp	Thr	Ala	Asn	Lys	Thr	Ser	Lys	Val		
				805					810				815				
gta	tat	gat	gtg	aat	gtg	gat	gat	aca	acc	att	cat	cta	aca	ggc	act	3212	
Val	Tyr	Asp	Val	Asn	Val	Asp	Asp	Thr	Thr	Ile	His	Leu	Thr	Gly	Thr		
				820					825				830				835

Asn Ala Ile Thr Val Ala Lys Asp Thr Thr Lys Asn Ala Gly Ala Val  
600 605 610

gat gac aat aaa aaa ctt ggc gtc aaa acc acc aaa ctg aac aaa aca	3260
Asp Asp Asn Lys Lys Leu Gly Val Lys Thr Thr Lys Leu Asn Lys Thr	
840 845 850	
agt gct aat ggt aat aca gca act aac ttt aat gtt aac tct agt gat	3308
Ser Ala Asn Gly Asn Thr Ala Thr Asn Phe Asn Val Asn Ser Ser Asp	
855 860 865	
gaa gat gcc ctt gtt aac gcc aaa gac atc gcc gaa aat cta aac acc	3356
Glu Asp Ala Leu Val Asn Ala Lys Asp Ile Ala Glu Asn Leu Asn Thr	
870 875 880	
cta gcc aag gaa att cac acc acc aaa ggc aca gca gac acc gcc cta	3404
Leu Ala Lys Glu Ile His Thr Thr Lys Gly Thr Ala Asp Thr Ala Leu	
885 890 895	
caa acc ttt acc gtt aaa aag gta gat gaa aat aat aat gct gat gac	3452
Gln Thr Phe Thr Val Lys Lys Val Asp Glu Asn Asn Asn Ala Asp Asp	
900 905 910 915	
gcc aac gcc atc acc gtg ggt caa aag aac gca aat aat caa gtc aac	3500
Ala Asn Ala Ile Thr Val Gly Gln Lys Asn Ala Asn Asn Gln Val Asn	
920 925 930	
acc cta aca ctc aaa ggt gaa aac ggt ctt aat att aaa acc gac aaa	3548
Thr Leu Thr Leu Lys Gly Glu Asn Gly Leu Asn Ile Lys Thr Asp Lys	
935 940 945	
aat ggt acg gtt acc ttt ggc att aac acc aca agc ggt ctt aaa gcc	3596
Asn Gly Thr Val Thr Phe Gly Ile Asn Thr Thr Ser Gly Leu Lys Ala	
950 955 960	
ggc aaa agc acc cta aac gac ggt ggc ttg tct att aaa aac ccc act	3644
Gly Lys Ser Thr Leu Asn Asp Gly Gly Leu Ser Ile Lys Asn Pro Thr	
965 970 975	
ggt agc gaa caa atc caa gtc ggt gct gat ggc gtg aag ttt gcc aag	3692
Gly Ser Glu Gln Ile Gln Val Gly Ala Asp Gly Val Lys Phe Ala Lys	
980 985 990 995	
ggt aat aat aat ggt gtt gta ggt gct ggc att gat ggc aca act cgc	3740
Val Asn Asn Asn Gly Val Val Gly Ala Gly Ile Asp Gly Thr Thr Arg	
1000 1005 1010	
att acc aga gat gaa att ggc ttt act ggg act aat ggc tca ctt gat	3788
Ile Thr Arg Asp Glu Ile Gly Phe Thr Gly Thr Asn Gly Ser Leu Asp	
1015 1020 1025	
aaa agc aaa ccc cac cta agc aaa gac ggc att aac gca ggt ggt aaa	3836
Lys Ser Lys Pro His Leu Ser Lys Asp Gly Ile Asn Ala Gly Gly Lys	
1030 1035 1040	
aag att acc aac att caa tca ggt gag att gcc caa aac agc cat gat	3884
Lys Ile Thr Asn Ile Gln Ser Gly Glu Ile Ala Gln Asn Ser His Asp	
1045 1050 1055	
gct gtg aca ggc ggc aag att tat gat tta aaa acc gaa ctt gaa aac	3932
Ala Val Thr Gly Gly Lys Ile Tyr Asp Leu Lys Thr Glu Leu Glu Asn	
1060 1065 1070 1075	

aaa atc agc agt act gcc aaa aca gca caa aac tca tta cac gaa ttc	3980
Lys Ile Ser Ser Thr Ala Lys Thr Ala Gln Asn Ser Leu His Glu Phe	
1080 1085 1090	
tca gta gca gat gaa caa ggt aat aac ttt acg gtt agt aac cct tac	4028
Ser Val Ala Asp Glu Gln Gly Asn Asn Phe Thr Val Ser Asn Pro Tyr	
1095 1100 1105	
tcc agt tat gac acc tca aag acc tct gat gtc atc acc ttt gca ggt	4076
Ser Ser Tyr Asp Thr Ser Lys Thr Ser Asp Val Ile Thr Phe Ala Gly	
1110 1115 1120	
gaa aac ggc att acc acc aag gta aat aaa ggt gtg gtg cgt gtg ggc	4124
Glu Asn Gly Ile Thr Thr Lys Val Asn Lys Gly Val Val Arg Val Gly	
1125 1130 1135	
att gac caa acc aaa ggc tta acc acg cct aag ctg acc gtg ggt aat	4172
Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr Val Gly Asn	
1140 1145 1150 1155	
aat aat ggc aaa ggc att gtc att gac agc caa aat ggt caa aat acc	4220
Asn Asn Gly Lys Gly Ile Val Ile Asp Ser Gln Asn Gly Gln Asn Thr	
1160 1165 1170	
atc aca gga cta agc aac act cta gct aat gtt acc aat gat aaa ggt	4268
Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn Asp Lys Gly	
1175 1180 1185	
agc gta cgc acc aca gaa cag ggc aat ata atc aaa gac gaa gac aaa	4316
Ser Val Arg Thr Thr Glu Gln Gly Asn Ile Ile Lys Asp Glu Asp Lys	
1190 1195 1200	
acc cgt gcc gcc agc att gtt gat gtg cta agc gca ggc ttt aac ttg	4364
Thr Arg Ala Ala Ser Ile Val Asp Val Leu Ser Ala Gly Phe Asn Leu	
1205 1210 1215	
caa ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat gac acc gtc	4412
Gln Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr Asp Thr Val	
1220 1225 1230 1235	
aac ttt gcc gat ggc aat gcc acc acc gct aag gtg acc tat gat gac	4460
Asn Phe Ala Asp Gly Asn Ala Thr Thr Ala Lys Val Thr Tyr Asp Asp	
1240 1245 1250	
aca agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg gat gat aca	4508
Thr Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val Asp Asp Thr	
1255 1260 1265	
acc att gaa gtt aaa gat aaa aaa ctt ggc gta aaa acc acc aca ttg	4556
Thr Ile Glu Val Lys Asp Lys Lys Leu Gly Val Lys Thr Thr Thr Leu	
1270 1275 1280	
acc agt act ggc aca ggt gct aat aaa ttt gcc cta agc aat caa gct	4604
Thr Ser Thr Gly Thr Gly Ala Asn Lys Phe Ala Leu Ser Asn Gln Ala	
1285 1290 1295	
act ggc gat gcg ctt gtc aag gcc agt gat atc gtt gct cat cta aac	4652
Thr Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Val Ala His Leu Asn	



1300	1305	1310	1315	
acc tta tct ggc gac atc caa act gcc aaa ggg gca agc caa gcg aac				4700
Thr Leu Ser Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser Gln Ala Asn				
1320		1325	1330	
aac tca gca ggc tat gtg gat gct gat ggc aat aag gtc atc tat gac				4748
Asn Ser Ala Gly Tyr Val Asp Ala Asp Gly Asn Lys Val Ile Tyr Asp				
1335	1340		1345	
agt acc gat aac aag tac tat caa gcc aaa aat gat ggc aca gtt gat				4796
Ser Thr Asp Asn Lys Tyr Tyr Gln Ala Lys Asn Asp Gly Thr Val Asp				
1350	1355		1360	
aaa acc aaa gaa gtt gcc aaa gac aaa ctg gtc gcc caa gcc caa acc				4844
Lys Thr Lys Lys Glu Val Ala Lys Asp Lys Leu Val Ala Gln Ala Gln Thr				
1365	1370		1375	
cca gat ggc aca ttg gct caa atg aat gtc aaa tca gtc att aac aaa				4892
Pro Asp Gly Thr Leu Ala Gln Met Asn Val Lys Ser Val Ile Asn Lys				
1380	1385	1390	1395	
gaa caa gta aat gat gcc aat aaa aag caa ggc atc aat gaa gac aac				4940
Glu Gln Val Asn Asp Ala Asn Lys Lys Gln Gly Ile Asn Glu Asp Asn				
1400		1405	1410	
gcc ttt gtt aaa gga ctt gaa aaa gcc gct tct gat aac aaa acc aaa				4988
Ala Phe Val Lys Gly Leu Glu Lys Ala Ala Ser Asp Asn Lys Thr Lys				
1415	1420		1425	
aac gcc gca gta act gtg ggt gat tta aat gcc gtt gcc caa aca ccg				5036
Asn Ala Ala Val Thr Val Gly Asp Leu Asn Ala Val Ala Gln Thr Pro				
1430	1435		1440	
ctg acc ttt gca ggg gat aca ggc aca acg gct aaa aaa ctg ggc gag				5084
Leu Thr Phe Ala Gly Asp Thr Gly Thr Thr Ala Lys Lys Leu Gly Glu				
1445	1450		1455	
act ttg acc atc aaa ggt ggg caa aca gac acc aat aag cta acc gat				5132
Thr Leu Thr Ile Lys Gly Gly Gln Thr Asp Thr Asn Lys Leu Thr Asp				
1460	1465	1470	1475	
aat aac atc ggt gtg gta gca ggt act gat ggc ttc act gtc aaa ctt				5180
Asn Asn Ile Gly Val Val Ala Gly Thr Asp Gly Phe Thr Val Lys Leu				
1480	1485		1490	
gcc aaa gac cta acc aat ctt aac agc gtt aat gca ggt ggc acc aaa				5228
Ala Lys Asp Leu Thr Asn Leu Asn Ser Val Asn Ala Gly Gly Thr Lys				
1495	1500		1505	
att gat gac aaa ggc gtg tct ttt gta gac tca agc ggt caa gcc aaa				5276
Ile Asp Asp Lys Gly Val Ser Phe Val Asp Ser Ser Gly Gln Ala Lys				
1510	1515		1520	
gca aac acc cct gtg cta agt gcc aat ggg ctg gac ctg ggt ggc aag				5324
Ala Asn Thr Pro Val Leu Ser Ala Asn Gly Leu Asp Leu Gly Gly Lys				
1525	1530		1535	
gtc atc agt aat gtg ggc aaa ggc aca aaa gat acc gac gct gcc aat				5372

Val Ile Ser Asn Val Gly Lys Gly Thr Lys Asp Thr Asp Ala Ala Asn 1540 1545 1550 1555	
gta caa cag tta aac gaa gta cgc aac ttg ttg ggt ctt ggt aat gct Val Gln Gln Leu Asn Glu Val Arg Asn Leu Leu Gly Leu Gly Asn Ala 1560 1565 1570	5420
ggt aat gat aac gct gac ggc aat cag gta aac att gcc gac atc aaa Gly Asn Asp Asn Ala Asp Gly Asn Gln Val Asn Ile Ala Asp Ile Lys 1575 1580 1585	5468
aaa gac cca aat tca ggt tca tca tct aac cgc act gtc atc aaa gca Lys Asp Pro Asn Ser Gly Ser Ser Ser Asn Arg Thr Val Ile Lys Ala 1590 1595 1600	5516
ggc acg gta ctt ggc ggt aaa ggt aat aac gat acc gaa aaa ctt gcc Gly Thr Val Leu Gly Gly Lys Gly Asn Asn Asp Thr Glu Lys Leu Ala 1605 1610 1615	5564
act ggt ggt ata caa gtg ggc gtg gat aaa gac ggc aac gct aac ggc Thr Gly Gly Ile Gln Val Gly Val Asp Lys Asp Gly Asn Ala Asn Gly 1620 1625 1630 1635	5612
gat tta agc aat gtt tgg gtc aaa acc caa aaa gat ggc agc aaa aaa Asp Leu Ser Asn Val Trp Val Lys Thr Gln Lys Asp Gly Ser Lys Lys 1640 1645 1650	5660
gcc ctg ctc gcc act tat aac gcc gca ggt cag acc aac tat ttg acc Ala Leu Leu Ala Thr Tyr Asn Ala Ala Gly Gln Thr Asn Tyr Leu Thr 1655 1660 1665	5708
aac aac ccc gca gaa gcc att gac aga ata aat gaa caa ggt atc cgc Asn Asn Pro Ala Glu Ala Ile Asp Arg Ile Asn Glu Gln Gly Ile Arg 1670 1675 1680	5756
ttc ttc cat gtc aac gat ggc aat caa gag cct gtg gta caa ggg cgt Phe Phe His Val Asn Asp Gly Asn Gln Glu Pro Val Val Gln Gly Arg 1685 1690 1695	5804
aac ggc att gac tca agt gcc tca ggc aag cac tca gtg gcg ata ggt Asn Gly Ile Asp Ser Ser Ala Ser Gly Lys His Ser Val Ala Ile Gly 1700 1705 1710 1715	5852
ttc cag gcc aag gca gat ggt gaa gcc gcc gtt gcc ata ggc aga caa Phe Gln Ala Lys Ala Asp Gly Glu Ala Ala Val Ala Ile Gly Arg Gln 1720 1725 1730	5900
acc caa gca ggc aac caa tcc atc gcc atc ggt gat aac gca caa gcc Thr Gln Ala Gly Asn Gln Ser Ile Ala Ile Gly Asp Asn Ala Gln Ala 1735 1740 1745	5948
acg ggc gat caa tcc atc gcc atc ggt aca ggc aat gtg gta gca ggt Thr Gly Asp Gln Ser Ile Ala Ile Gly Thr Gly Asn Val Val Ala Gly 1750 1755 1760	5996
aag cac tct ggt gcc atc ggc gac cca agc act gtt aag gct gat aac Lys His Ser Gly Ala Ile Gly Asp Pro Ser Thr Val Lys Ala Asp Asn 1765 1770 1775	6044

agt tac agt gtg ggt aat aac aac cag ttt acc gat gcc act caa acc	6092
Ser Tyr Ser Val Gly Asn Asn Asn Gln Phe Thr Asp Ala Thr Gln Thr	
1780 1785 1790 1795	
gat gtc ttt ggt gtg ggc aat aac atc acc gtg acc gaa agt aac tcg	6140
Asp Val Phe Gly Val Gly Asn Asn Ile Thr Val Thr Glu Ser Asn Ser	
1800 1805 1810	
gtt gcc tta ggt tca aac tct gcc atc agt gca ggc aca cac gca ggc	6188
Val Ala Leu Gly Ser Asn Ser Ala Ile Ser Ala Gly Thr His Ala Gly	
1815 1820 1825	
aca caa gcc aaa aaa tct gac ggc aca gca ggt aca acc acc aca gca	6236
Thr Gln Ala Lys Lys Ser Asp Gly Thr Ala Gly Thr Thr Thr Ala	
1830 1835 1840	
ggt gca acc ggt acg gtt aaa ggc ttt gct gga caa acg gcg gtt ggt	6284
Gly Ala Thr Gly Thr Val Lys Gly Phe Ala Gly Gln Thr Ala Val Gly	
1845 1850 1855	
gcg gtc tcc gtg ggt gcc tca ggt gct gaa cgc cgt atc caa aat gtg	6332
Ala Val Ser Val Gly Ala Ser Gly Ala Glu Arg Arg Ile Gln Asn Val	
1860 1865 1870 1875	
gca gca ggt gag gtc agt gcc acc agc acc gat gcg gtc aat ggt agc	6380
Ala Ala Gly Glu Val Ser Ala Thr Ser Thr Asp Ala Val Asn Gly Ser	
1880 1885 1890	
cag ttg tac aaa gcc acc caa agc att gcc aac gca acc aat gag ctt	6428
Gln Leu Tyr Lys Ala Thr Gln Ser Ile Ala Asn Ala Thr Asn Glu Leu	
1895 1900 1905	
gac cat cgt atc cac caa aac gaa aat aag gcc aat gca ggg att tca	6476
Asp His Arg Ile His Gln Asn Glu Asn Lys Ala Asn Ala Gly Ile Ser	
1910 1915 1920	
tca gcg atg gcg atg gcg tcc atg cca caa gcc tac att cct ggc aga	6524
Ser Ala Met Ala Met Ala Ser Met Pro Gln Ala Tyr Ile Pro Gly Arg	
1925 1930 1935	
tcc atg gtt acc ggg ggt att gcc acc cac aac ggt caa ggt gcg gtg	6572
Ser Met Val Thr Gly Gly Ile Ala Thr His Asn Gly Gln Gly Ala Val	
1940 1945 1950 1955	
gca gtg gga ctg tcg aag ctg tcg gat aat ggt caa tgg gta ttt aaa	6620
Ala Val Gly Leu Ser Lys Leu Ser Asp Asn Gly Gln Trp Val Phe Lys	
1960 1965 1970	
atc aat ggt tca gcc gat acc caa ggc cat gta ggg gcg gca gtt ggt	6668
Ile Asn Gly Ser Ala Asp Thr Gln Gly His Val Gly Ala Ala Val Gly	
1975 1980 1985	
gca ggt ttt cac ttt taagccataa atcgcaagat tttacttaaa aatcaatctc	6723
Ala Gly Phe His Phe	
1990	
accatagttg tataaaacag catcagcatc agtcatatta ctgatgctga tggtttttat	6783
cacttaaacc attttaccgc tcaagtgatt ctctttccacc atgaccaa atcgccattgat	6843

cataggtaaa cttattgagt aaattttatc aatgtagttg ttagatatgg ttaaaattgt 6903  
gccattgacc aaaaaatgac cgatttatcc cgaaaatttc tgattatgat ccgttgacct 6963  
gcaggtcgac 6973

6973

Figure 3. *M. catarrhalis* strain 4223 genomic 200kDa gene.

```

ccatggatat gggcaggtgt gctcgctgc cgtatgatgg cgatgacacc ccatttgccc 60
catatctgta cgatttgaca tgtgatatga tttaacatgt gacatgattt aacattgttt 120
aatactgttg ccatcattac cataatttag taacgcattt agtaacgcat ttgtaaaaat 180
cattgcgccc ctttatgtgt atcatatgaa tagaatatta tgattgtatc tgattattgt 240
atcagaatgg tgatgctata tgatgatgcc tacgagttga tttgggttaa tcaactctatg 300
atttgatata ttttgaaact aatctattga cttaaatacac catatggtta taatttagca 360
taatggtagg ctttttgtaa aaatcacatc gcaatattgt tctactgtta ctaccatgct 420
tgaatgacga tcccaatacac cagattcatt caagtgatgt gtttgtatac gcaccattta 480
ccctaattat ttcaatcaaa tgcctatgtc agcatgtatc attttttttaa ggtaaaccac 540
c atg aat cac atc tat aaa gtc atc ttt aac aaa gcc aca ggc aca ttt 589
  Met Asn His Ile Tyr Lys Val Ile Phe Asn Lys Ala Thr Gly Thr Phe
    1             5             10             15

atg gca gtg gca gag tac gcc aaa tcc cac agc acg ggg ggg ggt agc 637
Met Ala Val Ala Glu Tyr Ala Lys Ser His Ser Thr Gly Gly Gly Ser
              20              25              30

tgt gct aca ggg caa gtt ggc agt gta tgc act ctg agc ttt gcc cgt 685
Cys Ala Thr Gly Gln Val Gly Ser Val Cys Thr Leu Ser Phe Ala Arg
              35              40              45

att gcc gcg ctc gct gtc ctc gtg atc ggt gca acg ctc agt ggc agt 733
Ile Ala Ala Leu Ala Val Leu Val Ile Gly Ala Thr Leu Ser Gly Ser
              50              55              60

gct tat gct caa aaa aaa gat acc aaa cat atc gca att ggt gaa caa 781
Ala Tyr Ala Gln Lys Lys Asp Thr Lys His Ile Ala Ile Gly Glu Gln
              65              70              75              80

aac cag cca aga cgc tca ggc act gcc aag gcg gac ggt gat cga gcc 829
Asn Gln Pro Arg Arg Ser Gly Thr Ala Lys Ala Asp Gly Asp Arg Ala
              85              90              95

att gct att ggt gaa aat gct aac gca cag ggc ggt caa gcc atc gcc 877
Ile Ala Ile Gly Glu Asn Ala Asn Ala Gln Gly Gly Gln Ala Ile Ala
              100              105              110

atc ggt agt agt aat aaa act gtc aat gga agc agt ttg gat aag ata 925
Ile Gly Ser Ser Asn Lys Thr Val Asn Gly Ser Ser Leu Asp Lys Ile
              115              120              125

ggt acc gat gct acg ggt caa gag tcc atc gcc atc ggt ggt gat gta 973
Gly Thr Asp Ala Thr Gly Gln Glu Ser Ile Ala Ile Gly Gly Asp Val
              130              135              140

aag gct agt ggt gat gcc tcg att gcc atc ggt agt gat gac tta cat 1021
Lys Ala Ser Gly Asp Ala Ser Ile Ala Ile Gly Ser Asp Asp Leu His

```

145				150				155				160						
ttg	ctt	gat	cag	cat	ggg	aat	cct	aaa	cat	ccg	aaa	ggg	act	ctg	att	1069		
Leu	Leu	Asp	Gln	His	Gly	Asn	Pro	Lys	His	Pro	Lys	Gly	Thr	Leu	Ile			
				165				170				175						
aac	gat	ctt	att	aac	ggc	cat	gca	gta	tta	aaa	gaa	ata	cga	agc	tca	1117		
Asn	Asp	Leu	Ile	Asn	Gly	His	Ala	Val	Leu	Lys	Glu	Ile	Arg	Ser	Ser			
				180				185				190						
aag	gat	aat	gat	gta	aaa	tat	aga	cgc	aca	acc	gca	agc	gga	cac	gcc	1165		
Lys	Asp	Asn	Asp	Val	Lys	Tyr	Arg	Arg	Thr	Thr	Ala	Ser	Gly	His	Ala			
				195				200				205						
agt	act	gca	gtg	gga	gcc	atg	tca	tat	gca	cag	ggg	cat	ttt	tcc	aac	1213		
Ser	Thr	Ala	Val	Gly	Ala	Met	Ser	Tyr	Ala	Gln	Gly	His	Phe	Ser	Asn			
				210				215				220						
gcc	ttt	ggg	aca	cgg	gca	aca	gct	aaa	agt	gcc	tat	tcc	ttg	gca	gtg	1261		
Ala	Phe	Gly	Thr	Arg	Ala	Thr	Ala	Lys	Ser	Ala	Tyr	Ser	Leu	Ala	Val			
				225				230				235				240		
ggg	ctt	gcc	gcc	aca	gcc	gag	ggc	caa	tct	aca	atc	gct	att	ggg	tct	1309		
Gly	Leu	Ala	Ala	Thr	Ala	Glu	Gly	Gln	Ser	Thr	Ile	Ala	Ile	Gly	Ser			
				245				250				255						
gat	gca	aca	tct	agc	tcg	ttg	gga	gcg	ata	gcc	ctt	ggg	gca	ggg	act	1357		
Asp	Ala	Thr	Ser	Ser	Ser	Leu	Gly	Ala	Ile	Ala	Leu	Gly	Ala	Gly	Thr			
				260				265				270						
cgt	gct	cag	cta	cag	ggc	agt	att	gcc	cta	ggg	caa	ggg	tct	gtt	gtc	1405		
Arg	Ala	Gln	Leu	Gln	Gly	Ser	Ile	Ala	Leu	Gly	Gln	Gly	Ser	Val	Val			
				275				280				285						
act	cag	agt	gat	aat	aat	tct	aga	ccg	gcc	tat	aca	cca	aat	acc	cag	1453		
Thr	Gln	Ser	Asp	Asn	Asn	Ser	Arg	Pro	Ala	Tyr	Thr	Pro	Asn	Thr	Gln			
				290				295				300						
gca	cta	gac	ccc	aag	ttt	caa	gcc	acc	aat	aat	acg	aag	gcg	ggg	cca	1501		
Ala	Leu	Asp	Pro	Lys	Phe	Gln	Ala	Thr	Asn	Asn	Thr	Lys	Ala	Gly	Pro			
				305				310				315				320		
ctt	tcc	att	ggg	agt	aac	tct	atc	aaa	cgt	aaa	atc	atc	aat	gtc	ggg	1549		
Leu	Ser	Ile	Gly	Ser	Asn	Ser	Ile	Lys	Arg	Lys	Ile	Ile	Asn	Val	Gly			
				325				330				335						
gca	ggg	gtt	aat	aaa	acc	gat	gcg	gtc	aat	gtg	gca	cag	cta	gaa	gcg	1597		
Ala	Gly	Val	Asn	Lys	Thr	Asp	Ala	Val	Asn	Val	Ala	Gln	Leu	Glu	Ala			
				340				345				350						
gtg	gtg	aag	tgg	gct	aag	gag	cgt	aga	att	act	ttt	cag	ggg	gat	gat	1645		
Val	Val	Lys	Trp	Ala	Lys	Glu	Arg	Arg	Ile	Thr	Phe	Gln	Gly	Asp	Asp			
				355				360				365						
aac	agt	act	gac	gta	aaa	ata	ggg	ttg	gat	aat	act	tta	act	att	aaa	1693		
Asn	Ser	Thr	Asp	Val	Lys	Ile	Gly	Leu	Asp	Asn	Thr	Leu	Thr	Ile	Lys			
				370				375				380						
ggg	ggg	gca	gag	acc	aac	gca	tta	acc	gat	aat	aat	atc	ggg	gtg	gta	1741		

Gly 385	Gly	Ala	Glu	Thr	Asn 390	Ala	Leu	Thr	Asp	Asn 395	Asn	Ile	Gly	Val	Val 400	
aaa Lys	gag Glu	gct Ala	gat Asp	aat Asn	agt Ser	ggt Gly	ctg Leu	aaa Lys	gtt Val	aaa Lys	ctt Leu	gct Ala	aaa Lys	act Thr	tta Leu	1789
aac Asn	aat Asn	ctt Leu	act Thr	gag Glu	gtg Val	aat Asn	aca Thr	act Thr	aca Thr	tta Leu	aat Asn	gcc Ala	aca Thr	acc Thr	aca Thr	1837
gtt Val	aag Lys	gta Val	ggt Gly	agt Ser	agt Ser	agt Ser	agt Ser	act Thr	aca Thr	gct Ala	gaa Glu	tta Leu	ttg Leu	agt Ser	gat Asp	1885
agt Ser	tta Leu	acc Thr	ttt Phe	acc Thr	cag Gln	ccc Pro	aat Asn	aca Thr	ggc Gly	agt Ser	caa Gln	agc Ser	aca Thr	agc Ser	aaa Lys	1933
acc Thr	gtc Val	tat Tyr	ggc Gly	gtt Val	aat Asn	ggg Gly	gtg Val	aag Lys	ttt Phe	act Thr	aat Asn	aat Asn	gca Ala	gaa Glu	aca Thr	1981
aca Thr	gca Ala	gca Ala	atc Ile	ggc Gly	act Thr	act Thr	cgt Arg	att Ile	acc Thr	aga Arg	gat Asp	aaa Lys	att Ile	ggc Gly	ttt Phe	2029
gct Ala	cga Arg	gat Asp	ggt Gly	gat Asp	gtt Val	gat Asp	gaa Glu	aaa Lys	caa Gln	gca Ala	cca Pro	tat Tyr	ttg Leu	gat Asp	aaa Lys	2077
aaa Lys	caa Gln	ctt Leu	aaa Lys	gtg Val	ggt Gly	agt Ser	gtt Val	gca Ala	att Ile	acc Thr	ata Ile	gac Asp	aat Asn	ggc Gly	att Ile	2125
gat Asp	gca Ala	ggt Gly	aat Asn	aaa Lys	aag Lys	atc Ile	agt Ser	aat Asn	ctt Leu	gcc Ala	aaa Lys	ggt Gly	agc Ser	agt Ser	gct Ala	2173
aac Asn	gat Asp	gcg Ala	gtt Val	acc Thr	atc Ile	gaa Glu	cag Gln	ctc Leu	aaa Lys	gcc Ala	gcc Ala	aag Lys	cct Pro	act Thr	tta Leu	2221
aac Asn	gca Ala	ggc Gly	gct Ala	ggc Gly	atc Ile	agt Ser	gtc Val	aca Thr	cct Pro	act Thr	gaa Glu	ata Ile	tca Ser	gtt Val	gat Asp	2269
gct Ala	aag Lys	agt Ser	ggc Gly	aat Asn	gtt Val	acc Thr	gcc Ala	cca Pro	act Thr	tac Tyr	aac Asn	att Ile	ggc Gly	gtg Val	aaa Lys	2317
acc Thr	acc Thr	gag Glu	ctt Leu	aac Asn	agt Ser	gat Asp	ggc Gly	act Thr	agt Ser	gat Asp	aaa Lys	ttt Phe	agt Ser	gtt Val	aag Lys	2365
ggt Gly	agt Ser	ggt Gly	acg Thr	aac Asn	aat Asn	agc Ser	tta Leu	gtt Val	acc Thr	gcc Ala	gaa Glu	cat His	ttg Leu	gca Ala	agc Ser	2413

[illegible]

tat	cta	aat	gaa	gtc	aat	cga	acg	gct	gac	agt	gct	cta	caa	agc	ttt	2461
Tyr	Leu	Asn	Glu	Val	Asn	Arg	Thr	Ala	Asp	Ser	Ala	Leu	Gln	Ser	Phe	
625					630					635					640	

acc gtt aaa gaa gaa gac gat gat gac gcc aac gct atc acc gtg gct 2509  
Thr Val Lys Glu Glu Asp Asp Asp Ala Asn Ala Ile Thr Val Ala  
645 650 655

aaa gat acg aca aaa aat gcc ggc gca gtc agc atc tta aaa ctc aaa 2557  
Lys Asp Thr Thr Lys Asn Ala Gly Ala Val Ser Ile Leu Lys Leu Lys  
660 665 670

ggt aaa aac ggt cta acg gtt gct acc aaa aaa gat ggt acg gtt acc 2605  
 Gly Lys Asn Gly Leu Thr Val Ala Thr Lys Lys Asp Gly Thr Val Thr  
 675 680 685

ttt ggg ctt agc caa gat agc ggt ctg acc att ggc aaa agc acc cta 2653  
Phe Gly Leu Ser Gln Asp Ser Gly Leu Thr Ile Gly Lys Ser Thr Leu  
690 695 700

aac aac gat ggc ttg act gtt aaa gat acc aac gaa caa atc caa gtc 2701  
Asn Asn Asp Gly Leu Thr Val Lys Asp Thr Asn Glu Gln Ile Gln Val  
705 710 715 720

ggt gct aat ggc att aaa ttt act aat gtg aat ggt agt aat cca ggt 2749  
Gly Ala Asn Gly Ile Lys Phe Thr Asn Val Asn Gly Ser Asn Pro Gly  
725 730 735

act ggc att gca aat acc gct cgc att acc aga gat aaa att ggc ttt 2797  
Thr Gly Ile Ala Asn Thr Ala Arg Ile Thr Arg Asp Lys Ile Gly Phe  
740 745 750

gct ggt tct gat ggt gca gtt gat aca aac aaa cct tat ctt gat caa 2845  
Ala Gly Ser Asp Gly Ala Val Asp Thr Asn Lys Pro Tyr Leu Asp Gln  
755 760 765

gac aag cta caa gtt ggc aat gtt aag att acc aac act ggc att aac 2893  
Asp Lys Leu Gln Val Gly Asn Val Lys Ile Thr Asn Thr Gly Ile Asn  
770 775 780

gca ggt ggt aaa gcc atc aca ggg ctg tcc cca aca ctg cct agc att 2941  
Ala Gly Gly Lys Ala Ile Thr Gly Leu Ser Pro Thr Leu Pro Ser Ile  
785 790 795 800

gcc gat caa agt agc cgc aac ata gaa ctg ggc aat aca atc caa gac 2989  
Ala Asp Gln Ser Ser Arg Asn Ile Glu Leu Gly Asn Thr Ile Gln Asp  
805 810 815

aaa gac aaa tcc aac gct gcc agc att aat gat ata tta aat aca ggc 3037  
Lys Asp Lys Ser Asn Ala Ala Ser Ile Asn Asp Ile Leu Asn Thr Gly  
820 825 830

ttt aac cta aaa aat aat aac aac ccc att gac ttt gtc tcc act tat 3085  
Phe Asn Leu Lys Asn Asn Asn Asn Pro Ile Asp Phe Val Ser Thr Tyr  
835 840 845

gac att gtt gac ttt gcc aat ggc aat gcc acc acc gcc aca gta acc 3133  
Asp Ile Val Asp Phe Ala Asn Gly Asn Ala Thr Thr Ala Thr Val Thr  
850 855 860



cat gat acc gct aac aaa acc agt aaa gtg gta tat gat gtg aat gtg	3181
His Asp Thr Ala Asn Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val	
865 870 875 880	
gat gat aca acc att cat cta aca ggc act gat gac aat aaa aaa ctt	3229
Asp Asp Thr Thr Ile His Leu Thr Gly Thr Asp Asp Asn Lys Lys Leu	
885 890 895	
ggc gtc aaa acc acc aaa ctg aac aaa aca agt gct aat ggt aat aca	3277
Gly Val Lys Thr Thr Lys Leu Asn Lys Thr Ser Ala Asn Gly Asn Thr	
900 905 910	
gca act aac ttt aat gtt aac tct agt gat gaa gat gcc ctt gtt aac	3325
Ala Thr Asn Phe Asn Val Asn Ser Ser Asp Glu Asp Ala Leu Val Asn	
915 920 925	
gcc aaa gac atc gcc gaa aat cta aac acc cta gcc aag gaa att cac	3373
Ala Lys Asp Ile Ala Glu Asn Leu Asn Thr Leu Ala Lys Glu Ile His	
930 935 940	
acc acc aaa ggc aca gca gac acc gcc cta caa acc ttt acc gtt aaa	3421
Thr Thr Lys Gly Thr Ala Asp Thr Ala Leu Gln Thr Phe Thr Val Lys	
945 950 955 960	
aag gta gat gaa aat aat aat gct gat gac gcc aac gcc atc acc gtg	3469
Lys Val Asp Glu Asn Asn Asn Ala Asp Asp Ala Asn Ala Ile Thr Val	
965 970 975	
ggt caa aag aac gca aat aat caa gtc aac acc cta aca ctc aaa ggt	3517
Gly Gln Lys Asn Ala Asn Asn Gln Val Asn Thr Leu Thr Leu Lys Gly	
980 985 990	
gaa aac ggt ctt aat att aaa acc gac aaa aat ggt acg gtt acc ttt	3565
Glu Asn Gly Leu Asn Ile Lys Thr Asp Lys Asn Gly Thr Val Thr Phe	
995 1000 1005	
ggc att aac acc aca agc ggt ctt aaa gcc ggc aaa agc acc cta aac	3613
Gly Ile Asn Thr Thr Ser Gly Leu Lys Ala Gly Lys Ser Thr Leu Asn	
1010 1015 1020	
gac ggt ggc ttg tct att aaa aac ccc act ggt agc gaa caa atc caa	3661
Asp Gly Gly Leu Ser Ile Lys Asn Pro Thr Gly Ser Glu Gln Ile Gln	
1025 1030 1035 1040	
gtc ggt gct gat ggc gtg aag ttt gcc aag gtt aat aat aat ggt gtt	3709
Val Gly Ala Asp Gly Val Lys Phe Ala Lys Val Asn Asn Asn Gly Val	
1045 1050 1055	
gta ggt gct ggc att gat ggc aca act cgc att acc aga gat gaa att	3757
Val Gly Ala Gly Ile Asp Gly Thr Thr Arg Ile Thr Arg Asp Glu Ile	
1060 1065 1070	
ggc ttt act ggg act aat ggc tca ctt gat aaa agc aaa ccc cac cta	3805
Gly Phe Thr Gly Thr Asn Gly Ser Leu Asp Lys Ser Lys Pro His Leu	
1075 1080 1085	
agc aaa gac ggc att aac gca ggt ggt aaa aag att acc aac att caa	3853
Ser Lys Asp Gly Ile Asn Ala Gly Gly Lys Lys Ile Thr Asn Ile Gln	

1090	1095	1100	
tca ggt gag att gcc caa aac agc cat gat gct gtg aca ggc ggc aag Ser Gly Glu Ile Ala Gln Asn Ser His Asp Ala Val Thr Gly Gly Lys 1105 1110 1115 1120			3901
att tat gat tta aaa acc gaa ctt gaa aac aaa atc agc agt act gcc Ile Tyr Asp Leu Lys Thr Glu Leu Glu Asn Lys Ile Ser Ser Thr Ala 1125 1130 1135			3949
aaa aca gca caa aac tca tta cac gaa ttc tca gta gca gat gaa caa Lys Thr Ala Gln Asn Ser Leu His Glu Phe Ser Val Ala Asp Glu Gln 1140 1145 1150			3997
ggg aat aac ttt acg gtt agt aac cct tac tcc agt tat gac acc tca Gly Asn Asn Phe Thr Val Ser Asn Pro Tyr Ser Ser Tyr Asp Thr Ser 1155 1160 1165			4045
aag acc tct gat gtc atc acc ttt gca ggt gaa aac ggc att acc acc Lys Thr Ser Asp Val Ile Thr Phe Ala Gly Glu Asn Gly Ile Thr Thr 1170 1175 1180			4093
aag gta aat aaa ggt gtg gtg cgt gtg ggc att gac caa acc aaa ggc Lys Val Asn Lys Gly Val Val Arg Val Gly Ile Asp Gln Thr Lys Gly 1185 1190 1195 1200			4141
tta acc acg cct aag ctg acc gtg ggt aat aat aat ggc aaa ggc att Leu Thr Thr Pro Lys Leu Thr Val Gly Asn Asn Asn Gly Lys Gly Ile 1205 1210 1215			4189
gtc att gac agc caa aat ggt caa aat acc atc aca gga cta agc aac Val Ile Asp Ser Gln Asn Gly Gln Asn Thr Ile Thr Gly Leu Ser Asn 1220 1225 1230			4237
act cta gct aat gtt acc aat gat aaa ggt agc gta cgc acc aca gaa Thr Leu Ala Asn Val Thr Asn Asp Lys Gly Ser Val Arg Thr Thr Glu 1235 1240 1245			4285
cag ggc aat ata atc aaa gac gaa gac aaa acc cgt gcc gcc agc att Gln Gly Asn Ile Ile Lys Asp Glu Asp Lys Thr Arg Ala Ala Ser Ile 1250 1255 1260			4333
gtt gat gtg cta agc gca ggc ttt aac ttg caa ggc aat ggt gaa gcg Val Asp Val Leu Ser Ala Gly Phe Asn Leu Gln Gly Asn Gly Glu Ala 1265 1270 1275 1280			4381
gtt gac ttt gtc tcc act tat gac acc gtc aac ttt gcc gat ggc aat Val Asp Phe Val Ser Thr Tyr Asp Thr Val Asn Phe Ala Asp Gly Asn 1285 1290 1295			4429
gcc acc acc gct aag gtg acc tat gat gac aca agc aaa acc agt aaa Ala Thr Thr Ala Lys Val Thr Tyr Asp Asp Thr Ser Lys Thr Ser Lys 1300 1305 1310			4477
gtg gtc tat gat gtc aat gtg gat gat aca acc att gaa gtt aaa gat Val Val Tyr Asp Val Asn Val Asp Asp Thr Thr Ile Glu Val Lys Asp 1315 1320 1325			4525
aaa aaa ctt ggc gta aaa acc acc aca ttg acc agt act ggc aca ggt			4573

Lys Lys Leu Gly Val Lys Thr Thr Thr Leu Thr Ser Thr Gly Thr Gly	
1330	1335 1340
gct aat aaa ttt gcc cta agc aat caa gct act ggc gat gcg ctt gtc	4621
Ala Asn Lys Phe Ala Leu Ser Asn Gln Ala Thr Gly Asp Ala Leu Val	
1345	1350 1355 1360
aag gcc agt gat atc gtt gct cat cta aac acc tta tct ggc gac atc	4669
Lys Ala Ser Asp Ile Val Ala His Leu Asn Thr Leu Ser Gly Asp Ile	
1365	1370 1375
caa act gcc aaa ggg gca agc caa gcg aac aac tca gca ggc tat gtg	4717
Gln Thr Ala Lys Gly Ala Ser Gln Ala Asn Asn Ser Ala Gly Tyr Val	
1380	1385 1390
gat gct gat ggc aat aag gtc atc tat gac agt acc gat aac aag tac	4765
Asp Ala Asp Gly Asn Lys Val Ile Tyr Asp Ser Thr Asp Asn Lys Tyr	
1395	1400 1405
tat caa gcc aaa aat gat ggc aca gtt gat aaa acc aaa gaa gtt gcc	4813
Tyr Gln Ala Lys Asn Asp Gly Thr Val Asp Lys Thr Lys Glu Val Ala	
1410	1415 1420
aaa gac aaa ctg gtc gcc caa gcc caa acc cca gat ggc aca ttg gct	4861
Lys Asp Lys Leu Val Ala Gln Ala Gln Thr Pro Asp Gly Thr Leu Ala	
1425	1430 1435 1440
caa atg aat gtc aaa tca gtc att aac aaa gaa caa gta aat gat gcc	4909
Gln Met Asn Val Lys Ser Val Ile Asn Lys Glu Gln Val Asn Asp Ala	
1445	1450 1455
aat aaa aag caa ggc atc aat gaa gac aac gcc ttt gtt aaa gga ctt	4957
Asn Lys Lys Gln Gly Ile Asn Glu Asp Asn Ala Phe Val Lys Gly Leu	
1460	1465 1470
gaa aaa gcc gct tct gat aac aaa acc aaa aac gcc gca gta act gtg	5005
Glu Lys Ala Ala Ser Asp Asn Lys Thr Lys Asn Ala Ala Val Thr Val	
1475	1480 1485
ggt gat tta aat gcc gtt gcc caa aca ccg ctg acc ttt gca ggg gat	5053
Gly Asp Leu Asn Ala Val Ala Gln Thr Pro Leu Thr Phe Ala Gly Asp	
1490	1495 1500
aca ggc aca acg gct aaa aaa ctg ggc gag act ttg acc atc aaa ggt	5101
Thr Gly Thr Thr Ala Lys Lys Leu Gly Glu Thr Leu Thr Ile Lys Gly	
1505	1510 1515 1520
ggg caa aca gac acc aat aag cta acc gat aat aac atc ggt gtg gta	5149
Gly Gln Thr Asp Thr Asn Lys Leu Thr Asp Asn Asn Ile Gly Val Val	
1525	1530 1535
gca ggt act gat ggc ttc act gtc aaa ctt gcc aaa gac cta acc aat	5197
Ala Gly Thr Asp Gly Phe Thr Val Lys Leu Ala Lys Asp Leu Thr Asn	
1540	1545 1550
ctt aac agc gtt aat gca ggt ggc acc aaa att gat gac aaa ggc gtg	5245
Leu Asn Ser Val Asn Ala Gly Gly Thr Lys Ile Asp Asp Lys Gly Val	
1555	1560 1565

tct ttt gta gac tca agc ggt caa gcc aaa gca aac acc cct gtg cta	5293
Ser Phe Val Asp Ser Ser Gly Gln Ala Lys Ala Asn Thr Pro Val Leu	
1570 1575 1580	
agt gcc aat ggg ctg gac ctg ggt ggc aag gtc atc agt aat gtg ggc	5341
Ser Ala Asn Gly Leu Asp Leu Gly Gly Lys Val Ile Ser Asn Val Gly	
1585 1590 1595 1600	
aaa ggc aca aaa gat acc gac gct gcc aat gta caa cag tta aac gaa	5389
Lys Gly Thr Lys Asp Thr Asp Ala Ala Asn Val Gln Gln Leu Asn Glu	
1605 1610 1615	
gta cgc aac ttg ttg ggt ctt ggt aat gct ggt aat gat aac gct gac	5437
Val Arg Asn Leu Leu Gly Leu Gly Asn Ala Gly Asn Asp Asn Ala Asp	
1620 1625 1630	
ggc aat cag gta aac att gcc gac atc aaa aaa gac cca aat tca ggt	5485
Gly Asn Gln Val Asn Ile Ala Asp Ile Lys Lys Asp Pro Asn Ser Gly	
1635 1640 1645	
tca tca tct aac cgc act gtc atc aaa gca ggc acg gta ctt ggc ggt	5533
Ser Ser Ser Asn Arg Thr Val Ile Lys Ala Gly Thr Val Leu Gly Gly	
1650 1655 1660	
aaa ggt aat aac gat acc gaa aaa ctt gcc act ggt ggt ata caa gtg	5581
Lys Gly Asn Asn Asp Thr Glu Lys Leu Ala Thr Gly Gly Ile Gln Val	
1665 1670 1675 1680	
ggc gtg gat aaa gac ggc aac gct aac ggc gat tta agc aat gtt tgg	5629
Gly Val Asp Lys Asp Gly Asn Ala Asn Gly Asp Leu Ser Asn Val Trp	
1685 1690 1695	
gtc aaa acc caa aaa gat ggc agc aaa aaa gcc ctg ctc gcc act tat	5677
Val Lys Thr Gln Lys Asp Gly Ser Lys Lys Ala Leu Leu Ala Thr Tyr	
1700 1705 1710	
aac gcc gca ggt cag acc aac tat ttg acc aac aac ccc gca gaa gcc	5725
Asn Ala Ala Gly Gln Thr Asn Tyr Leu Thr Asn Asn Pro Ala Glu Ala	
1715 1720 1725	
att gac aga ata aat gaa caa ggt atc cgc ttc ttc cat gtc aac gat	5773
Ile Asp Arg Ile Asn Glu Gln Gly Ile Arg Phe Phe His Val Asn Asp	
1730 1735 1740	
ggc aat caa gag cct gtg gta caa ggg cgt aac ggc att gac tca agt	5821
Gly Asn Gln Glu Pro Val Val Gln Gly Arg Asn Gly Ile Asp Ser Ser	
1745 1750 1755 1760	
gcc tca ggc aag cac tca gtg gcg ata ggt ttc cag gcc aag gca gat	5869
Ala Ser Gly Lys His Ser Val Ala Ile Gly Phe Gln Ala Lys Ala Asp	
1765 1770 1775	
ggc gaa gcc gcc gtt gcc ata ggc aga caa acc caa gca ggc aac caa	5917
Gly Glu Ala Ala Val Ala Ile Gly Arg Gln Thr Gln Ala Gly Asn Gln	
1780 1785 1790	
tcc atc gcc atc ggt gat aac gca caa gcc acg ggc gat caa tcc atc	5965
Ser Ile Ala Ile Gly Asp Asn Ala Gln Ala Thr Gly Asp Gln Ser Ile	
1795 1800 1805	

gcc atc ggt aca ggc aat gtg gta gca ggt aag cac tct ggt gcc atc Ala Ile Gly Thr Gly Asn Val Val Ala Gly Lys His Ser Gly Ala Ile 1810 1815 1820	6013
ggc gac cca agc act gtt aag gct gat aac agt tac agt gtg ggt aat Gly Asp Pro Ser Thr Val Lys Ala Asp Asn Ser Tyr Ser Val Gly Asn 1825 1830 1835 1840	6061
aac aac cag ttt acc gat gcc act caa acc gat gtc ttt ggt gtg ggc Asn Asn Gln Phe Thr Asp Ala Thr Gln Thr Asp Val Phe Gly Val Gly 1845 1850 1855	6109
aat aac atc acc gtg acc gaa agt aac tcg gtt gcc tta ggt tca aac Asn Asn Ile Thr Val Thr Glu Ser Asn Ser Val Ala Leu Gly Ser Asn 1860 1865 1870	6157
tct gcc atc agt gca ggc aca cac gca ggc aca caa gcc aaa aaa tct Ser Ala Ile Ser Ala Gly Thr His Ala Gly Thr Gln Ala Lys Lys Ser 1875 1880 1885	6205
gac ggc aca gca ggt aca acc acc aca gca ggt gca acc ggt acg gtt Asp Gly Thr Ala Gly Thr Thr Thr Thr Ala Gly Ala Thr Gly Thr Val 1890 1895 1900	6253
aaa ggc ttt gct gga caa acg gcg gtt ggt gcg gtc tcc gtg ggt gcc Lys Gly Phe Ala Gly Gln Thr Ala Val Gly Ala Val Ser Val Gly Ala 1905 1910 1915 1920	6301
tca ggt gct gaa cgc cgt atc caa aat gtg gca gca ggt gag gtc agt Ser Gly Ala Glu Arg Arg Ile Gln Asn Val Ala Ala Gly Glu Val Ser 1925 1930 1935	6349
gcc acc agc acc gat gcg gtc aat ggt agc cag ttg tac aaa gcc acc Ala Thr Ser Thr Asp Ala Val Asn Gly Ser Gln Leu Tyr Lys Ala Thr 1940 1945 1950	6397
caa agc att gcc aac gca acc aat gag ctt gac cat cgt atc cac caa Gln Ser Ile Ala Asn Ala Thr Asn Glu Leu Asp His Arg Ile His Gln 1955 1960 1965	6445
aac gaa aat aag gcc aat gca ggg att tca tca gcg atg gcg atg gcg Asn Glu Asn Lys Ala Asn Ala Gly Ile Ser Ser Ala Met Ala Met Ala 1970 1975 1980	6493
tcc atg cca caa gcc tac att cct ggc aga tcc atg gtt acc ggg ggt Ser Met Pro Gln Ala Tyr Ile Pro Gly Arg Ser Met Val Thr Gly Gly 1985 1990 1995 2000	6541
att gcc acc cac aac ggt caa ggt gcg gtg gca gtg gga ctg tcg aag Ile Ala Thr His Asn Gly Gln Gly Ala Val Ala Val Gly Leu Ser Lys 2005 2010 2015	6589
ctg tcg gat aat ggt caa tgg gta ttt aaa atc aat ggt tca gcc gat Leu Ser Asp Asn Gly Gln Trp Val Phe Lys Ile Asn Gly Ser Ala Asp 2020 2025 2030	6637
acc caa ggc cat gta ggg gcg gca gtt ggt gca ggt ttt cac ttt Thr Gln Gly His Val Gly Ala Ala Val Gly Ala Gly Phe His Phe	6682

2035

2040

2045

taagccataa atcgcaagat ttactttaa aatcaatctc accatagttg tataaaacag 6742  
catcagcatc agtcatatta ctgatgctga tgttttttat cacttaaacc attttacgc 6802  
tcaagtgatt ctctttcacc atgaccaa atcgccattgat cataggtaaa cttattgagt 6862  
aaattttatc aatgtagttg ttagatatgg ttaaaattgt gccattgacc aaaaaatgac 6922  
cgatttatcc cgaaaatttc tgattatgat ccgttgacct gcaggtcgac 6972

65220"6431960

Figure 4. *M. catarrhalis* strain Q8 200kDa gene

ATG aat cac atc tat aaa gtc atc ttt aac aaa gcc aca ggc aca ttt	48
Met Asn His Ile Tyr Lys Val Ile Phe Asn Lys Ala Thr Gly Thr Phe	
1 5 10 15	
atg gcc gtg gcg gaa tat gcc aaa tcc cac agt acg <u>ggg ggg ggt</u> agc	96
Met Ala Val Ala Glu Tyr Ala Lys Ser His Ser Thr Gly Gly Gly Ser	
20 25 30	
tgt gct aca ggg caa gtt ggc agt gta cgc act cta agc ttt gcc cgt	144
Cys Ala Thr Gly Gln Val Gly Ser Val Arg Thr Leu Ser Phe Ala Arg	
35 40 45	
att gcc gcg ctc gct gtc ctc gtg atc ggt gcg acg ctc aat ggc agt	192
Ile Ala Ala Leu Ala Val Leu Val Ile Gly Ala Thr Leu Asn Gly Ser	
50 55 60	
gct tat gct caa caa att act acc aag atc gaa att ggt caa aca aac	240
Ala Tyr Ala Gln Gln Ile Thr Thr Lys Ile Glu Ile Gly Gln Thr Asn	
65 70 75 80	
aag ata aac aac acg ctg aaa ggc gat gcc cta gcg aca ggt gaa gca	288
Lys Ile Asn Asn Thr Leu Lys Gly Asp Ala Leu Ala Thr Gly Glu Ala	
85 90 95	
tcc att gct ttt ggt agt ctt tct aag gca caa ggc tct caa gct att	336
Ser Ile Ala Phe Gly Ser Leu Ser Lys Ala Gln Gly Ser Gln Ala Ile	
100 105 110	
gct atc ggt agt gtc aaa cca gat cct aat aat ggt agt aat ggt aat	384
Ala Ile Gly Ser Val Lys Pro Asp Pro Asn Asn Gly Ser Asn Gly Asn	
115 120 125	
gta ggt tcc cac gcc aaa ggt aac gag tcc atc gcc atc ggt ggt gat	432
Val Gly Ser His Ala Lys Gly Asn Glu Ser Ile Ala Ile Gly Gly Asp	
130 135 140	
gta ttg gct gag ggt gat gcc tcg att gcc atc ggt agt gat gac tta	480
Val Leu Ala Glu Gly Asp Ala Ser Ile Ala Ile Gly Ser Asp Asp Leu	
145 150 155 160	
tat ttg cct aag aat ctt gat ctg aag aat gaa ttt cac aaa ctt att	528
Tyr Leu Pro Lys Asn Leu Asp Leu Lys Asn Glu Phe His Lys Leu Ile	
165 170 175	
cat ggc cat gaa ata tta aaa aaa ata caa acc tca acc gat ggt aaa	576
His Gly His Glu Ile Leu Lys Lys Ile Gln Thr Ser Thr Asp Gly Lys	
180 185 190	
atc aaa tat cga cgc aca aga gca caa ggg cac gcc agt act gca gtg	624
Ile Lys Tyr Arg Arg Thr Arg Ala Gln Gly His Ala Ser Thr Ala Val	
195 200 205	
gga gcc atg tca tat gca cag ggt cat ttt tcc aac gcc ttt ggt aca	672
Gly Ala Met Ser Tyr Ala Gln Gly His Phe Ser Asn Ala Phe Gly Thr	
210 215 220	

tac Tyr 225	gca Ala	aca Thr	gct Ala	gaa Glu 230	gct Ala	gcc Ala	tat Tyr	tcc Ser	ttg Leu 235	gca Ala	gta Val	ggt Gly	ctt Leu	gcc Ala 240	gcc Ala	720
caa Gln	gcc Ala	aca Thr	aaa Lys	caa Gln 245	tct Ser	tca Ser	atc Ile	gct Ala	gtt Val 250	ggt Gly	tcc Ser	aat Asn	gca Ala	aaa Lys 255	gct Ala	768
aac Asn	gcg Ala	ttt Phe	gca Ala 260	gcg Ala	aca Thr	gcc Ala	att Ile	ggt Gly 265	gga Gly	aat Asn	act Thr	gta Val	gtt Val 270	aat Asn	ttg Leu	816
ggt Gly	cga Arg	ggc Gly 275	gtt Val	gcc Ala	cta Leu	ggt Gly	ttt Phe 280	ggt Gly	tct Ser	cag Gln	atc Ile	ctt Leu 285	gat Asp	agg Arg	gat Asp	864
aat Asn 290	aat Asn	aca Thr	gat Asp	gcc Ala	agt Ser	gcc Ala 295	tat Tyr	gta Val	cca Pro	cta Leu	ggt Gly 300	aaa Lys	acg Thr	tta Leu	gca Ala	912
gac Asp 305	cag Gln	tat Tyr	aaa Lys	gcc Ala 310	acc Thr	cgc Arg	cag Gln	ggt Gly	gat Asp	tct Ser 315	acg Thr	gat Asp	ata Ile	ttt Phe 320	tcc Ser	960
att Ile	ggt Gly	aat Asn	agt Ser	aat Asn 325	aat Asn	aat Asn	aat Asn	agc Ser	agt Ser 330	atc Ile	agg Arg	cgt Arg	aaa Lys	atc Ile 335	atc Ile	1008
aat Asn	gtc Val	ggt Gly	gcg Ala 340	ggt Gly	tct Ser	cgg Arg	gat Asp	acc Thr 345	gat Asp	gcg Ala	gtc Val	aat Asn	gtg Val 350	gca Ala	cag Gln	1056
ctt Leu	aaa Lys	ttg Leu 355	gtg Val	gag Glu	gaa Glu	ctg Leu	gct Ala 360	aat Asn	cgt Arg	aaa Lys	att Ile	act Thr 365	ttt Phe	aag Lys	ggt Gly	1104
gat Asp	ggt Gly 370	gac Asp	aat Asn	aat Asn	agc Ser	aat Asn 375	agc Ser	gta Val	gaa Glu	aga Arg	ggt Gly 380	ttg Leu	ggc Gly	aat Asn	act Thr	1152
tta Leu 385	act Thr	att Ile	aaa Lys	ggt Gly	gat Asp 390	gca Ala	cag Gln	acc Thr	aac Asn	gca Ala 395	tta Leu	acc Thr	gaa Glu	gct Ala	aac Asn 400	1200
atc Ile	ggt Gly	gtg Val	gta Val	aca Thr 405	gat Asp	ggc Gly	aat Asn	ggt Gly	ctg Leu 410	aaa Lys	gtt Val	aaa Lys	ctt Leu	gct Ala 415	aaa Lys	1248
gag Glu	ctg Leu	act Thr	gga Gly 420	ttg Leu	acc Thr	agt Ser	gtc Val	tcc Ser 425	gct Ala	acc Thr	aac Asn	aaa Lys	atc Ile 430	acc Thr	gtt Val	1296
agt Ser	aat Asn	acc Thr 435	aac Asn	aac Asn	aac Asn	aac Asn	gcc Ala 440	gag Glu	cta Leu	caa Gln	agc Ser	ggt Gly 445	ggt Gly	ttg Leu	acc Thr	1344
ttt Phe	agc Ser 450	cca Pro	ata Ile	aca Thr	ggt Gly	aca Thr 455	aaa Lys	aca Thr	gat Asp	aaa Lys	acc Thr 460	gtc Val	tac Tyr	agc Ser	att Ile	1392

```

ttt agc cca ata aca ggt aca aaa aca gat aaa acc gtc tac agc att    1392
Phe Ser Pro Ile Thr Gly Thr Lys Thr Asp Lys Thr Val Tyr Ser Ile
      450                      455                      460

```



gat gga ttg aag ttt act aat gat agt aat agt ata gca act aaa ggt	1440
Asp Gly Leu Lys Phe Thr Asn Asp Ser Asn Ser Ile Ala Thr Lys Gly	
465 470 475 480	
act act cgt att acc aaa aag aaa att ggt ttt gct ggt act aat gat	1488
Thr Thr Arg Ile Thr Lys Lys Lys Ile Gly Phe Ala Gly Thr Asn Asp	
485 490 495	
gga gtt gat gaa agc aaa cct tat ctt gac aac gaa aag cta aaa gtt	1536
Gly Val Asp Glu Ser Lys Pro Tyr Leu Asp Asn Glu Lys Leu Lys Val	
500 505 510	
ggc aac agc acc cta aac agt ggt agc ttg act gtt aat aac acc act	1584
Gly Asn Ser Thr Leu Asn Ser Gly Ser Leu Thr Val Asn Asn Thr Thr	
515 520 525	
ggt aat aaa caa atc caa gtc ggt gct aat ggc att aaa ttt gcc aca	1632
Gly Asn Lys Gln Ile Gln Val Gly Ala Asn Gly Ile Lys Phe Ala Thr	
530 535 540	
gtc gct aat aat gtt gca aat acc tca gca aca gtc ggc act gct cgt	1680
Val Ala Asn Asn Val Ala Asn Thr Ser Ala Thr Val Gly Thr Ala Arg	
545 550 555 560	
att acc gaa gag aaa att ggt ttt gct ggt act aat gat gga gtt gat	1728
Ile Thr Glu Glu Lys Ile Gly Phe Ala Gly Thr Asn Asp Gly Val Asp	
565 570 575	
gaa caa gca cca tat ttg gat aaa gaa cga ctt aaa gtg ggt cgt gtt	1776
Glu Gln Ala Pro Tyr Leu Asp Lys Glu Arg Leu Lys Val Gly Arg Val	
580 585 590	
gaa att acc aca gat agt ggt att aat gct ggt aat cac aag att acc	1824
Glu Ile Thr Thr Asp Ser Gly Ile Asn Ala Gly Asn His Lys Ile Thr	
595 600 605	
gga ctt act aat ggt ata gca aat acc gat gcg gtt acc atc aaa cag	1872
Gly Leu Thr Asn Gly Ile Ala Asn Thr Asp Ala Val Thr Ile Lys Gln	
610 615 620	
ctc aaa gac gcc aag cct act tta aac gca ggc gat ggc atc agt att	1920
Leu Lys Asp Ala Lys Pro Thr Leu Asn Ala Gly Asp Gly Ile Ser Ile	
625 630 635 640	
aat agt aat aac ggg gat cta gtt gat agt agt ggc aat att acc acc	1968
Asn Ser Asn Asn Gly Asp Leu Val Asp Ser Ser Gly Asn Ile Thr Thr	
645 650 655	
cca act tat aac att agc gtg aaa acc act aag ctt aac agt aat ggc	2016
Pro Thr Tyr Asn Ile Ser Val Lys Thr Thr Lys Leu Asn Ser Asn Gly	
660 665 670	
acc agt ggt aat aat aaa ttt agt gtt agt aat gct cat gat aac aat	2064
Thr Ser Gly Asn Asn Lys Phe Ser Val Ser Asn Ala His Asp Asn Asn	
675 680 685	
agc tta gtt acc gcc aaa gat ttg gca gac tat cta aat aaa gtc aat	2112
Ser Leu Val Thr Ala Lys Asp Leu Ala Asp Tyr Leu Asn Lys Val Asn	

690					695					700										
gaa Glu 705	acg Thr	gct Ala	gac Asp	agt Ser	gct Ala 710	cta Leu	cca Pro	agc Ser	ttt Phe	aaa Lys 715	gtc Val	caa Gln	aac Asn	ggg Gly	gat Asp 720	2160				
aat Asn	agc Ser	aac Asn	aac Asn	gcc Ala 725	atc Ile	acc Thr	gtg Val	ggg Gly	aaa Lys 730	gat Asp	aca Thr	aac Asn	ggc Gly	aag Lys 735	acc Thr	2208				
ttc Phe	aac Asn	acc Thr	tta Leu 740	aaa Lys	ctc Leu	aaa Lys	ggg Gly	gaa Glu 745	aac Asn	ggg Gly	gtt Val	aat Asn	att Ile 750	acg Thr	acc Thr	2256				
aat Asn	aga Arg	gcc Ala 755	aca Thr	ggg Gly	aca Thr	gtt Val	acc Thr 760	ttt Phe	ggc Gly	att Ile	gac Asp	caa Gln 765	agt Ser	aat Asn	ggg Gly	2304				
ctc Leu 770	acc Thr	acg Thr	cct Pro	aag Lys	ctg Leu	acc Thr 775	gtg Val	ggg Gly	agc Ser	gat Asp	aca Thr 780	aat Asn	ggg Gly	aat Asn	cga Arg	2352				
ttg Leu 785	gtt Val	att Ile	gag Glu	caa Gln 790	gtc Val	cct Pro	agc Ser	gct Ala	gac Asp	ggg Gly 795	aac Asn	agc Ser	acc Thr	aaa Lys	aac Asn 800	2400				
atc Ile	att Ile	aaa Lys	gga Gly	ttg Leu 805	tcc Ser	cca Pro	aca Thr	ctg Leu	cct Pro 810	agc Ser	att Ile	gcc Ala	agt Ser	cca Pro 815	agt Ser	2448				
ggc Gly	cgc Arg	aac Asn	ata Ile 820	gca Ala	ctg Leu	ggc Gly	aat Asn	aca Thr 825	atc Ile	gaa Glu	gaa Glu	aaa Lys	gac Asp 830	aaa Lys	tcc Ser	2496				
aac Asn	gct Ala 835	gcc Ala	agc Ser	att Ile	gat Asp	gat Asp	gtg Val 840	cta Leu	aat Asn	gca Ala	ggc Gly	ttt Phe 845	aac Asn	cta Leu	aaa Lys	2544				
aat Asn 850	aat Asn	ggc Gly	aaa Lys	gac Asp	aaa Lys	gac Asp 855	ttt Phe	gtc Val	tcc Ser	act Thr 860	tat Tyr	gac Asp	act Thr	gtt Val	gac Asp	2592				
ttt Phe 865	atc Ile	gat Asp	ggc Gly	aat Asn	gcc Ala 870	acc Thr	acc Thr	gcc Ala	aca Thr	gta Val 875	act Thr	tat Tyr	gat Asp	gaa Glu	gcc Ala 880	2640				
aat Asn	caa Gln	acc Thr	agt Ser	aaa Lys 885	gtg Val	gcg Ala	tat Tyr	gat Asp	gtg Val 890	aat Asn	gtg Val	gat Asp	gag Glu	aaa Lys 895	acc Thr	2688				
att Ile	gaa Glu	ctg Leu	aca Thr 900	ggc Gly	gat Asp	aat Asn	ggc Gly	aag Lys 905	aaa Lys	caa Gln	ctt Leu	ggc Gly	gtc Val 910	aaa Lys	acc Thr	2736				
atc Ile	aaa Lys 915	ctg Leu	acc Thr	gaa Glu	aca Thr	agt Ser	act Thr 920	aat Asn	ggg Gly	aat Asn	gca Ala	act Thr 925	aca Thr	ttt Phe	agt Ser	2784				
acc	gac	gat	gac	cat	gcc	ctt	gtt	aaa	gcc	agt	gat	atc	gcc	ggc	aat	2832				

acc gac gat gac cat gcc ctt gtt aaa gcc agt gat atc gcc ggc aat 2832

Thr	Asp	Asp	Asp	His	Ala	Leu	Val	Lys	Ala	Ser	Asp	Ile	Ala	Gly	Asn		
930						935					940						
cta	aac	acc	cta	gcc	gag	gaa	att	cac	acc	acc	aaa	ggc	aca	gca	aac	2880	
Leu	Asn	Thr	Leu	Ala	Glu	Glu	Ile	His	Thr	Thr	Lys	Gly	Thr	Ala	Asn		
945					950					955					960		
acc	gcc	cta	caa	acc	ttt	acc	gtt	aaa	aag	gta	gat	gaa	aat	gat	aag	2928	
Thr	Ala	Leu	Gln	Thr	Phe	Thr	Val	Lys	Lys	Val	Asp	Glu	Asn	Asp	Lys		
				965					970					975			
gct	gat	gac	acc	aac	gcc	atc	acc	gtg	ggg	aaa	gat	ggc	aca	agt	ggg	2976	
Ala	Asp	Asp	Thr	Asn	Ala	Ile	Thr	Val	Gly	Lys	Asp	Gly	Thr	Ser	Gly		
			980					985					990				
aaa	gtc	aac	acc	tta	aaa	ctc	aaa	ggg	aaa	aac	ggg	ctt	gat	att	aaa	3024	
Lys	Val	Asn	Thr	Leu	Lys	Leu	Lys	Gly	Lys	Asn	Gly	Leu	Asp	Ile	Lys		
		995				1000						1005					
acc	gac	aaa	gat	ggg	acg	gtt	acc	ttt	ggc	att	aac	acc	caa	agc	ggg	3072	
Thr	Asp	Lys	Asp	Gly	Thr	Val	Thr	Phe	Gly	Ile	Asn	Thr	Gln	Ser	Gly		
	1010					1015					1020						
ctt	aaa	gcc	ggc	gac	agc	acc	act	cta	aac	aac	aat	ggc	ttg	tct	att	3120	
Leu	Lys	Ala	Gly	Asp	Ser	Thr	Thr	Leu	Asn	Asn	Asn	Gly	Leu	Ser	Ile		
1025					1030					1035					1040		
aaa	aac	acc	gct	agt	aac	gaa	caa	atc	caa	gtc	ggg	gct	gat	ggc	gtg	3168	
Lys	Asn	Thr	Ala	Ser	Asn	Glu	Gln	Ile	Gln	Val	Gly	Ala	Asp	Gly	Val		
				1045				1050					1055				
aag	ttt	gcc	atg	gtt	aat	aat	ggg	gtt	gta	ggg	gct	ggc	att	gat	ggc	3216	
Lys	Phe	Ala	Met	Val	Asn	Asn	Gly	Val	Val	Gly	Ala	Gly	Ile	Asp	Gly		
		1060					1065						1070				
aca	act	cgc	att	acc	aga	gat	gaa	att	ggc	ttt	act	ggg	act	aat	ggc	3264	
Thr	Thr	Arg	Ile	Thr	Arg	Asp	Glu	Ile	Gly	Phe	Thr	Gly	Thr	Asn	Gly		
		1075				1080						1085					
tca	ctt	gat	aaa	agc	aaa	ccc	cac	cta	agc	aaa	gac	ggc	att	aac	gca	3312	
Ser	Leu	Asp	Lys	Ser	Lys	Pro	His	Leu	Ser	Lys	Asp	Gly	Ile	Asn	Ala		
	1090					1095					1100						
ggg	ggg	aaa	aag	att	acc	aac	att	caa	tca	ggg	gag	att	gcc	aaa	aac	3360	
Gly	Gly	Lys	Lys	Ile	Thr	Asn	Ile	Gln	Ser	Gly	Glu	Ile	Ala	Lys	Asn		
1105				1110					1115				1120				
agc	cat	gat	gct	gtg	aca	ggc	ggc	aag	att	tat	gat	tta	aaa	acc	gaa	3408	
Ser	His	Asp	Ala	Val	Thr	Gly	Gly	Lys	Ile	Tyr	Asp	Leu	Lys	Thr	Glu		
				1125				1130					1135				
ctt	gaa	aat	aaa	atc	agc	agt	act	gcc	aaa	aca	gca	caa	aac	tca	tta	3456	
Leu	Glu	Asn	Lys	Ile	Ser	Ser	Thr	Ala	Lys	Thr	Ala	Gln	Asn	Ser	Leu		
			1140					1145					1150				
cac	gaa	ttc	tca	gta	gca	gat	gaa	caa	ggg	aat	aac	ttt	acg	gtt	agt	3504	
His	Glu	Phe	Ser	Val	Ala	Asp	Glu	Gln	Gly	Asn	Asn	Phe	Thr	Val	Ser		
		1155					1160					1165					

aac cct tac tcc agt tat gac acc tca aag acc tct gat gtc atc acc	3552
Asn Pro Tyr Ser Ser Tyr Asp Thr Ser Lys Thr Ser Asp Val Ile Thr	
1170 1175 1180	
ttt gca ggt gaa aac ggc att acc acc aag gta aat aaa ggt gtg gtg	3600
Phe Ala Gly Glu Asn Gly Ile Thr Thr Lys Val Asn Lys Gly Val Val	
1185 1190 1195 1200	
cgt gtg ggc att gac caa acc aaa ggc tta acc acg cct aag ctg acc	3648
Arg Val Gly Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr	
1205 1210 1215	
gtg ggt aat aat aat ggc aaa ggc att gtc att aac agc caa aat ggt	3696
Val Gly Asn Asn Asn Gly Lys Gly Ile Val Ile Asn Ser Gln Asn Gly	
1220 1225 1230	
caa aat acc atc aca gga cta agc aac act cta gct aat gtt acc aat	3744
Gln Asn Thr Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn	
1235 1240 1245	
gat aaa ggt agc gta cgc acc aca gaa cag ggc aat ata atc aaa gac	3792
Asp Lys Gly Ser Val Arg Thr Thr Glu Gln Gly Asn Ile Ile Lys Asp	
1250 1255 1260	
gaa gac aaa acc cgt gcc gcc agc att gtt gat gtg cta agc gca ggc	3840
Glu Asp Lys Thr Arg Ala Ala Ser Ile Val Asp Val Leu Ser Ala Gly	
1265 1270 1275 1280	
ttt aac ttg caa ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat	3888
Phe Asn Leu Gln Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr	
1285 1290 1295	
gac acc gtc aac ttt gcc aat ggc aat acc acc acc gct aag gtg acc	3936
Asp Thr Val Asn Phe Ala Asn Gly Asn Thr Thr Thr Ala Lys Val Thr	
1300 1305 1310	
tat gat gac aca agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg	3984
Tyr Asp Asp Thr Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val	
1315 1320 1325	
gat gat aca acc att gaa gtt aaa gat aaa aaa ctt ggc gta aaa acc	4032
Asp Asp Thr Thr Ile Glu Val Lys Asp Lys Lys Leu Gly Val Lys Thr	
1330 1335 1340	
acc aca ttg acc agt act ggc aca ggt gct aat aaa ttt gcc cta agc	4080
Thr Thr Leu Thr Ser Thr Gly Thr Gly Ala Asn Lys Phe Ala Leu Ser	
1345 1350 1355 1360	
aat caa gct act ggc gat gcg ctt gtc aag gcc agt gat atc gtt gct	4128
Asn Gln Ala Thr Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Val Ala	
1365 1370 1375	
cat cta aac acc tta tct ggc gac atc caa act gcc aaa ggg gca agc	4176
His Leu Asn Thr Leu Ser Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser	
1380 1385 1390	
caa gcg aac aac tca gca ggc tat gtg gat gct gat ggc aat aag gtc	4224
Gln Ala Asn Asn Ser Ala Gly Tyr Val Asp Ala Asp Gly Asn Lys Val	
1395 1400 1405	

atc tat gac agt acc gat aac aag tac tat caa gcc aaa aat gat ggc Ile Tyr Asp Ser Thr Asp Asn Lys Tyr Tyr Gln Ala Lys Asn Asp Gly 1410 1415 1420	4272
aca gtt gat aaa acc aaa gaa gtt gcc aaa gac aaa ctg gtc gcc caa Thr Val Asp Lys Thr Lys Glu Val Ala Lys Asp Lys Leu Val Ala Gln 1425 1430 1435 1440	4320
gcc caa acc cca gat ggc aca ttg gct caa atg aat gtc aaa tca gtc Ala Gln Thr Pro Asp Gly Thr Leu Ala Gln Met Asn Val Lys Ser Val 1445 1450 1455	4368
att aac aaa gaa caa gta aat gat gcc aat aaa aag caa ggc atc aat Ile Asn Lys Glu Gln Val Asn Asp Ala Asn Lys Lys Gln Gly Ile Asn 1460 1465 1470	4416
gaa gac aac gcc ttt gtt aaa gga ctt gaa aaa gcc gct tct gat aac Glu Asp Asn Ala Phe Val Lys Gly Leu Glu Lys Ala Ala Ser Asp Asn 1475 1480 1485	4464
aaa acc aaa aac gcc gca gta act gtg ggt gat tta aat gcc gtt gcc Lys Thr Lys Asn Ala Ala Val Thr Val Gly Asp Leu Asn Ala Val Ala 1490 1495 1500	4512
caa aca ccg ctg acc ttt gca ggg gat aca ggc aca acg gct aaa aaa Gln Thr Pro Leu Thr Phe Ala Gly Asp Thr Gly Thr Thr Ala Lys Lys 1505 1510 1515 1520	4560
ctg ggc gag act ttg acc atc aaa ggt ggg caa aca gac acc aat aag Leu Gly Glu Thr Leu Thr Ile Lys Gly Gly Gln Thr Asp Thr Asn Lys 1525 1530 1535	4608
cta acc gat aat aac atc ggt gtg gta gca ggt act gat ggc ttc act Leu Thr Asp Asn Asn Ile Gly Val Val Ala Gly Thr Asp Gly Phe Thr 1540 1545 1550	4656
gtc aaa ctt gcc aaa gac cta acc aat ctt aac agc gtt aat gca ggt Val Lys Leu Ala Lys Asp Leu Thr Asn Leu Asn Ser Val Asn Ala Gly 1555 1560 1565	4704
ggc acc aaa att gat gaa aaa ggc atc tct ttt gta gac gca aac ggt Gly Thr Lys Ile Asp Glu Lys Gly Ile Ser Phe Val Asp Ala Asn Gly 1570 1575 1580	4752
caa gcc aaa gca aac acc cct gtg cta agt gcc aat ggg ctg gac ctg Gln Ala Lys Ala Asn Thr Pro Val Leu Ser Ala Asn Gly Leu Asp Leu 1585 1590 1595 1600	4800
ggt ggc aag gtc atc agt aat gtg ggc aaa ggc aca aaa gat acc gac Gly Gly Lys Val Ile Ser Asn Val Gly Lys Gly Thr Lys Asp Thr Asp 1605 1610 1615	4848
gct gcc aat gta caa cag tta aac gaa gta cgc aac ttg ttg ggt ctt Ala Ala Asn Val Gln Gln Leu Asn Glu Val Arg Asn Leu Leu Gly Leu 1620 1625 1630	4896
ggt aat gat aac gct gac ggc aat cag gta aac att gcc gac atc aaa Gly Asn Asp Asn Ala Asp Gly Asn Gln Val Asn Ile Ala Asp Ile Lys	4944

1635	1640	1645	
aaa gac cca aat tca ggt tca tca tct aac cgc act gtc atc aaa gca			4992
Lys Asp Pro Asn Ser Gly Ser Ser Ser Asn Arg Thr Val Ile Lys Ala			
1650	1655	1660	
ggc acg gta ctt ggc ggt aaa ggt aat aac gat acc gaa aaa ctt gcc			5040
Gly Thr Val Leu Gly Gly Lys Gly Asn Asn Asp Thr Glu Lys Leu Ala			
1665	1670	1675	1680
act ggt ggt gta caa gtg ggc gtg gat aaa gac ggc aac gct aac ggc			5088
Thr Gly Gly Val Gln Val Gly Val Asp Lys Asp Gly Asn Ala Asn Gly			
1685	1690	1695	
gat tta agc aat gtt tgg gtc aaa acc caa aaa gat ggc agc aaa aaa			5136
Asp Leu Ser Asn Val Trp Val Lys Thr Gln Lys Asp Gly Ser Lys Lys			
1700	1705	1710	
gcc ctg ctc gcc act tat aac gcc gca ggt cag acc aac tat gtg acc			5184
Ala Leu Leu Ala Thr Tyr Asn Ala Ala Gly Gln Thr Asn Tyr Val Thr			
1715	1720	1725	
aac aac ccc gca gaa gcc att gac aga ata aat gaa caa ggt atc cgc			5232
Asn Asn Pro Ala Glu Ala Ile Asp Arg Ile Asn Glu Gln Gly Ile Arg			
1730	1735	1740	
ttc ttc cat gtc aac gat ggc aat caa gag cct gtg gta caa ggg cgt			5280
Phe Phe His Val Asn Asp Gly Asn Gln Glu Pro Val Val Gln Gly Arg			
1745	1750	1755	1760
aac ggc att gac tca agt gcc tca ggc aag cac tca gtg gcg ata ggt			5328
Asn Gly Ile Asp Ser Ser Ala Ser Gly Lys His Ser Val Ala Ile Gly			
1765	1770	1775	
ttc cag gcc aag gca gat ggt gaa gcc gcc gtt gcc ata ggc aga caa			5376
Phe Gln Ala Lys Ala Asp Gly Glu Ala Ala Val Ala Ile Gly Arg Gln			
1780	1785	1790	
acc caa gca ggc aac caa tcc atc gcc atc ggt gat aac gca caa gcc			5424
Thr Gln Ala Gly Asn Gln Ser Ile Ala Ile Gly Asp Asn Ala Gln Ala			
1795	1800	1805	
acg ggc gat caa tcc atc gcc atc ggt aca ggc aat gtg gta gca ggt			5472
Thr Gly Asp Gln Ser Ile Ala Ile Gly Thr Gly Asn Val Val Ala Gly			
1810	1815	1820	
aag cac tct ggt gcc atc ggc gac cca agc act gtt aag gct gat aac			5520
Lys His Ser Gly Ala Ile Gly Asp Pro Ser Thr Val Lys Ala Asp Asn			
1825	1830	1835	1840
agt tac agt gtg ggt aat aac aac cag ttt acc gat gcc act caa acc			5568
Ser Tyr Ser Val Gly Asn Asn Asn Gln Phe Thr Asp Ala Thr Gln Thr			
1845	1850	1855	
gat gtc ttt ggt gtg ggc aat aac atc acc gtg acc gaa agt aac tcg			5616
Asp Val Phe Gly Val Gly Asn Asn Ile Thr Val Thr Glu Ser Asn Ser			
1860	1865	1870	
gtt gcc tta ggt tca aac tct gcc atc agt gca ggc aca cac gca ggc			5664



Figure 5. *Moraxella catarrhalis* les1 200kDa

ATG aat cac atc tat aaa gtc atc ttt aac aaa gcc aca ggc aca ttt	48
Met Asn His Ile Tyr Lys Val Ile Phe Asn Lys Ala Thr Gly Thr Phe	
1 5 10 15	
atg gcc gtg gca gag tgc gcc aaa tcc cac agc gga <u>ggg</u> agt agc agt	96
Met Ala Val Ala Glu Cys Ala Lys Ser His Ser Gly Gly Ser Ser Ser	
20 25 30	
agt acc gca gga cag gtg ggc agc tct cct gtc atc cgc ctg act cgt	144
Ser Thr Ala Gly Gln Val Gly Ser Ser Pro Val Ile Arg Leu Thr Arg	
35 40 45	
gtt gcc acg ctc gct atc cta gtg atc ggt gcg acg ctc aat ggc agt	192
Val Ala Thr Leu Ala Ile Leu Val Ile Gly Ala Thr Leu Asn Gly Ser	
50 55 60	
gct tat gct caa aat aat agc aag atc gca ttt ggt acc aca ggc aac	240
Ala Tyr Ala Gln Asn Asn Ser Lys Ile Ala Phe Gly Thr Thr Gly Asn	
65 70 75 80	
aat gac aat gcc tcg gct agc aat gaa gca tcc att gct att ggt agt	288
Asn Asp Asn Ala Ser Ala Ser Asn Glu Ala Ser Ile Ala Ile Gly Ser	
85 90 95	
ctt gct aag gca cat gcc aat caa gct att gct atc ggt ggt agc aaa	336
Leu Ala Lys Ala His Ala Asn Gln Ala Ile Ala Ile Gly Gly Ser Lys	
100 105 110	
cca gat cct cgt aat caa gcg gct aat cag aag gca ggt tcc cac gcc	384
Pro Asp Pro Arg Asn Gln Ala Ala Asn Gln Lys Ala Gly Ser His Ala	
115 120 125	
aaa ggt aaa gag tcc atc gcc atc ggt ggt gat gta ctg gct gag ggt	432
Lys Gly Lys Glu Ser Ile Ala Ile Gly Gly Asp Val Leu Ala Glu Gly	
130 135 140	
gat gcc tcg att gcc att ggt agt gat gac tta tat ttg gat agg aat	480
Asp Ala Ser Ile Ala Ile Gly Ser Asp Asp Leu Tyr Leu Asp Arg Asn	
145 150 155 160	
agc act aac tct aaa tat cca aat ggt ctt ctt agc act ctt att caa	528
Ser Thr Asn Ser Lys Tyr Pro Asn Gly Leu Leu Ser Thr Leu Ile Gln	
165 170 175	
aac cat aca gta tta cgc caa ata cga gac tca aat ggt tct cag aaa	576
Asn His Thr Val Leu Arg Gln Ile Arg Asp Ser Asn Gly Ser Gln Lys	
180 185 190	
tat aga cgc aca gca gca gaa gga cac gcc agt act gca gtg gga gcc	624
Tyr Arg Arg Thr Ala Ala Glu Gly His Ala Ser Thr Ala Val Gly Ala	
195 200 205	
atg gca tat gca aag ggt cat ttt gcc aac gcc ttt ggt aca cgg tca	672
Met Ala Tyr Ala Lys Gly His Phe Ala Asn Ala Phe Gly Thr Arg Ser	



210				215				220								
aca Thr 225	gct Ala	gaa Glu	ggc Gly	aac Asn	tat Tyr 230	tcc Ser	ttg Leu	gca Ala	gta Val	ggg Gly 235	ctt Leu	acc Thr	gcc Ala	aaa Lys	gcc Ala 240	720
gaa Glu	aaa Lys	gga Gly	tat Tyr	aca Thr 245	atc Ile	gct Ala	att Ile	ggg Gly	tct Ser 250	aat Asn	gca Ala	caa Gln	gct Ala	atc Ile 255	aat Asn	768
tat Tyr	gga Gly	gca Ala	cta Leu 260	gcc Ala	ctt Leu	ggg Gly	gca Ala	gat Asp 265	act Thr	cga Arg	gtt Val	gat Asp 270	ttg Leu	gat Asp	tac Tyr	816
ggg Gly	att Ile	gcc Ala 275	cta Leu	ggg Gly	tat Tyr	ggg Gly	tct Ser 280	cag Gln	atc Ile	ctt Leu	aat Asn 285	aat Asn	aat Asn	aat Asn	aat Asn	864
aat Asn 290	aat Asn	aat Asn	aaa Lys	gcc Ala	tat Tyr	gta Val 295	cca Pro	gaa Glu	ggg Gly	aat Asn 300	ggg Gly	tca Ser	aac Asn	ata Ile	aaa Lys	912
tcg Ser 305	tct Ser	aaa Lys	gcc Ala	acc Thr 310	ggc Gly	aat Asn	ggg Gly	tta Leu	ttt Phe	tcc Ser 315	att Ile	ggg Gly	agt Ser	agc Ser	act Thr 320	960
atc Ile	aag Lys	cgt Arg	aaa Lys 325	atc Ile	atc Ile	aat Asn	gtc Val	ggg Gly	gca Ala 330	ggg Gly	tat Tyr	gag Glu	gat Asp	acc Thr 335	gat Asp	1008
gcg Ala	gtc Val	aat Asn	gtg Val 340	gca Ala	cag Gln	cta Leu	aaa Lys	gcg Ala 345	gtg Val	gag Glu	aat Asn	ctg Leu	gct Ala 350	aag Lys	cgt Arg	1056
caa Gln	att Ile	act Thr 355	ttt Phe	aag Lys	ggg Gly	gat Asp 360	gat Asp	aac Asn	ggg Gly	act Thr	ggc Gly	gtt Val 365	aag Lys	aaa Lys	aaa Lys	1104
ctg Leu	ggc Gly 370	gag Glu	act Thr	tta Leu	acc Thr 375	att Ile	aaa Lys	ggg Gly	ggg Gly	gag Glu	acc Thr 380	caa Gln	gcg Ala	gac Asp	aag Lys	1152
cta Leu 385	acc Thr	gat Asp	aat Asn	aat Asn	aac Asn 390	att Ile	ggg Gly	gtg Val	gta Val	aca Thr 395	gat Asp	aat Asn	aat Asn	act Thr	ggg Gly 400	1200
ctg Leu	aaa Lys	gtt Val	aaa Lys	ctt Leu 405	gct Ala	aaa Lys	aac Asn	cta Leu	agc Ser 410	ggg Gly	ctt Leu	gaa Glu	aca Thr	gtt Val 415	agc Ser	1248
acc Thr	aaa Lys	aac Asn	cta Leu 420	acc Thr	gcc Ala	agc Ser	gag Glu	aaa Lys 425	gtt Val	acg Thr	gta Val	ggg Gly	agt Ser 430	ggg Gly	aat Asn	1296
aac Asn	acc Thr	gct Ala 435	gag Glu	cta Leu	caa Gln	agc Ser	ggg Gly	ggg Gly	tta Leu	acc Thr	ttt Phe	acc Thr 445	cca Pro	aca Thr	aca Thr	1344

aat gca agc aca gac	aaa acc gtc tat ggc act gat ggg ctt aag ttt	1392
Asn Ala Ser Thr Asp	Lys Thr Val Tyr Gly Thr Asp Gly Leu Lys Phe	
450	455 460	
act gat aat tct aat acg gca ctt gaa gat act act cgt atc acc aaa	1440	
Thr Asp Asn Ser Asn Thr Ala Leu Glu Asp Thr Thr Arg Ile Thr Lys		
465	470 475 480	
gat aaa att ggt ttt agc aat aaa gct ggt aca gtt gat gaa aac aaa	1488	
Asp Lys Ile Gly Phe Ser Asn Lys Ala Gly Thr Val Asp Glu Asn Lys		
	485 490 495	
cct tat ctt gat aaa gac aag cta aaa gtt ggc aac agc acc cta aac	1536	
Pro Tyr Leu Asp Lys Asp Lys Leu Lys Val Gly Asn Ser Thr Leu Asn		
	500 505 510	
aac ggt ggc ttg act gtt aat aac acc att ggt ggt agc aat aaa caa	1584	
Asn Gly Gly Leu Thr Val Asn Asn Thr Ile Gly Gly Ser Asn Lys Gln		
	515 520 525	
atc caa gtc ggt gct gat ggc att aaa ttt gcc gat gtg aat gtt aat	1632	
Ile Gln Val Gly Ala Asp Gly Ile Lys Phe Ala Asp Val Asn Val Asn		
	530 535 540	
gta tca aat gcc gca aaa ttc ggc act act cgt att acc gaa gag gaa	1680	
Val Ser Asn Ala Ala Lys Phe Gly Thr Thr Arg Ile Thr Glu Glu Glu		
	545 550 555 560	
att ggc ttt gct gat gct gat ggt aaa gtt gat aaa aag tca cca tat	1728	
Ile Gly Phe Ala Asp Ala Asp Gly Lys Val Asp Lys Lys Ser Pro Tyr		
	565 570 575	
ttg gat aaa aaa caa ctt caa gtg ggt ggt gtt aaa att acc aaa gac	1776	
Leu Asp Lys Lys Gln Leu Gln Val Gly Gly Val Lys Ile Thr Lys Asp		
	580 585 590	
agt ggc att aat gca ggt gat caa aag atc agt aat gtt aaa gat gca	1824	
Ser Gly Ile Asn Ala Gly Asp Gln Lys Ile Ser Asn Val Lys Asp Ala		
	595 600 605	
acg gac gat acc gat gca gtc act tat aaa cag ctt aaa caa gtc caa	1872	
Thr Asp Asp Thr Asp Ala Val Thr Tyr Lys Gln Leu Lys Gln Val Gln		
	610 615 620	
caa gac gcc gac ggt gcc cta caa agc ttc tct att cgt gat gaa aaa	1920	
Gln Asp Ala Asp Gly Ala Leu Gln Ser Phe Ser Ile Arg Asp Glu Lys		
	625 630 635 640	
ggt cag gaa ttt acg att agt aac ttg tat tct aat ggt aat acc cca	1968	
Gly Gln Glu Phe Thr Ile Ser Asn Leu Tyr Ser Asn Gly Asn Thr Pro		
	645 650 655	
aat acc ttt gag acc atc acc ttt gca ggt gaa aac ggc atc agt atc	2016	
Asn Thr Phe Glu Thr Ile Thr Phe Ala Gly Glu Asn Gly Ile Ser Ile		
	660 665 670	

agc aat gac ata gcc aaa ggt aaa gtc aaa gtt ggt att gac cca atc	2064
Ser Asn Asp Ile Ala Lys Gly Lys Val Lys Val Gly Ile Asp Pro Ile	
675 680 685	
aat ggt ctc acc acg cct aag ctg acc gtg ggt agc gat aaa gat ggt	2112
Asn Gly Leu Thr Thr Pro Lys Leu Thr Val Gly Ser Asp Lys Asp Gly	
690 695 700	
aaa act caa ttg gtt att gag caa gtg gct agc ggt aac gac acc aaa	2160
Lys Thr Gln Leu Val Ile Glu Gln Val Ala Ser Gly Asn Asp Thr Lys	
705 710 715 720	
aac atc att aga gga ttg tcc cca aca ctg cct agc att acc aat gca	2208
Asn Ile Ile Arg Gly Leu Ser Pro Thr Leu Pro Ser Ile Thr Asn Ala	
725 730 735	
ggt ggc gta cgc acc aca gaa cag ggc aat aca atc acc agc gac gaa	2256
Gly Gly Val Arg Thr Thr Glu Gln Gly Asn Thr Ile Thr Ser Asp Glu	
740 745 750	
gac aaa tcc aaa gcc gcc agt atc ggt gat ata tta aat aca ggc ttt	2304
Asp Lys Ser Lys Ala Ala Ser Ile Gly Asp Ile Leu Asn Thr Gly Phe	
755 760 765	
aac cta aaa aat aat agc aac tcc gtt ggc ttt gtc tcc act tat aac	2352
Asn Leu Lys Asn Asn Ser Asn Ser Val Gly Phe Val Ser Thr Tyr Asn	
770 775 780	
act gtt gac ttt atc gat ggc aat gcc acc acc gct aag gta act tac	2400
Thr Val Asp Phe Ile Asp Gly Asn Ala Thr Thr Ala Lys Val Thr Tyr	
785 790 795 800	
gat gaa acc aat caa acc agt aaa gta act tat gat gtc aat gtg gat	2448
Asp Glu Thr Asn Gln Thr Ser Lys Val Thr Tyr Asp Val Asn Val Asp	
805 810 815	
gag aaa acc att gaa ctc aca ggc gat aat ggc aag aca aac aaa att	2496
Glu Lys Thr Ile Glu Leu Thr Gly Asp Asn Gly Lys Thr Asn Lys Ile	
820 825 830	
ggc gtc aaa acc acc aca ctg acc aca aca aat gct aat ggt aaa gca	2544
Gly Val Lys Thr Thr Thr Leu Thr Thr Thr Asn Ala Asn Gly Lys Ala	
835 840 845	
acc aac ttt agt acc acc gat aac gat gcc ctt gtt aac gcc aaa gac	2592
Thr Asn Phe Ser Thr Thr Asp Asn Asp Ala Leu Val Asn Ala Lys Asp	
850 855 860	
atc gcc gaa aat cta aac acc cta gcc aag gaa att cac acc acc aaa	2640
Ile Ala Glu Asn Leu Asn Thr Leu Ala Lys Glu Ile His Thr Thr Lys	
865 870 875 880	
ggc aca gca gac acc gcc cta caa acc ttt aaa gtc aaa aaa gac ggt	2688
Gly Thr Ala Asp Thr Ala Leu Gln Thr Phe Lys Val Lys Lys Asp Gly	
885 890 895	
gca act gat gac gaa acc atc acc gtg ggt aaa gat ggt aca caa aac	2736

Ala Thr Asp Asp Glu Thr Ile Thr Val Gly Lys Asp Gly Thr Gln Asn	
900 905 910	
ggc aag acc gtc aac act cta aaa ctc aaa ggt gaa aac ggt cta acg	2784
Gly Lys Thr Val Asn Thr Leu Lys Leu Lys Gly Glu Asn Gly Leu Thr	
915 920 925	
gtt gct acc aat aaa gat ggt acg gtt acc ttt ggc att aac acc caa	2832
Val Ala Thr Asn Lys Asp Gly Thr Val Thr Phe Gly Ile Asn Thr Gln	
930 935 940	
agc ggt ctt aaa gcc ggc gac agc acc act cta aac aaa gat ggc ttg	2880
Ser Gly Leu Lys Ala Gly Asp Ser Thr Thr Leu Asn Lys Asp Gly Leu	
945 950 955 960	
tct att aaa aac ccc gct agt aac gaa caa atc caa gtc ggt gct gat	2928
Ser Ile Lys Asn Pro Ala Ser Asn Glu Gln Ile Gln Val Gly Ala Asp	
965 970 975	
ggc gtg aag ttt gcc aag gtt gat aag ggt aat tca agc act ggc att	2976
Gly Val Lys Phe Ala Lys Val Asp Lys Gly Asn Ser Ser Thr Gly Ile	
980 985 990	
gat ggc aca agc cgt atc acc aaa gat caa att ggc ttt act ggg gct	3024
Asp Gly Thr Ser Arg Ile Thr Lys Asp Gln Ile Gly Phe Thr Gly Ala	
995 1000 1005	
aat ggc tca ctt gat acc acc aaa ccc cac cta acc aaa gac aag ctt	3072
Asn Gly Ser Leu Asp Thr Thr Lys Pro His Leu Thr Lys Asp Lys Leu	
1010 1015 1020	
aaa gtg ggt gaa gtt gaa att acc aac act ggc att aac gca ggt ggt	3120
Lys Val Gly Glu Val Glu Ile Thr Asn Thr Gly Ile Asn Ala Gly Gly	
1025 1030 1035 1040	
aaa aag att acc aac att caa tca ggt gat att acc caa aac agc aat	3168
Lys Lys Ile Thr Asn Ile Gln Ser Gly Asp Ile Thr Gln Asn Ser Asn	
1045 1050 1055	
gat gct gtg aca ggc ggt cgg gtt tat gat tta aaa acc gaa ctt gaa	3216
Asp Ala Val Thr Gly Gly Arg Val Tyr Asp Leu Lys Thr Glu Leu Glu	
1060 1065 1070	
agc aaa atc aac agt gct gct aaa aca gca caa aac tca tta cac gaa	3264
Ser Lys Ile Asn Ser Ala Ala Lys Thr Ala Gln Asn Ser Leu His Glu	
1075 1080 1085	
ttc tca gta gca gat gaa caa ggt aat cac ttt acg gtt agt aac cct	3312
Phe Ser Val Ala Asp Glu Gln Gly Asn His Phe Thr Val Ser Asn Pro	
1090 1095 1100	
tac tcc agt tat gac acc tca aag acc tct gat gtc atc acc ttt gca	3360
Tyr Ser Ser Tyr Asp Thr Ser Lys Thr Ser Asp Val Ile Thr Phe Ala	
1105 1110 1115 1120	
ggc gaa aac ggc att acc acc aag gta aat aaa ggt gtg gtg cgt gtg	3408
Gly Glu Asn Gly Ile Thr Thr Lys Val Asn Lys Gly Val Val Arg Val	

1125						1130						1135						
ggc att gac caa acc aaa ggc tta acc acg cct aag ctg acc gtg ggt	3456																	
Gly Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr Val Gly																		
1140 1145 1150																		
aat aat aat ggc aaa ggc att gtc att gac agt aaa gat ggt caa aat	3504																	
Asn Asn Asn Gly Lys Gly Ile Val Ile Asp Ser Lys Asp Gly Gln Asn																		
1155 1160 1165																		
acc atc aca gga cta agc aac act cta gct aat gtt acc aat gat ggt	3552																	
Thr Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn Asp Gly																		
1170 1175 1180																		
gca gga cac gca cta agc caa ggg ctt gcc aat gac acc gac aaa acc	3600																	
Ala Gly His Ala Leu Ser Gln Gly Leu Ala Asn Asp Thr Asp Lys Thr																		
1185 1190 1195 1200																		
cgt gcc gcc agc att ggt gat gtg cta aac gca ggc ttt aac ttg caa	3648																	
Arg Ala Ala Ser Ile Gly Asp Val Leu Asn Ala Gly Phe Asn Leu Gln																		
1205 1210 1215																		
ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat gac act gtt gac	3696																	
Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr Asp Thr Val Asp																		
1220 1225 1230																		
ttt atc gat ggc aat gcc acc acc gct aag gtg acc tat gat gac aca	3744																	
Phe Ile Asp Gly Asn Ala Thr Thr Ala Lys Val Thr Tyr Asp Asp Thr																		
1235 1240 1245																		
agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg gat aat aaa acc	3792																	
Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val Asp Asn Lys Thr																		
1250 1255 1260																		
att gaa gtg aca agt gat aaa aaa ctt ggc gtc aaa acc acc aca ctg	3840																	
Ile Glu Val Thr Ser Asp Lys Lys Leu Gly Val Lys Thr Thr Thr Leu																		
1265 1270 1275 1280																		
acc aaa aca agt gct aat ggt aat gca acc aaa ttt agt gcc gcc gat	3888																	
Thr Lys Thr Ser Ala Asn Gly Asn Ala Thr Lys Phe Ser Ala Ala Asp																		
1285 1290 1295																		
ggc gat gcc ctt gtt aaa gcc agt gat atc gcc acc cat cta aat acc	3936																	
Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Ala Thr His Leu Asn Thr																		
1300 1305 1310																		
ttg gct ggc gac atc caa acc gcc aaa ggg gca agc caa gca agc agc	3984																	
Leu Ala Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser Gln Ala Ser Ser																		
1315 1320 1325																		
tca gca agc tat gtg gat gct gat ggc aac aag gtc atc tat gac agt	4032																	
Ser Ala Ser Tyr Val Asp Ala Asp Gly Asn Lys Val Ile Tyr Asp Ser																		
1330 1335 1340																		
acc gat aag aag tac tat caa gtc aat gac aag ggt caa gtg gac aaa	4080																	
Thr Asp Lys Lys Tyr Tyr Gln Val Asn Asp Lys Gly Gln Val Asp Lys																		
1345 1350 1355 1360																		

1125

1135

ggc att gac caa acc aaa ggc tta acc acg cct aag ctg acc gtg ggt 3456  
Gly Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr Val Gly  
1140 1145 1150

aat aat aat ggc aaa ggc att gtc att gac agt aaa gat ggt caa aat 3504  
Asn Asn Asn Gly Lys Gly Ile Val Ile Asp Ser Lys Asp Gly Gln Asn  
1155 1160 1165

acc atc aca gga cta agc aac act cta gct aat gtt acc aat gat ggt 3552  
Thr Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn Asp Gly  
1170 1175 1180

gca gga cac gca cta agc caa ggg ctt gcc aat gac acc gac aaa acc 3600  
Ala Gly His Ala Leu Ser Gln Gly Leu Ala Asn Asp Thr Asp Lys Thr  
1185 1190 1195 1200

cgt gcc gcc agc att ggt gat gtg cta aac gca ggc ttt aac ttg caa 3648  
Arg Ala Ala Ser Ile Gly Asp Val Leu Asn Ala Gly Phe Asn Leu Gln  
1205 1210 1215

ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat gac act gtt gac 3696  
Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr Asp Thr Val Asp  
1220 1225 1230

ttt atc gat ggc aat gcc acc acc gct aag gtg acc tat gat gac aca 3744  
Phe Ile Asp Gly Asn Ala Thr Thr Ala Lys Val Thr Tyr Asp Asp Thr  
1235 1240 1245

agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg gat aat aaa acc 3792  
Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val Asp Asn Lys Thr  
1250 1255 1260

att gaa gtg aca agt gat aaa aaa ctt ggc gtc aaa acc acc aca ctg 3840  
Ile Glu Val Thr Ser Asp Lys Lys Leu Gly Val Lys Thr Thr Thr Leu  
1265 1270 1275 1280

acc aaa aca agt gct aat ggt aat gca acc aaa ttt agt gcc gcc gat 3888  
Thr Lys Thr Ser Ala Asn Gly Asn Ala Thr Lys Phe Ser Ala Ala Asp  
1285 1290 1295

ggc gat gcc ctt gtt aaa gcc agt gat atc gcc acc cat cta aat acc 3936  
Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Ala Thr His Leu Asn Thr  
1300 1305 1310

ttg gct ggc gac atc caa acc gcc aaa ggg gca agc caa gca agc agc 3984  
Leu Ala Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser Gln Ala Ser Ser  
1315 1320 1325

```
tca gca agc tat gtg gat gct gat ggc aac aag gtc atc tat gac agt    4032
Ser Ala Ser Tyr Val Asp Ala Asp Gly Asn Lys Val Ile Tyr Asp Ser
      1330              1335              1340
```

acc gat aag aag tac tat caa gtc aat gac aag ggt caa gtg gac aaa 4080  
Thr Asp Lys Lys Tyr Tyr Gln Val Asn Asp Lys Gly Gln Val Asp Lys  
1345 1350 1355 1360

aac aaa gaa gtt gcc aaa gac aaa ctg gtc gcc caa gcc caa acc cca	4128
Asn Lys Glu Val Ala Lys Asp Lys Leu Val Ala Gln Ala Gln Thr Pro	
1365 1370 1375	
gat ggc aca ttg gct caa atg aat gtc aaa tca gtc att aac aaa gag	4176
Asp Gly Thr Leu Ala Gln Met Asn Val Lys Ser Val Ile Asn Lys Glu	
1380 1385 1390	
caa gta aat gat gcc aat aaa aag caa ggc atc aat gaa gac aac gcc	4224
Gln Val Asn Asp Ala Asn Lys Lys Gln Gly Ile Asn Glu Asp Asn Ala	
1395 1400 1405	
ttt atc aaa ggg ctt gaa aac gcc gcc aaa gac acc aaa acc aaa aac	4272
Phe Ile Lys Gly Leu Glu Asn Ala Ala Lys Asp Thr Lys Thr Lys Asn	
1410 1415 1420	
gcc gca gta act gtg ggt gat tta aat gcc gtt gcc caa aca ccg ctg	4320
Ala Ala Val Thr Val Gly Asp Leu Asn Ala Val Ala Gln Thr Pro Leu	
1425 1430 1435 1440	
acc ttt gca ggg gat aca ggc aca acg gct aaa aaa ctg ggc gag act	4368
Thr Phe Ala Gly Asp Thr Gly Thr Thr Ala Lys Lys Leu Gly Glu Thr	
1445 1450 1455	
ttg acc atc aaa ggt ggg caa aca gac acc aat aag cta acc gat aat	4416
Leu Thr Ile Lys Gly Gly Gln Thr Asp Thr Asn Lys Leu Thr Asp Asn	
1460 1465 1470	
aac atc ggt gtg gta gca ggt act gat ggc ttc act gtc aaa ctt gcc	4464
Asn Ile Gly Val Val Ala Gly Thr Asp Gly Phe Thr Val Lys Leu Ala	
1475 1480 1485	
aaa gac cta acc aat ctt aac agc gtt aat gca ggt ggc acc aga att	4512
Lys Asp Leu Thr Asn Leu Asn Ser Val Asn Ala Gly Gly Thr Arg Ile	
1490 1495 1500	
gat gaa aaa ggc atc tct ttt gta gac gca aac ggt caa gcc aaa gca	4560
Asp Glu Lys Gly Ile Ser Phe Val Asp Ala Asn Gly Gln Ala Lys Ala	
1505 1510 1515 1520	
aac acc cct gtg cta agt gcc aat ggg ctg gac ctg ggt ggc aaa cgc	4608
Asn Thr Pro Val Leu Ser Ala Asn Gly Leu Asp Leu Gly Gly Lys Arg	
1525 1530 1535	
atc agt aac atc ggt gca gct gtt gat gat aac gat gcg gtg aac ttt	4656
Ile Ser Asn Ile Gly Ala Ala Val Asp Asp Asn Asp Ala Val Asn Phe	
1540 1545 1550	
aag cag ttt aat gaa gtt gcc aaa acg gtc aac aac cta aac aac caa	4704
Lys Gln Phe Asn Glu Val Ala Lys Thr Val Asn Asn Leu Asn Asn Gln	
1555 1560 1565	
agt aac tca ggt gcg tca tta ccc ttt gtg gta acc gat gcc aat ggc	4752
Ser Asn Ser Gly Ala Ser Leu Pro Phe Val Val Thr Asp Ala Asn Gly	
1570 1575 1580	

aag ccc atc aat ggc acc gat ggc aag ccc caa aaa gcc atc aag ggc Lys Pro Ile Asn Gly Thr Asp Gly Lys Pro Gln Lys Ala Ile Lys Gly 1585 1590 1595 1600	4800
gcc gat ggt aaa tac tat cac gcc aac gcc aac ggc gta cct gtg gac Ala Asp Gly Lys Tyr Tyr His Ala Asn Ala Asn Gly Val Pro Val Asp 1605 1610 1615	4848
aaa gat ggc aag ccc atc acc gat gcg gac aaa ctt gcc aat ctg gca Lys Asp Gly Lys Pro Ile Thr Asp Ala Asp Lys Leu Ala Asn Leu Ala 1620 1625 1630	4896
gct cat ggc aaa ccc ctt gat gca ggt cat caa gtg gtg gca agc cta Ala His Gly Lys Pro Leu Asp Ala Gly His Gln Val Val Ala Ser Leu 1635 1640 1645	4944
ggc ggc aac tca gat gcc atc acc cta acc aac atc aag tcc act ttg Gly Gly Asn Ser Asp Ala Ile Thr Leu Thr Asn Ile Lys Ser Thr Leu 1650 1655 1660	4992
cca caa att gac aca cca aac aca ggt aat gcc aat gca ggg caa gcc Pro Gln Ile Asp Thr Pro Asn Thr Gly Asn Ala Asn Ala Gly Gln Ala 1665 1670 1675 1680	5040
caa agt ctg ccc agc cta tca gca gca cag caa agt aat gct gcc agt Gln Ser Leu Pro Ser Leu Ser Ala Ala Gln Gln Ser Asn Ala Ala Ser 1685 1690 1695	5088
gtc aaa gat gtg cta aat gta ggc ttt aac ttg cag acc aat cac aat Val Lys Asp Val Leu Asn Val Gly Phe Asn Leu Gln Thr Asn His Asn 1700 1705 1710	5136
caa gtg gac ttt gtc aaa gcc tat gat acc gtc aac ttt gtc aat ggt Gln Val Asp Phe Val Lys Ala Tyr Asp Thr Val Asn Phe Val Asn Gly 1715 1720 1725	5184
aca ggt gcc gac atc aca agc gtg cgt agt gct gat ggc acg atg agt Thr Gly Ala Asp Ile Thr Ser Val Arg Ser Ala Asp Gly Thr Met Ser 1730 1735 1740	5232
aac atc acc gtc aac acc gcc tta gca gcg acc gat gat gat ggc aat Asn Ile Thr Val Asn Thr Ala Leu Ala Ala Thr Asp Asp Asp Gly Asn 1745 1750 1755 1760	5280
gtg ctt atc aaa gcc aaa gat ggt aag ttc tac aaa gca gac gac ctc Val Leu Ile Lys Ala Lys Asp Gly Lys Phe Tyr Lys Ala Asp Asp Leu 1765 1770 1775	5328
atg cca aac ggc tca cta aaa gca ggc aaa tca gcc agt gat gcc aaa Met Pro Asn Gly Ser Leu Lys Ala Gly Lys Ser Ala Ser Asp Ala Lys 1780 1785 1790	5376
act cca act ggt cta agc ctt gtt aac ccc aat gct ggt aaa ggc agt Thr Pro Thr Gly Leu Ser Leu Val Asn Pro Asn Ala Gly Lys Gly Ser 1795 1800 1805	5424
aca ggc gat gca gtg gct ctt aat aac tta tca aaa gcg gta ttt aaa	5472

Thr Gly Asp Ala Val Ala Leu Asn Asn Leu Ser Lys Ala Val Phe Lys	
1810	1815 1820
tcc aaa gat ggt aca act act acc aca gta agc tct gat ggc atc agt	5520
Ser Lys Asp Gly Thr Thr Thr Thr Val Ser Ser Asp Gly Ile Ser	
1825	1830 1835 1840
atc caa ggc aaa gat aac agc agc atc acc cta agc aaa gat ggg ctg	5568
Ile Gln Gly Lys Asp Asn Ser Ser Ile Thr Leu Ser Lys Asp Gly Leu	
	1845 1850 1855
aat gta ggc ggt aag gtc atc agc aat gtg ggt aaa ggc aca aaa gac	5616
Asn Val Gly Gly Lys Val Ile Ser Asn Val Gly Lys Gly Thr Lys Asp	
	1860 1865 1870
acc gac gct gcc aat gta caa cag tta aac gaa gta cgc aac ttg ttg	5664
Thr Asp Ala Ala Asn Val Gln Gln Leu Asn Glu Val Arg Asn Leu Leu	
	1875 1880 1885
ggt ctt ggt aat gct ggt aat gat aac gct gac ggc aat cag gta aac	5712
Gly Leu Gly Asn Ala Gly Asn Asp Asn Ala Asp Gly Asn Gln Val Asn	
	1890 1895 1900
att gcc gac atc aaa aaa gac cca aat tca ggt tca tca tct aac cgc	5760
Ile Ala Asp Ile Lys Lys Asp Pro Asn Ser Gly Ser Ser Ser Asn Arg	
	1905 1910 1915 1920
act gtc atc aaa gca ggc acg gta ctt ggc ggt aaa ggt aat aac gat	5808
Thr Val Ile Lys Ala Gly Thr Val Leu Gly Gly Lys Gly Asn Asn Asp	
	1925 1930 1935
acc gaa aaa ctt gcc act ggt ggt gta caa gtg ggc gtg gat aaa gac	5856
Thr Glu Lys Leu Ala Thr Gly Gly Val Gln Val Gly Val Asp Lys Asp	
	1940 1945 1950
ggc aac gct aac ggc gat tta agc aat gtt tgg gtc aaa acc caa aaa	5904
Gly Asn Ala Asn Gly Asp Leu Ser Asn Val Trp Val Lys Thr Gln Lys	
	1955 1960 1965
gat ggc agc aaa aaa gcc ctg ctc gcc act tat aac gcc gca ggt cag	5952
Asp Gly Ser Lys Lys Ala Leu Leu Ala Thr Tyr Asn Ala Ala Gly Gln	
	1970 1975 1980
acc aac tat ttg acc aac aac ccc gca gaa gcc att gac aga ata aat	6000
Thr Asn Tyr Leu Thr Asn Asn Pro Ala Glu Ala Ile Asp Arg Ile Asn	
	1985 1990 1995 2000
gaa caa ggt atc cgc ttc ttc cat gtc aac gat ggc aat caa gag cct	6048
Glu Gln Gly Ile Arg Phe Phe His Val Asn Asp Gly Asn Gln Glu Pro	
	2005 2010 2015
gtg gta caa ggg cgt aac ggc att gac tca agt gcc tca ggc aag cac	6096
Val Val Gln Gly Arg Asn Gly Ile Asp Ser Ser Ala Ser Gly Lys His	
	2020 2025 2030
tca gtg gcg ata ggt ttc cag gcc aag gca gat ggt gaa gcc gcc gtt	6144
Ser Val Ala Ile Gly Phe Gln Ala Lys Ala Asp Gly Glu Ala Ala Val	



2035	2040	2045	
gcc ata ggc aga caa acc caa gca ggc aac caa tcc atc gcc atc ggt Ala Ile Gly Arg Gln Thr Gln Ala Gly Asn Gln Ser Ile Ala Ile Gly 2050	2055	2060	6192
gat aac gca caa gcc acg ggc gat caa tcc atc gcc atc ggt aca ggc Asp Asn Ala Gln Ala Thr Gly Asp Gln Ser Ile Ala Ile Gly Thr Gly 2065	2070	2075 2080	6240
aat gtg gta aca ggt aag cac tct ggt gcc atc ggc gac cca agc act Asn Val Val Thr Gly Lys His Ser Gly Ala Ile Gly Asp Pro Ser Thr 2085	2090	2095	6288
gtt aag gct gat aac agt tac agt gtg ggt aat aac aac cag ttt atc Val Lys Ala Asp Asn Ser Tyr Ser Val Gly Asn Asn Asn Gln Phe Ile 2100	2105	2110	6336
gat gcc act cag acc gat gtc ttt ggt gtg ggc aat aac atc acc gtg Asp Ala Thr Gln Thr Asp Val Phe Gly Val Gly Asn Asn Ile Thr Val 2115	2120	2125	6384
acc gaa agt aac tcg gtt gcc tta ggt tca aac tct gcc atc agt gca Thr Glu Ser Asn Ser Val Ala Leu Gly Ser Asn Ser Ala Ile Ser Ala 2130	2135	2140	6432
ggc aca cac gca ggc aca caa gcc aaa aaa tct gac ggc aca gca ggt Gly Thr His Ala Gly Thr Gln Ala Lys Lys Ser Asp Gly Thr Ala Gly 2145	2150	2155 2160	6480
aca acc acc aca gca ggt gca aca ggt acg gtt aaa ggc ttt gct gga Thr Thr Thr Thr Ala Gly Ala Thr Gly Thr Val Lys Gly Phe Ala Gly 2165	2170	2175	6528
caa acg gcg gtt ggt gcg gtc tcc gtg ggt gcc tca ggt gct gaa cgc Gln Thr Ala Val Gly Ala Val Ser Val Gly Ala Ser Gly Ala Glu Arg 2180	2185	2190	6576
cgt atc caa aat gtg gca gca ggt gag gtc agt gcc acc agc acc gat Arg Ile Gln Asn Val Ala Ala Gly Glu Val Ser Ala Thr Ser Thr Asp 2195	2200	2205	6624
gcg gtc aat ggt agc cag ttg tac aaa gcc acc caa ggc att gcc aac Ala Val Asn Gly Ser Gln Leu Tyr Lys Ala Thr Gln Gly Ile Ala Asn 2210	2215	2220	6672
gca acc aat gag ctt gac cat cgt atc cac caa aac gaa aat aaa gcc Ala Thr Asn Glu Leu Asp His Arg Ile His Gln Asn Glu Asn Lys Ala 2225	2230	2235 2240	6720
aat gca ggg att tca tca gcg atg gcg atg gcg tcc atg cca caa gcc Asn Ala Gly Ile Ser Ser Ala Met Ala Met Ala Ser Met Pro Gln Ala 2245	2250	2255	6768
tac att cct ggc aga tcc atg gtt acc ggg ggt att gcc acc cac aac Tyr Ile Pro Gly Arg Ser Met Val Thr Gly Gly Ile Ala Thr His Asn 2260	2265	2270	6816

ggt	caa	ggt	gcg	gtg	gca	gtg	gga	ctg	tcg	aag	ctg	tcg	gat	aat	ggt	6864
Gly	Gln	Gly	Ala	Val	Ala	Val	Gly	Leu	Ser	Lys	Leu	Ser	Asp	Asn	Gly	
		2275					2280						2285			
caa	tgg	gta	ttt	aaa	atc	aat	ggt	tca	gcc	gat	acc	caa	ggc	cat	gta	6912
Gln	Trp	Val	Phe	Lys	Ile	Asn	Gly	Ser	Ala	Asp	Thr	Gln	Gly	His	Val	
	2290						2295					2300				
ggg	gcg	gca	gtt	ggt	gca	ggt	ttt	cac	ttt							6942
Gly	Ala	Ala	Val	Gly	Ala	Gly	Phe	His	Phe							
2305						2310										

66220" 6TGTSEE0

[illegible]

[illegible]

Q8  
LES-1

[illegible][illegible][illegible]

	1010	1020	1030	1040	1050	1060	1070	1080	1090	1100	
DKNGTVTFGIN	TTSG	LKAK	ST-	LDNG	LSIK	NTGSE	QIQV	GADGV	KFAK	VNNN	---
GVVG	GAGID	TTTR	DRBE	IGFT	GTNG	SLDK	SPHL	SKDGIN	AGGKI	---	4223
..D.	..D.	..Q.	..D.	..T.	..NN.	..TASN.	..M.	..---	..---	..---	Q8
..N.D.	..D.	..Q.	..D.	..T.	..KD.	..ASN.	..DK.	..NSST.	..S.	..K.Q.	..A.
..TT.	..TT.	..TT.	..TT.	..TT.	..TT.	..TT.	..TT.	..TT.	..TT.	..TT.	..TT.
..T.	..KL	..KV.	..EVE.	..TNTG	..INAGGKI	..LES-1					

[illegible]

1210	1220	1230	1240	1250	1260	1270	1280	1290	1300	
LTTPKLTGVNNGKGI	VDSONQNTITGLS	NTLANVTNDKGS	VRTTEQGNIIK	DEKTRAASIV	DVLSAGFNI	QNGEAVDF	VSTYDITV	NFADGNATTA		4223
.....N.	.....N.	.....N.	.....N.	.....N.	.....N.	.....N.	.....N.	.....N.	.....N.	Q8
.....KD	.....AGHALS	..LAN- T	.....G	..N	.....G	..N	.....D	..I	.....	LES-1

55220" 64379560

1

1310 1320 1330 1340 1350 1360 1370 1380 1390 1400  
KVYDDTSKTSKVYDVNVDDTTIEVK-DKKLGVTTLTSTGTGANKFALSNOATGDALVKASDI VAHLNLTSGDIQTAKGASQANNSAGYVDADGNKVI  
.....NK.....TS.....K.SANG.ATKF.A-D.....AT.....A.....SS..S.....  
4223  
Q8  
LES-1

1410 1420 1430 1440 1450 1460 1470 1480 1490 1500  
YDSTDNKYYQAKNDGTVDKTRKVAKDLVQAQTPDGTIAQMNVKSVINKEQVNDANKKQGINEDNAFVKGLEKAASDNKTKNAAVTVGDLNVAQTPLT  
.....K.....VNDK.Q...N.....I...N.K.T.....  
4223  
Q8  
LES-1

1510 1520 1530 1540 1550 1560 1570 1580 1590  
FAGDTGTAKK-LGETLTIKGGQTDNKLTDN-NIGVVAGTDGFTVKLAKDLTNLSNVNAGTKIDDKGVSVFVDSSGQAKANTPVLSANGLDL-----  
.....E..I...AN.....  
.....R..E..I...AN.....GGKRI  
4223  
Q8  
LES-1

-----  
SNI GAAVDDND AVNFKQ FNEVAKTVNNLNNQSN SGASLPFVVTDANGKP INGTGKPKQAIKGADKYYHANANGVPVDKDKPITDADKLANLAHAKP  
-----  
4223  
Q8  
LES-1

-----  
LDAGHQVVASLGGNSDAITLTNIIKSTLTPQIDTPNTGNANAGQAQSLPSLSAAQQSNAASVKDVLNVGFNLQTNHNQVDFVKAYDTVNFVNGTGADITSVR  
-----  
4223  
Q8  
LES-1

-----  
SADGTM SNITWNTALAAATDDDGNVLIKAKDKGFYKADDLMPNGSLKAGKSASDAKPTPTGLSLVNPNAKGSTGDAVALNNLSKAVFKSKDGTTTTIVSSD  
-----  
4223  
Q8  
LES-1

662320" 67373650

1600  
-----GGKVISNVG  
-----  
GISIQKDNSSITLSKDGLNV.....

4223  
Q8  
LES-1

1610 1620 1630 1640 1650 1660 1670 1680 1690 1700  
KGTKDTDAANVQQLNEVRNLLGLGNAGNDNADGNQVNIADIKKDPNSGSSNRVTIKAGTVLGGKGNNDTEKLAIGGIQVGVDDKDGNGDLSNVVWKTQ  
.....  
.....V.....  
.....V.....

4223  
Q8  
LES-1

1710 1720 1730 1740 1750 1760 1770 1780 1790 1800  
KDGSKALLATYNAAGQTNYLTNPAEAIIDRINEQGIRFFHVNDGNQEVVQGRNGIDSSASGKHSVAIGFQAKADGEAAVAIGRQTQAGNQSIAGDNA  
.....V.....  
.....  
.....

4223  
Q8  
LES-1

1810 1820 1830 1840 1850 1860 1870 1880 1890 1900  
QATGDQSIAIGTGNVAGKHSGAIGDPSTVKADNSYSVGNNNQFTDATQTDVFGVGNNTVTESNSVALGSNSAISAGTHAGTQAKKSDGTAGTTTTAGA  
.....  
.....T.....I.....  
.....

4223  
Q8  
LES-1

1910 1920 1930 1940 1950 1960 1970 1980 1990 2000  
TGTVKGFAQTAVGAVSVGASGAERRIQNVAAGEVSAITSDAVNGSQLYKATQSIANATNELDHRHQNENKANAGISSAMAMASMPQAYIPGRSMVTGG  
.....  
.....G.....  
.....

4223  
Q8  
LES-1

2010 2020 2030 2040  
IATHNGQGAVALVGLSKLSDNGQWVFKINGSADTQGHVGAAGVAGGFHF\*  
.....\*  
.....\*  
.....\*

4223  
Q8  
LES-1

FIGURE 7

# Construction of Plasmids Expressing Portions of the 200 kDa Protein Gene from Strain 4223




Figure 8. *M. catarrhalis* M56 200kDa gene in pKS348.

ATG atc ggt gca acg ctc agt ggc agt gct tat gct caa aaa aaa gat	48
Met Ile Gly Ala Thr Leu Ser Gly Ser Ala Tyr Ala Gln Lys Lys Asp	
1 5 10 15	
acc aaa cat atc gca att ggt gaa caa aac cag cca aga cgc tca ggc	96
Thr Lys His Ile Ala Ile Gly Glu Gln Asn Gln Pro Arg Arg Ser Gly	
20 25 30	
act gcc aag gcg gac ggt gat cga gcc att gct att ggt gaa aat gct	144
Thr Ala Lys Ala Asp Gly Asp Arg Ala Ile Ala Ile Gly Glu Asn Ala	
35 40 45	
aac gca cag ggc ggt caa gcc atc gcc atc ggt agt agt aat aaa act	192
Asn Ala Gln Gly Gly Gln Ala Ile Ala Ile Gly Ser Ser Asn Lys Thr	
50 55 60	
gtc aat gga agc agt ttg gat aag ata ggt acc gat gct acg ggt caa	240
Val Asn Gly Ser Ser Leu Asp Lys Ile Gly Thr Asp Ala Thr Gly Gln	
65 70 75 80	
gag tcc atc gcc atc ggt ggt gat gta aag gct agt ggt gat gcc tcg	288
Glu Ser Ile Ala Ile Gly Gly Asp Val Lys Ala Ser Gly Asp Ala Ser	
85 90 95	
att gcc atc ggt agt gat gac tta cat ttg ctt gat cag cat ggt aat	336
Ile Ala Ile Gly Ser Asp Asp Leu His Leu Leu Asp Gln His Gly Asn	
100 105 110	
cct aaa cat ccg aaa ggt act ctg att aac gat ctt att aac ggc cat	384
Pro Lys His Pro Lys Gly Thr Leu Ile Asn Asp Leu Ile Asn Gly His	
115 120 125	
gca gta tta aaa gaa ata cga agc tca aag gat aat gat gta aaa tat	432
Ala Val Leu Lys Glu Ile Arg Ser Ser Lys Asp Asn Asp Val Lys Tyr	
130 135 140	
aga cgc aca acc gca agc gga cac gcc agt act gca gtg gga gcc atg	480
Arg Arg Thr Thr Ala Ser Gly His Ala Ser Thr Ala Val Gly Ala Met	
145 150 155 160	
tca tat gca cag ggt cat ttt tcc aac gcc ttt ggt aca cgg gca aca	528
Ser Tyr Ala Gln Gly His Phe Ser Asn Ala Phe Gly Thr Arg Ala Thr	
165 170 175	
gct aaa agt gcc tat tcc ttg gca gtg ggt ctt gcc gcc aca gcc gag	576
Ala Lys Ser Ala Tyr Ser Leu Ala Val Gly Leu Ala Ala Thr Ala Glu	
180 185 190	
ggc caa tct aca atc gct att ggt tct gat gca aca tct agc tcg ttg	624
Gly Gln Ser Thr Ile Ala Ile Gly Ser Asp Ala Thr Ser Ser Ser Leu	
195 200 205	
gga gcg ata gcc ctt ggt gca ggt act cgt gct cag cta cag ggc agt	672
Gly Ala Ile Ala Leu Gly Ala Gly Thr Arg Ala Gln Leu Gln Gly Ser	



210	215	220	
att gcc cta ggt caa ggt tct gtt gtc act cag agt gat aat aat tct			720
Ile Ala Leu Gly Gln Gly Ser Val Val Thr Gln Ser Asp Asn Asn Ser			
225	230	235	240
aga ccg gcc tat aca cca aat acc cag gca cta gac ccc aag ttt caa			768
Arg Pro Ala Tyr Thr Pro Asn Thr Gln Ala Leu Asp Pro Lys Phe Gln			
	245	250	255
gcc acc aat aat acg aag gcg ggt cca ctt tcc att ggt agt aac tct			816
Ala Thr Asn Asn Thr Lys Ala Gly Pro Leu Ser Ile Gly Ser Asn Ser			
	260	265	270
atc aaa cgt aaa atc atc aat gtc ggt gca ggt gtt aat aaa acc gat			864
Ile Lys Arg Lys Ile Ile Asn Val Gly Ala Gly Val Asn Lys Thr Asp			
	275	280	285
gcg gtc aat gtg gca cag cta gaa gcg gtg gtg aag tgg gct aag gag			912
Ala Val Asn Val Ala Gln Leu Glu Ala Val Val Lys Trp Ala Lys Glu			
	290	295	300
cgt aga att act ttt cag ggt gat gat aac agt act gac gta aaa ata			960
Arg Arg Ile Thr Phe Gln Gly Asp Asp Asn Ser Thr Asp Val Lys Ile			
305	310	315	320
ggg ttg gat aat act tta act att aaa ggt ggt gca gag acc aac gca			1008
Gly Leu Asp Asn Thr Leu Thr Ile Lys Gly Gly Ala Glu Thr Asn Ala			
	325	330	335
tta acc gat aat aat atc ggt gtg gta aaa gag gct gat aat agt ggt			1056
Leu Thr Asp Asn Asn Ile Gly Val Val Lys Glu Ala Asp Asn Ser Gly			
	340	345	350
ctg aaa gtt aaa ctt gct aaa act tta aac aat ctt act gag gtg aat			1104
Leu Lys Val Lys Leu Ala Lys Thr Leu Asn Asn Leu Thr Glu Val Asn			
	355	360	365
aca act aca tta aat gcc aca acc aca gtt aag gta ggt agt agt agt			1152
Thr Thr Thr Leu Asn Ala Thr Thr Thr Val Lys Val Gly Ser Ser Ser			
	370	375	380
agt act aca gct gaa tta ttg agt gat agt tta acc ttt acc cag ccc			1200
Ser Thr Thr Ala Glu Leu Leu Ser Asp Ser Leu Thr Phe Thr Gln Pro			
385	390	395	400
aat aca ggc agt caa agc aca agc aaa acc gtc tat ggc gtt aat ggg			1248
Asn Thr Gly Ser Gln Ser Thr Ser Lys Thr Val Tyr Gly Val Asn Gly			
	405	410	415
gtg aag ttt act aat aat gca gaa aca aca gca gca atc ggc act act			1296
Val Lys Phe Thr Asn Asn Ala Glu Thr Thr Ala Ala Ile Gly Thr Thr			
	420	425	430
cgt att acc aga gat aaa att ggc ttt gct cga gat ggt gat gtt gat			1344
Arg Ile Thr Arg Asp Lys Ile Gly Phe Ala Arg Asp Gly Asp Val Asp			
	435	440	445

gaa aaa caa gca cca tat ttg gat aaa aaa caa ctt aaa gtg ggt agt	1392
Glu Lys Gln Ala Pro Tyr Leu Asp Lys Lys Gln Leu Lys Val Gly Ser	
450 455 460	
ggt gca att acc ata gac aat ggc att gat gca ggt aat aaa aag atc	1440
Val Ala Ile Thr Ile Asp Asn Gly Ile Asp Ala Gly Asn Lys Lys Ile	
465 470 475 480	
agt aat ctt gcc aaa ggt agc agt gct aac gat gcg gtt acc atc gaa	1488
Ser Asn Leu Ala Lys Gly Ser Ser Ala Asn Asp Ala Val Thr Ile Glu	
485 490 495	
cag ctc aaa gcc gcc aag cct act tta aac gca ggc gct ggc atc agt	1536
Gln Leu Lys Ala Ala Lys Pro Thr Leu Asn Ala Gly Ala Gly Ile Ser	
500 505 510	
gtc aca cct act gaa ata tca gtt gat gct aag agt ggc aat gtt acc	1584
Val Thr Pro Thr Glu Ile Ser Val Asp Ala Lys Ser Gly Asn Val Thr	
515 520 525	
gcc cca act tac aac att ggc gtg aaa acc acc gag ctt aac agt gat	1632
Ala Pro Thr Tyr Asn Ile Gly Val Lys Thr Thr Glu Leu Asn Ser Asp	
530 535 540	
ggc act agt gat aaa ttt agt gtt aag ggt agt ggt acg aac aat agc	1680
Gly Thr Ser Asp Lys Phe Ser Val Lys Gly Ser Gly Thr Asn Asn Ser	
545 550 555 560	
tta gtt acc gcc gaa cat ttg gca agc tat cta aat gaa gtc aat cga	1728
Leu Val Thr Ala Glu His Leu Ala Ser Tyr Leu Asn Glu Val Asn Arg	
565 570 575	
acg gct gac agt gct cta caa agc ttt acc gtt aaa gaa gaa gac gat	1776
Thr Ala Asp Ser Ala Leu Gln Ser Phe Thr Val Lys Glu Glu Asp Asp	
580 585 590	
gat gac gcc aac gct atc acc gtg gct aaa gat acg aca aaa aat gcc	1824
Asp Asp Ala Asn Ala Ile Thr Val Ala Lys Asp Thr Thr Lys Asn Ala	
595 600 605	
ggc gca gtc agc atc tta aaa ctc aaa ggt aaa aac ggt cta acg gtt	1872
Gly Ala Val Ser Ile Leu Lys Leu Lys Gly Lys Asn Gly Leu Thr Val	
610 615 620	
gct acc aaa aaa gat ggt acg gtt acc ttt ggg ctt agc caa gat agc	1920
Ala Thr Lys Lys Asp Gly Thr Val Thr Phe Gly Leu Ser Gln Asp Ser	
625 630 635 640	
ggc ctg acc att ggc aaa agc acc cta aac aac gat ggc ttg act gtt	1968
Gly Leu Thr Ile Gly Lys Ser Thr Leu Asn Asn Asp Gly Leu Thr Val	
645 650 655	
aaa gat acc aac gaa caa atc caa gtc ggt gct aat ggc att aaa ttt	2016
Lys Asp Thr Asn Glu Gln Ile Gln Val Gly Ala Asn Gly Ile Lys Phe	
660 665 670	

act aat gtg aat ggt agt aat cca ggt act ggc att gca aat acc gct	2064
Thr Asn Val Asn Gly Ser Asn Pro Gly Thr Gly Ile Ala Asn Thr Ala	
675 680 685	
cgc att acc aga gat aaa att ggc ttt gct ggt tct gat ggt gca gtt	2112
Arg Ile Thr Arg Asp Lys Ile Gly Phe Ala Gly Ser Asp Gly Ala Val	
690 695 700	
gat aca aac aaa cct tat ctt gat caa gac aag cta caa gtt ggc aat	2160
Asp Thr Asn Lys Pro Tyr Leu Asp Gln Asp Lys Leu Gln Val Gly Asn	
705 710 715 720	
gtt aag att acc aac act ggc att aac gca ggt ggt aaa gcc atc aca	2208
Val Lys Ile Thr Asn Thr Gly Ile Asn Ala Gly Gly Lys Ala Ile Thr	
725 730 735	
ggg ctg tcc cca aca ctg cct agc att gcc gat caa agt agc cgc aac	2256
Gly Leu Ser Pro Thr Leu Pro Ser Ile Ala Asp Gln Ser Ser Arg Asn	
740 745 750	
ata gaa ctg ggc aat aca atc caa gac aaa gac aaa tcc aac gct gcc	2304
Ile Glu Leu Gly Asn Thr Ile Gln Asp Lys Asp Lys Ser Asn Ala Ala	
755 760 765	
agc att aat gat ata tta aat aca ggc ttt aac cta aaa aat aat aac	2352
Ser Ile Asn Asp Ile Leu Asn Thr Gly Phe Asn Leu Lys Asn Asn Asn	
770 775 780	
aac ccc att gac ttt gtc tcc act tat gac att gtt gac ttt gcc aat	2400
Asn Pro Ile Asp Phe Val Ser Thr Tyr Asp Ile Val Asp Phe Ala Asn	
785 790 795 800	
ggc aat gcc acc acc gcc aca gta acc cat gat acc gct aac aaa acc	2448
Gly Asn Ala Thr Thr Ala Thr Val Thr His Asp Thr Ala Asn Lys Thr	
805 810 815	
agt aaa gtg gta tat gat gtg aat gtg gat gat aca acc att cat cta	2496
Ser Lys Val Val Tyr Asp Val Asn Val Asp Asp Thr Thr Ile His Leu	
820 825 830	
aca ggc act gat gac aat aaa aaa ctt ggc gtc aaa acc acc aaa ctg	2544
Thr Gly Thr Asp Asp Asn Lys Lys Leu Gly Val Lys Thr Thr Lys Leu	
835 840 845	
aac aaa aca agt gct aat ggt aat aca gca act aac ttt aat gtt aac	2592
Asn Lys Thr Ser Ala Asn Gly Asn Thr Ala Thr Asn Phe Asn Val Asn	
850 855 860	
tct agt gat gaa gat gcc ctt gtt aac gcc aaa gac atc gcc gaa aat	2640
Ser Ser Asp Glu Asp Ala Leu Val Asn Ala Lys Asp Ile Ala Glu Asn	
865 870 875 880	
cta aac acc cta gcc aag gaa att cac acc acc aaa ggc aca gca gac	2688
Leu Asn Thr Leu Ala Lys Glu Ile His Thr Thr Lys Gly Thr Ala Asp	
885 890 895	
acc gcc cta caa acc ttt acc gtt aaa aag gta gat gaa aat aat aat	2736

Thr	Ala	Leu	Gln	Thr	Phe	Thr	Val	Lys	Lys	Val	Asp	Glu	Asn	Asn	Asn		
			900					905					910				
gct	gat	gac	gcc	aac	gcc	atc	acc	gtg	ggg	caa	aag	aac	gca	aat	aat	2784	
Ala	Asp	Asp	Ala	Asn	Ala	Ile	Thr	Val	Gly	Gln	Lys	Asn	Ala	Asn	Asn		
		915					920					925					
caa	gtc	aac	acc	cta	aca	ctc	aaa	ggg	gaa	aac	ggg	ctt	aat	att	aaa	2832	
Gln	Val	Asn	Thr	Leu	Thr	Leu	Lys	Gly	Glu	Asn	Gly	Leu	Asn	Ile	Lys		
	930					935					940						
acc	gac	aaa	aat	ggg	acg	gtt	acc	ttt	ggc	att	aac	acc	aca	agc	ggg	2880	
Thr	Asp	Lys	Asn	Gly	Thr	Val	Thr	Phe	Gly	Ile	Asn	Thr	Thr	Ser	Gly		
945					950					955					960		
ctt	aaa	gcc	ggc	aaa	agc	acc	cta	aac	gac	ggg	ggc	ttg	tct	att	aaa	2928	
Leu	Lys	Ala	Gly	Lys	Ser	Thr	Leu	Asn	Asp	Gly	Gly	Leu	Ser	Ile	Lys		
			965						970					975			
aac	ccc	act	ggg	agc	gaa	caa	atc	caa	gtc	ggg	gct	gat	ggc	gtg	aag	2976	
Asn	Pro	Thr	Gly	Ser	Glu	Gln	Ile	Gln	Val	Gly	Ala	Asp	Gly	Val	Lys		
		980						985					990				
ttt	gcc	aag	gtt	aat	aat	aat	ggg	gtt	gta	ggg	gct	ggc	att	gat	ggc	3024	
Phe	Ala	Lys	Val	Asn	Asn	Asn	Gly	Val	Val	Gly	Ala	Gly	Ile	Asp	Gly		
		995				1000						1005					
aca	act	cgc	att	acc	aga	gat	gaa	att	ggc	ttt	act	ggg	act	aat	ggc	3072	
Thr	Thr	Arg	Ile	Thr	Arg	Asp	Glu	Ile	Gly	Phe	Thr	Gly	Thr	Asn	Gly		
	1010					1015					1020						
tca	ctt	gat	aaa	agc	aaa	ccc	cac	cta	agc	aaa	gac	ggc	att	aac	gca	3120	
Ser	Leu	Asp	Lys	Ser	Lys	Pro	His	Leu	Ser	Lys	Asp	Gly	Ile	Asn	Ala		
	1025				1030					1035					1040		
ggg	ggg	aaa	aag	att	acc	aac	att	caa	tca	ggg	gag	att	gcc	caa	aac	3168	
Gly	Gly	Lys	Lys	Ile	Thr	Asn	Ile	Gln	Ser	Gly	Glu	Ile	Ala	Gln	Asn		
			1045					1050					1055				
agc	cat	gat	gct	gtg	aca	ggc	ggc	aag	att	tat	gat	tta	aaa	acc	gaa	3216	
Ser	His	Asp	Ala	Val	Thr	Gly	Gly	Lys	Ile	Tyr	Asp	Leu	Lys	Thr	Glu		
		1060					1065					1070					
ctt	gaa	aac	aaa	atc	agc	agt	act	gcc	aaa	aca	gca	caa	aac	tca	tta	3264	
Leu	Glu	Asn	Lys	Ile	Ser	Ser	Thr	Ala	Lys	Thr	Ala	Gln	Asn	Ser	Leu		
	1075						1080				1085						
cac	gaa	ttc	tca	gta	gca	gat	gaa	caa	ggg	aat	aac	ttt	acg	gtt	agt	3312	
His	Glu	Phe	Ser	Val	Ala	Asp	Glu	Gln	Gly	Asn	Asn	Phe	Thr	Val	Ser		
	1090					1095					1100						
aac	cct	tac	tcc	agt	tat	gac	acc	tca	aag	acc	tct	gat	gtc	atc	acc	3360	
Asn	Pro	Tyr	Ser	Ser	Tyr	Asp	Thr	Ser	Lys	Thr	Ser	Asp	Val	Ile	Thr		
	1105				1110					1115				1120			
ttt	gca	ggg	gaa	aac	ggc	att	acc	acc	aag	gta	aat	aaa	ggg	gtg	gtg	3408	
Phe	Ala	Gly	Glu	Asn	Gly	Ile	Thr	Thr	Lys	Val	Asn	Lys	Gly	Val	Val		

1125	1130	1135	
cgt gtg ggc att gac caa acc aaa ggc tta acc acg cct aag ctg acc			3456
Arg Val Gly Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr			
1140	1145	1150	
gtg ggt aat aat aat ggc aaa ggc att gtc att gac agc caa aat ggt			3504
Val Gly Asn Asn Asn Gly Lys Gly Ile Val Ile Asp Ser Gln Asn Gly			
1155	1160	1165	
caa aat acc atc aca gga cta agc aac act cta gct aat gtt acc aat			3552
Gln Asn Thr Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn			
1170	1175	1180	
gat aaa ggt agc gta cgc acc aca gaa cag ggc aat ata atc aaa gac			3600
Asp Lys Gly Ser Val Arg Thr Thr Glu Gln Gly Asn Ile Ile Lys Asp			
1185	1190	1195	1200
gaa gac aaa acc cgt gcc gcc agc att gtt gat gtg cta agc gca ggc			3648
Glu Asp Lys Thr Arg Ala Ala Ser Ile Val Asp Val Leu Ser Ala Gly			
1205	1210	1215	
ttt aac ttg caa ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat			3696
Phe Asn Leu Gln Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr			
1220	1225	1230	
gac acc gtc aac ttt gcc gat ggc aat gcc acc acc gct aag gtg acc			3744
Asp Thr Val Asn Phe Ala Asp Gly Asn Ala Thr Thr Ala Lys Val Thr			
1235	1240	1245	
tat gat gac aca agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg			3792
Tyr Asp Asp Thr Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val			
1250	1255	1260	
gat gat aca acc att gaa gtt aaa gat aaa aaa ctt ggc gta aaa acc			3840
Asp Asp Thr Thr Ile Glu Val Lys Asp Lys Lys Leu Gly Val Lys Thr			
1265	1270	1275	1280
acc aca ttg acc agt act ggc aca ggt gct aat aaa ttt gcc cta agc			3888
Thr Thr Leu Thr Ser Thr Gly Thr Gly Ala Asn Lys Phe Ala Leu Ser			
1285	1290	1295	
aat caa gct act ggc gat gcg ctt gtc aag gcc agt gat atc gtt gct			3936
Asn Gln Ala Thr Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Val Ala			
1300	1305	1310	
cat cta aac acc tta tct ggc gac atc caa act gcc aaa ggg gca agc			3984
His Leu Asn Thr Leu Ser Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser			
1315	1320	1325	
caa gcg aac aac tca gca ggc tat gtg gat gct gat ggc aat aag gtc			4032
Gln Ala Asn Asn Ser Ala Gly Tyr Val Asp Ala Asp Gly Asn Lys Val			
1330	1335	1340	
atc tat gac agt acc gat aac aag tac tat caa gcc aaa aat gat ggc			4080
Ile Tyr Asp Ser Thr Asp Asn Lys Tyr Tyr Gln Ala Lys Asn Asp Gly			
1345	1350	1355	1360


aca gtt gat aaa acc aaa gaa gtt gcc aaa gac aaa ctg gtc gcc caa	4128
Thr Val Asp Lys Thr Lys Glu Val Ala Lys Asp Lys Leu Val Ala Gln	
1365 1370 1375	
gcc caa acc cca gat ggc aca ttg gct caa atg aat gtc aaa tca gtc	4176
Ala Gln Thr Pro Asp Gly Thr Leu Ala Gln Met Asn Val Lys Ser Val	
1380 1385 1390	
att aac aaa gaa caa gta aat gat gcc aat aaa aag caa ggc atc aat	4224
Ile Asn Lys Glu Gln Val Asn Asp Ala Asn Lys Lys Gln Gly Ile Asn	
1395 1400 1405	
gaa gac aac gcc ttt gtt aaa gga ctt gaa aaa gcc gct tct gat aac	4272
Glu Asp Asn Ala Phe Val Lys Gly Leu Glu Lys Ala Ala Ser Asp Asn	
1410 1415 1420	
aaa acc aaa aac gcc gca gta act gtg ggt gat tta aat gcc gtt gcc	4320
Lys Thr Lys Asn Ala Ala Val Thr Val Gly Asp Leu Asn Ala Val Ala	
1425 1430 1435 1440	
caa aca ccg ctg acc ttt gca ggg gat aca ggc aca acg gct aaa aaa	4368
Gln Thr Pro Leu Thr Phe Ala Gly Asp Thr Gly Thr Thr Ala Lys Lys	
1445 1450 1455	
ctg ggc gag act ttg acc atc aaa ggt ggg caa aca gac acc aat aag	4416
Leu Gly Glu Thr Leu Thr Ile Lys Gly Gly Gln Thr Asp Thr Asn Lys	
1460 1465 1470	
cta acc gat aat aac atc ggt gtg gta gca ggt act gat ggc ttc act	4464
Leu Thr Asp Asn Asn Ile Gly Val Val Ala Gly Thr Asp Gly Phe Thr	
1475 1480 1485	
gtc aaa ctt gcc aaa gac cta acc aat ctt aac agc gtt aat gca ggt	4512
Val Lys Leu Ala Lys Asp Leu Thr Asn Leu Asn Ser Val Asn Ala Gly	
1490 1495 1500	
ggc acc aaa att gat gac aaa ggc gtg tct ttt gta gac tca agc ggt	4560
Gly Thr Lys Ile Asp Asp Lys Gly Val Ser Phe Val Asp Ser Ser Gly	
1505 1510 1515 1520	
caa gcc aaa gca aac acc cct gtg cta agt gcc aat ggg ctg gac ctg	4608
Gln Ala Lys Ala Asn Thr Pro Val Leu Ser Ala Asn Gly Leu Asp Leu	
1525 1530 1535	
ggt ggc aag gtc atc agt aat gtg ggc aaa ggc aca aaa gat acc gac	4656
Gly Gly Lys Val Ile Ser Asn Val Gly Lys Gly Thr Lys Asp Thr Asp	
1540 1545 1550	
gct gcc aat gta caa cag tta aac gaa gta cgc aac ttg ttg ggt ctt	4704
Ala Ala Asn Val Gln Gln Leu Asn Glu Val Arg Asn Leu Leu Gly Leu	
1555 1560 1565	
ggt aat gct ggt aat gat aac gct gac ggc aat cag gta aac att gcc	4752
Gly Asn Ala Gly Asn Asp Asn Ala Asp Gly Asn Gln Val Asn Ile Ala	
1570 1575 1580	



Ser Asn Ser Val Ala Leu Gly Ser Asn Ser Ala Ile Ser Ala Gly Thr	
1810	1815 1820
cac gca ggc aca caa gcc aaa aaa tct gac ggc aca gca ggt aca acc	5520
His Ala Gly Thr Gln Ala Lys Lys Ser Asp Gly Thr Ala Gly Thr Thr	
1825	1830 1835 1840
acc aca gca ggt gca acc ggt acg gtt aaa ggc ttt gct gga caa acg	5568
Thr Thr Ala Gly Ala Thr Gly Thr Val Lys Gly Phe Ala Gly Gln Thr	
	1845 1850 1855
gcg gtt ggt gcg gtc tcc gtg ggt gcc tca ggt gct gaa cgc cgt atc	5616
Ala Val Gly Ala Val Ser Val Gly Ala Ser Gly Ala Glu Arg Arg Ile	
	1860 1865 1870
caa aat gtg gca gca ggt gag gtc agt gcc acc agc acc gat gcg gtc	5664
Gln Asn Val Ala Ala Gly Glu Val Ser Ala Thr Ser Thr Asp Ala Val	
	1875 1880 1885
aat ggt agc cag ttg tac aaa gcc acc caa agc att gcc aac gca acc	5712
Asn Gly Ser Gln Leu Tyr Lys Ala Thr Gln Ser Ile Ala Asn Ala Thr	
	1890 1895 1900
aat gag ctt gac cat cgt atc cac caa aac gaa aat aag gcc aat gca	5760
Asn Glu Leu Asp His Arg Ile His Gln Asn Glu Asn Lys Ala Asn Ala	
	1905 1910 1915 1920
ggg att tca tca gcg atg gcg atg gcg tcc atg cca caa gcc tac att	5808
Gly Ile Ser Ser Ala Met Ala Met Ala Ser Met Pro Gln Ala Tyr Ile	
	1925 1930 1935
cct ggc aga tcc atg gtt acc ggg ggt att gcc acc cac aac ggt caa	5856
Pro Gly Arg Ser Met Val Thr Gly Gly Ile Ala Thr His Asn Gly Gln	
	1940 1945 1950
ggt gcg gtg gca gtg gga ctg tcg aag ctg tcg gat aat ggt caa tgg	5904
Gly Ala Val Ala Val Gly Leu Ser Lys Leu Ser Asp Asn Gly Gln Trp	
	1955 1960 1965
gta ttt aaa atc aat ggt tca gcc gat acc caa ggc cat gta ggg gcg	5952
Val Phe Lys Ile Asn Gly Ser Ala Asp Thr Gln Gly His Val Gly Ala	
	1970 1975 1980
gca gtt ggt gca ggt ttt cac ttt taagccataa atcgcaagat tttacttaaa	6006
Ala Val Gly Ala Gly Phe His Phe	
	1985 1990
aatcaatctc accatagttg tataaaacag catcagcatc agtcatatta ctgatgctga	6066
tggttttttat cacttaaacc attttaccgc tcaagtgatt ctctttcacc atgaccaa	6126
cgccattgat cataggtaaa cttattgagt aaattttatc aatgtagttg ttagatatgg	6186
ttaaaattgt gccattgacc aaaaaatgac cgatttatcc cgaaaatttc tgattatgat	6246
ccgttgacct gca	6259




Figure 9A Construction of pKS294




652220 "6T9T9E60

Figure 9B Construction of pKS294



652220"6T9T9E60

Figure 10. Construction of pKS348



652220"6T3T3E60

FIGURE 11

Purification of r200 kDa Protein from *E. coli*

***E. coli* Whole Cell**





FIGURE 12

Expression of M56 r200 kDa Protein Gene in *E. coli*



A: KS358 induced when O.D. <sup>at</sup> 600 nm was 0.26


B: KS358 induced when O.D. at 600 nm was 0.44

a: strain 4223 lysate

b: KS358 cultured overnight

FIGURE 13

Purification of M56 r200 kDa Protein (4223)



1. *E. coli* Whole cells
2. Soluble proteins after 50 mM Tris/ NaCl, pH 8, extraction
3. Soluble proteins after Tris/ Triton X-100/ EDTA extraction
4. Soluble proteins after Tris/ OG extraction
5. Pellet after Tris/ OG extraction
- 6-7. Purified 200 kDa protein

FIGURE 14

Anti-M56 r200 kDa Antibody Titers in Mice




FIGURE 15

Anti-M56 r200 kDa Antibody Titers in Guinea Pigs







FIGURE 16

PCR amplification of DNA fragments carrying a portion of the  
200 kDa protein gene from chromosomal DNA of RH408



[illegible]

*M. catarrhalis* strain 4223 200 kDa

C C A T G G A T A T G G G C A G G T G T G C T C G C C T G C C G T A T G A T G G C G A T G A C A C C C C A T T T G C C C

C A T A T C T G T A C G A T T T G A C A T G T G A T A T G A T T T A A C A T G T G A C A T G A T T T A A C A T T G T T T

AATACTGTTGCCATCATTACCATAAATTTAGTAACGCATTTAGTAACGCATTGTAAAAAT  
130 140 150 160 170 180

CATTGCGCCCTTTATGTGTATCATATGAATAGAAATATTATGATTGTATCTGATTATTGT

ATCAGAAATGGTGATGCTATATGATGATGCCTACGAGTTGATTTGGGTTAATCACTCTATG

ATTTGATATATTTTGAAACTAATCTATTGACTTAAATCACCATATGGTTATAATTTAGCA

T A A T G G T A G G C T T T T T G T A A A A A T C A C A T C G C A A T A T T G T T C T A C T G T T A C T A C C A T G C T

TGAATGACGATCCCAATCACCAGATTTCATTCAAGTGATGTGTTTGTATACGCACCATTTTA

C C C T A A T T A T T T C A A T C A A A T G C C T A T G T C A G C A T G T A T C A T T T T T T A A G G T A A A C C A C

MET ASN HIS ILE TYR LYS VAL ILE PHE ASN LYS ALA<sup>12</sup> THR GLY THR PHE MET ALA VAL<sup>19</sup> ALA  
 CATGAATC CATCTATAAAGTCATCTTTAAACAAAGCCACAGGCACATTTATGGCAGTGGC  
 550 560 570 580 590 600

GLU TYR ALA LYS SER HIS SER THR GLY GLY GLY SER CYS ALA THR GLY GLN VAL GLY<sup>39</sup> SER  
 AGAGTACGCCAAATCCACAGCACGGGGGGGGGTAGCTGTGCTACAGGGCAAGTTGGCAG  
 610 620 630 640 650 660

VAL CYS THR LEU SER PHE ALA ARG ILE ALA ALA LEU ALA VAL LEU VAL<sup>56</sup> ILE GLY ALA THR  
TGTATGCACTCTGAGCTTTGCCCGTATTGCCGCGCTCGCTGTCCTCGTGATCGGTGCAAC  
670 680 690 700 710 720

FIGURE 18  
3' Half Constructs of 200 kD Protein Gene




Figure 19 Construction of pQWE





Figure 20 Construction of pQWF



652220-071960

Docket No.  
1038-921 MIS:jb

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**RECOMBINANT HIGH MOLECULAR WEIGHT MAJOR OUTER MEMBRANE PROTEIN OF MORAXELLA**

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as United States Application No. or PCT International Application Number \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

**Michael I. Stewart (24,973)**

Send Correspondence to: **Sim & McBurney**  
**6th Floor, 330 University Avenue**  
**Toronto, Ontario**  
**M5G 1R7, Canada.**

Direct Telephone Calls to: *(name and telephone number)*  
**Michael I. Stewart (416) 595-1155**

Full name of sole or first inventor <b>Sheena M. Loosmore</b>	
Sole or first inventor's signature	Date
Residence <b>Aurora, Ontario, Canada.</b>	
Citizenship <b>Canadian</b>	
Post Office Address <b>70 Crawford Rose Drive, Aurora, Ontario, Canada, L4G 4R4.</b>	

Full name of second inventor, if any <b>Ken Sasaki</b>	
Second inventor's signature	Date
Residence <b>Willowdale, Ontario, Canada.</b>	
Citizenship <b>Japanese</b>	
Post Office Address <b>Apt. 512, 1131 Steeles Avenue West, Willowdale, Ontario, Canada, M2R 3W8.</b>	



Full name of third inventor, if any

**Yan Ping Yang**

Third inventor's signature

Date

Residence

**Willowdale, Ontario, Canada.**

Citizenship

**Canadian**

Post Office Address

**Apt. 709, 120 Torresdale Avenue, Willowdale, Ontario, Canada, M2R 3N7.**

Full name of fourth inventor, if any

**Michel H. Klein**

Fourth inventor's signature

Date

Residence

**Willowdale, Ontario, Canada.**

Citizenship

**Canadian**

Post Office Address

**16 Munro Boulevard, Willowdale, Ontario, Canada, M2P 1B9.**

Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address